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ABSTRACT  
 
Parkinson’s disease (PD) is a major neurodegenerative disorder characterized by 
progressive and substantial loss of dopaminergic neurons in the substantia nigra 
compacta (SNc). Currently, no available drugs prevent the progressive loss of nigral 
dopaminergic neurons. The mechanisms underlying the dopaminergic degenerative 
process observed in PD are not well understood, which has hampered development of 
successful neuroprotective drugs. Tyrosine hydroxylase (TH) is the rate-limiting enzyme 
in dopamine synthesis. Severely reduced TH positive neurons and TH fibers in 
dopaminergic terminal fields of PD patients and the successful application of L-DOPA 
therapy for Parkinson's disease suggest that this enzyme has a primary role in the 
progression of this disease. Previously, we found that the caspase-3 mediated proteolytic 
activation of Protein Kinase C δ (PKCδ), a member of the novel PKC isoform family, 
plays a critical role in oxidative stress-induced dopaminergic cell death in cell culture 
models of PD. In the present study, we report a novel interaction between PKCδ and TH, 
in which the kinase modulates dopamine synthesis by negatively regulating TH activity 
via protein phosphatase 2A (PP2A).  We observed that PKCδ is highly expressed in 
nigral dopaminergic neurons and co-localizes with TH in the mouse brain.  Interestingly, 
suppression of PKCδ activity with the kinase inhibitor rottlerin, PKCδ-siRNA, or with 
PKCδ dominant negative mutant effectively increased a number of key biochemical 
events in the dopamine pathway, including TH-ser40 phosphorylation, TH enzymatic 
activity, and dopamine synthesis in neuronal cell culture models.  Additionally, we 
found that PKCδ not only physically associates with the PP2A catalytic subunit (PP2Ac) 
but also phosphorylates the phosphatase to increase its activity.  Notably, inhibition of 
PKCδ reduced the dephosphorylation activity of PP2A and thereby increased TH-ser40 
phosphorylation, TH activity, and dopamine synthesis.  To further validate our findings, 
we used the PKCδ knockout (PKCδ -/-) mouse model.  Consistent with other results, we 
found greater TH-ser40 phosphorylation and reduced PP2A activity in the substantia 
nigra of PKCδ -/- mice than wild-type mice.  Importantly, this was accompanied by an 
increased dopamine level in the striatum of PKCδ -/- mice. Taken together, these results 
suggest that PKCδ phosphorylates PP2Ac to enhance its activity, and thereby reduces 
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TH-ser40 phosphorylation and TH activity and ultimately dopamine synthesis. 
Suppression of PKCδ activity with the kinase inhibitor rottlerin can increase 
dopamine synthesis in neuronal cell culture models. Thus, we treated C57 black mice 
with the PKCδ inhibitor rottlerin and found that rottlerin can effectively increase a 
number of key neurochemical events in the dopamine pathway, including TH 
phosphorylation, TH enzymatic activity, and striatal dopamine and DOPAC levels.  
Time course studies revealed that TH-ser31 and -ser40 phosphorylation and dopamine 
synthesis were increased within 1hr of rottlerin treatment.  Increased dopamine 
synthesis was accompanied by stimulation of locomotor activity and stereotypic behavior. 
Consistent with the pharmacological effects of rottlerin, naïve PKCδ-knockout mice 
showed enhanced striatal dopamine levels and behavioral function as compared to 
wild-type mice. These results suggest that inhibition of PKCδ in the nigrostriatal 
dopaminergic system can enhance dopaminergic neurotransmission and neurobehavioral 
characteristics in animal models.   
Previously, we discovered that proteolytic activation of PKCδ mediated by 
caspase-3 plays a critical role in oxidative stress-induced dopaminergic cell death in cell 
culture models of PD.  Proteolytic cleavage of PKCδ (74 kDa) by caspase-3 results in a 
41-kDa catalytic subunit and a 38-kDa regulatory subunit, leading to a persistent 
activation of the kinase (Kaul et al., 2003; Yang et al., 2004). Blockade of proteolytic 
activation of PKCδ by overexpression of the kinase-dominant negative PKCδ mutant, 
cleavage-resistant PKCδ mutant, or siRNA directed against PKCδ almost completely 
prevented the dopaminergic cell death.  Therefore, in the present study, we examined the 
neuroprotective efficacy of the PKCδ inhibitor rottlerin in both primary cell culture and 
animal models.  Herein, we report that rottlerin not only protects against MPP+-induced 
degeneration of TH-positive neurons in primary mesencephalic culture models but, most 
importantly, is clearly neuroprotective in an MPTP (1-methyl 4-phenyl 
1,2,3,6-tetrahydropyridine) animal model of Parkinson’s disease. Administration of 
rottlerin, either intraperitoneally or orally, to C57 black mice showed significant 
protection against MPTP-induced locomotor deficits and striatal depletion of dopamine 
and its metabolite DOPAC. Importantly, stereological analysis of nigral neurons revealed 
rottlerin treatment significantly protected against MPTP-induced TH-positive neuronal 
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loss in the substantia nigra compacta.  Our findings demonstrate the neuroprotective 
effect of rottlerin in both cell culture and preclinical animal models of PD, and suggest 
that pharmacological modulation of PKCδ may offer a novel therapeutic strategy for 
treatment of PD. 
Manganese (Mn) exposure causes manganism, a neurological disorder similar to 
PD. However, the cellular mechanism by which Mn induces dopaminergic neuronal cell 
death remains unclear. We found that caspase-3-dependent proteolytic activation of 
protein kinase Cδ (PKCδ) plays a key role in Mn-induced apoptotic cell death. In the 
present study, we report that chronic Mn treatment suppresses TH activity without 
causing any cytotoxicity, and is accompanied by an increase of PKCδ cleavage in the 
dopaminergic cells. The reduced TH activity by chronic Mn treatment can be attenuated 
by the PKCδ inhibitor rottlerin. Here we also showed that Mn treatment can increase 
PP2A activity, which may contribute to the decreased TH activity induced by MnCl2. The 
increased PP2A activity induced by chronic MnCl2 treatment is suppressed by the PKCδ 
inhibitor rottlerin, which may suggest that the activation of PKCδ induced by Mn 
exposure can increase PP2A activity, which might decrease TH activity induced by 
chronic Mn treatment. We suggest that Mn-mediated regulation of TH through PKCδ and 
PP2A may have important implications in neurological dopaminergic system disorders, 
such as Parkinson’s disease and Manganism. 
Collectively, these results suggest that PKCδ phosphorylates PP2A to enhance its 
activity and thereby reduces TH-ser40 phosphorylation and TH activity and ultimately 
dopamine synthesis. Regulation of dopaminergic function through PKCδ and PP2A may 
be important for neurobehavioral function and metal-mediated neurological dopaminergic 
system disorders. Inhibition of PKCδ in the nigrostriatal dopaminergic system can offer 
dual benefits of neuroprotection and enhanced dopaminergic function in the development 
of therapeutic agents for treatment of Parkinson’s disease. 
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CHARPTER 1: GENERAL INTRODUCTION  
 
 
Dissertation organization  
 
Alternative thesis format is used for this thesis, which includes modified versions of several 
manuscripts either published or to be submitted for publication. The thesis contains a general 
introduction, four research papers, a general conclusion, and an acknowledgement. 
References for each individual section are listed at the end of corresponding chapters, except 
for the background and literature review: references for these are listed following the general 
conclusion. The general introduction (Chapter I) consistly provides the current knowledge of 
the etiopathogenesis of Parkinson’s disease and describes the overview of the research 
objective. Background and literature review I provide background information about the 
PKC protein in dopaminergic system, particularly focusing on the role of the PKCδ isoform 
in the survival of DA neurons and DA neurotransmission. Background and literature review 
II of the chapter summarizes the current available pharmacotherapeutic treatment options for 
the Parkinson’s animal models. Chapter II “Protein kinase Cδ negatively regulates tyrosine 
hydroxylase activity and dopamine synthesis by enhancing protein phosphatase-2A activity 
in dopaminergic neurons” is a research paper published in the Journal of Neuroscience (27: 
5349-62, 2007). Chapter III “Neuroprotective Effect of PKCδ Inhibitor Rottlerin in Cell 
Culture and Animal Models of Parkinson’s Disease” has been published in Journal of 
Pharmacology and Experimental Therapeutics (322:913-22, 2007). Chapter IV “Inhibition of 
PKCdelta (PKCδ) isoform in the substantia nigra enhances dopamine synthesis and 
neurobehavioral alterations in mice: Dual neuroprotective strategies in Parkinson’s disease” 
and chapter V “Effects of Manganese on tyrosine hydroxylase activity and phosphorylation 
in dopaminergic neuronal cells” will be submitted for publication soon. 
This dissertation contains the experimental results obtained by the author during her 
Ph.D study under the supervision of his major professor, Dr.Anumantha G. Kanthsamy.  
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Introduction 
 
Parkinson’s disease (PD) is a major neurodegenerative disorder characterized by 
progressive and substantial loss of dopaminergic neurons in the substantia nigra compacta 
(SNc), resulting in debilitating motor signs including tremors, bradykinesia, and rigidity. The 
PKC family consists of more than 12 isoforms and is subdivided into three major subfamilies, 
which include conventional PKC (α, βI, βII, γ), novel PKC (δ, ε, µ, η, θ), and atypical PKC 
(τ, λ, ζ) (Gschwendt 1999; Dempsey et al., 2000; Maher et al., 2001; Kanthasamy et al., 
2003).  PKCδ, a key member of the novel PKC family, plays a role in a variety of cell 
functions including cell differentiation, proliferation, and secretion.  Our recent studies 
demonstrate that PKCδ is an oxidative stress-sensitive kinase, and activation of this kinase 
via caspase-3 dependent proteolysis induces apoptotic cell death in cell culture models of 
Parkinson’s disease (Kanthasamy et al., 2003; Kaul et al., 2003; Yang et al., 2004; 
Latchoumycandane et al., 2005). Blockade of proteolytic activation of PKCδ by 
overexpression of the kinase-dominant negative PKCδ mutant, cleavage-resistant PKCδ 
mutant, or siRNA directed against PKCδ almost completely prevented the dopaminergic cell 
death (Kaul et al., 2003; Kitazawa et al., 2003; Anantharam et al., 2004; Yang et al., 2004; 
Latchoumycandane et al., 2005). We also observed a high level of PKCδ expression in the 
nigral dopaminergic neurons and a physical association of PKCδ with tyrosine hydroxylase 
(TH). TH is a rate-limiting enzyme in the biosynthesis of catecholamines and catalyzes the 
first step of a biochemical synthetic pathway in which L-tyrosine is converted to 
L-3,4-dihydroxyphenylalanine (L-dopa). Severely reduced TH positive neurons and TH 
fibers in dopaminergic terminal fields and the successful application of L-DOPA therapy for 
Parkinson's disease suggest that this enzyme has a primary role in progression of this disease. 
Phosphorylation and dephosphorylation of TH represent important post-translational 
regulatory mechanisms that mainly determine the amount of catecholamine synthesis.  A 
number of phosphorylation sites have been identified in TH, and phosphorylation of TH 
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greatly influences the enzyme activity (Lee et al., 1989). General PKCs can phosphorylate 
TH-ser40 and TH-ser31 (Albert et al., 1984; McTigue et al., 1985; Tachikawa et al., 1987; 
Cahill et al., 1989; Haycock et al., 1992; Bunn and Saunders 1995; Bobrovskaya et al., 1998); 
however, direct phosphorylation of TH by PKA and not by PKC results in activation of the 
enzymatic activity (Funakoshi et al., 1991).  The role of PKC isoforms in the regulation of 
TH activity is not well studied. The present studies investigate the physiological role of 
PKCδ in regulating dopamine synthesis and the development of therapeutic agents for 
treatment of Parkinson’s disease. 
 
 
Background and Literature Review I 
Protein Kinase C delta (PKCδ) in dopaminergic system 
 
Dopamine (DA) is one of the major neurotransmitters within the basal ganglia system 
and is synthesized and secreted by dopaminergic neurons, which are localized in the substantia 
nigra. Alterations in DA neurotransmission have been implicated in a number of human 
neuropathologies ranging from Parkinson’s disease to attention deficit disorder, schizophrenia 
to drug abuse.  The proteins that play a key role in DA synthesis and DA neurotransmission 
are tyrosine hydroxylase (TH), dopamine transporter (DAT), and dopamine receptors.  In 
addition, several other proteins such as α-synuclein, parkin, MAP kinases, 14-3-3, and heat 
shock proteins have all been suggested to play crucial roles in DA synthesis and DA 
neurotransmission.  Investigations into signal transduction mechanisms and potential 
involvement of these molecules in brain disorders have progressed at a breathtaking pace.  
Phosphorylation-dephosphorylation is one of the key mechanisms by which the 
activity of several cell signaling molecules is regulated in vivo.  Studies have shown the 
activities of TH, the rate limiting enzyme in DA synthesis, DAT,, D1/D2-receptors, parkin, 
α-synuclein, and 14-3-3 can be regulated by some or all of various kinases such as PKA, PKC, 
MAP kinases, CAM kinases, and tyrosine kinases. 
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PKC is a multigene family involved in a plethora of cellular signaling cascades and 
divergent biologic functions.  PKCs have been demonstrated to play a role in cell death, 
development, differentiation, homeostasis, migration, contraction, secretion, and immunity.  
PKCδ, a novel PKC isoform, has been implicated in the regulation of cell cycle progression 
and survival.  PKCδ has also been implicated as a tumor suppressor and has been reported to 
positively and negatively regulate apoptotic cell death. Recently, we established that PKCδ 
plays a critical role in dopaminergic degeneration in cell culture and animal models of 
Parkinson’s disease. The specific emphasis of this chapter will be to review the role of PKC in 
the survival of DA neurons and in DA neurotransmission.  
Protein Kinase C  
Protein kinase C (PKC) is a ubiquitous enzyme originally described as a Ca2+-activated, 
phospholipid-dependent serine-threonine protein kinase. PKCs are activated by GPCRs, 
tyrosine kinases, and by non-receptor-mediated signaling cascades. Molecular cloning and 
biochemical analysis have revealed the existence of 12 isoforms (Fig. 1.), which are classified 
into three distinct sub-family groups based on their activation patterns, namely, conventional 
or classical PKC (cPKC), novel PKC (nPKC), and atypical PKC (aPKC) (Gschwendt, 1999; 
Dempsey et al., 2000; Maher, 2001; Kanthasamy et al., 2003).   
 
 
 
 
 
 
 
  
 
(Kikkawa et al., 2002) 
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PKCα, βI, βII, and γ are members of the conventional PKC family and require calcium, 
phosphatidylserine, and diacylglycerol (DAG) for their activation, whereas members of the 
novel PKC family, PKCδ, ε, η, θ, and μ, are activated by phosphatidylserine and DAG and do 
not require calcium for activation. On the other hand, the members of the atypical family, 
PKCζ and λ(ι), require phosphatidylserine but not calcium or DAG for their activation. The 
conventional PKCs are made up of four conserved (C1–C4) and five variable regions (V1–V5). 
The C1 region contains cysteine-rich zinc finger-like motifs, is immediately preceded by an 
autoinhibitory pseudosubstrate sequence, and contains the recognition site for 
phosphatidylserine, DAG, and phorbol ester. The C2 region of some PKC isoforms is rich in 
acidic residues and binds Ca2+. The C3 and C4 regions contain the ATP and substrate-binding 
sites, respectively.  The novel PKC isoforms lack the C2 region and therefore do not require 
Ca2+ for activation. The atypical PKCs (aPKC), ζ and λ/ι, have only one cysteine-rich zinc 
finger-like motif and are dependent on phosphatidylserine, but are unaffected by DAG, 
phorbol esters, or Ca2+. 
Protein Kinase C-delta  
Protein kinase Cδ (PKCδ), a member of the novel PKC family, is a widely expressed 
PKC isoform in mammalian tissues and was first isolated from the rat cDNA library 
(Kanthasamy et al., 2003).  PKCδ is ubiquitously expressed in most tissues and cell types 
(Leibersperger et al., 1991; Wetsel et al., 1992).  A high expression level of PKCδ was found 
in murine epidermis, placenta, uterus, brain, lung, and kidney (Leibersperger et al., 1991).  
PKCδ contains N-terminal regulatory and C-terminal catalytic fragments connected by a hinge 
region harboring the caspase-3 recognition and cleavage motif (Fig. 2.).  The regulatory 
fragment contains the C1 domain that confers the binding for lipid molecules (diacylglycerol, 
DAG or phorbol 12-myristate 13-acetate, TPA) and the C2-like domain that lacks the Ca2+ 
binding capacity.  The regulatory fragment also contains pseudosubstrate that binds to the 
catalytic site in the tertiary structure and keeps the kinase inactivated. 
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                                               (Nishizuka et al., 1992) 
PKCδ activation mechanisms:  
A variety of stimuli including reactive oxygen species (Konishi et al., 2001; 
Majumder et al., 2001), chemicals (Reyland et al., 1999; Anantharam et al., 2002), ultraviolet 
radiation (Chen et al., 1999), growth factors (Denning et al., 1996), and cytokines (Carpenter 
et al., 2002) can activate PKCδ.  At least three distinct activation mechanisms have been 
reported for PKCδ to date:  a) membrane translocation, b) proteolytic cleavage, and c) 
tyrosine phosphorylation.  
Membrane translocation: PKCδ is primarily activated by translocation to the plasma 
membrane upon stimulation with the lipid signaling molecules phosphatidyl serine (PS), 
diacylglycerol (DAG), or phorbol ester (TPA). The lipid signaling molecules bind to the 
cysteine-rich zinc-finger like domain (C1) present in the regulatory subunit and expose the 
catalytic domain, allowing substrates to bind to the site.  Subsequent to membrane 
translocation and upon exposure of the catalytic site, the PKCδ kinase activity is regulated by 
many upstream serine-threonine kinases, primarily via phosphorylation of Thr-505, Ser-643, 
and Ser-662 present in the catalytic subunit.  These ser/thr residues have also been 
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demonstrated to be autophosphorylated, thus enhancing the catalytic activity when PKCδ is 
in a low activity form (Le Good et al., 1998).  Furthermore, recent studies have shown that, 
in addition to the plasma membrane, PKCδ also translocates to the nucleus, mitochondria, 
cytosol, and other subcellular organelles.  
Tyrosine phosphorylation: Tyrosine phosphorylation of PKCδ has been reported to 
either increase or decrease the kinase activity, depending on the type of cellular stimulation.  
Some of the non-receptor tyrosine kinases that phosphorylate PKCδ during H2O2 treatment 
are Src (Haendeler et al., 2003), Lck (Hardwick and Sefton, 1997) and Syk (Takada et al., 
2003).  Several studies have reported the phosphorylation of tyrosine residues Y52 and 
Y187 in the N-terminus of the protein, Y512 and Y523 in the C-terminus, and Y311 in the 
intermediate hinge region, which connects the regulatory and catalytic domain (Blake et al., 
1999; Kanthasamy et al., 2003).  Konishi et al. (2001) demonstrated that H2O2 treatment 
induces the phosphorylation of PKCδ at various tyrosine residues including Y311, Y332, and 
Y512, but phosphorylation at Y311 is critical for initiation of PKCδ catalytic activity in COS 
cells.  Y311 and Y332 phosphorylated PKCδ  recovered from H　 2O2-treated cells has been 
found to be constitutively active and independent of DAG (Konishi et al., 1997; Konishi et 
al., 2001). Prooxidant etoposide has also been shown to induce PKCδ tyrosine 
phosphorylation at Y311 in C6 glial cells. Recently, using pharmacological and genetic tools, 
we demonstrated that phosphorylation of PKCδ at Y311 precedes and is essential for 
caspase-3-dependent proteolytic activation.  Since Y311 is in close proximity to the 
caspase-3 cleavage site 324DIPD327, Y311 phosphorylation may cause conformational 
change to expose the caspase cleavage site.   In this study we demonstrated that the p60src 
peptide inhibitor, tyrosine specific kinase inhibitor peptide (TSKI), significantly blocked 
H2O2-induced PKCδ Y311 phosphorylation, cleavage, and kinase activity, suggesting that 
p60src may be an upstream kinase responsible for the Tyr-311 phosphorylation in 
dopaminergic cells.  In addition, we also demonstrated dopaminergic neuronal cells 
expressing tyrosine phosphorylation defective PKCδY311F mutant also prevented H2O2 and 
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MPP+-induced PKCδ cleavage and activation of PKCδ. Our studies clearly demonstrated that 
Y311 phosphorylation is essential for oxidative-stress mediated proteolytic activation of 
PKCδ and neuronal apoptosis.  On the other hand, Okhrimenko et al. (2005) demonstrated 
that phosphorylation of PKCδ on Y155 was essential for TRIAL induced proteolytic 
cleavage of PKCδ and subsequent translocation to ER to exert its antiapoptotic effect in 
A172 glioma cells.  
Caspase-3-dependent proteolytic cleavage of PKCδ: In addition to plasma membrane 
translocation, several studies have demonstrated a novel form of PKCδ activation in which 
the kinase is proteolytically cleaved by caspase-3.  Caspase-3 cleaves PKCδ adjacent to the 
Asp 327 at the caspase-3 recognition site DIPD↓N to yield 41-kDa catalytically active and 
38-kDa regulatory PKCδ fragments, resulting in permanent dissociation of the regulatory 
subunit from the catalytic subunit for persistent kinase activity. PKCδ mutants, in which the 
aspartate residue at position 327 has been mutated to an alanine residue, have been shown to 
be caspase-3 cleavage resistant.  The proteolytic activation of PKCδ depends upon the type 
of cell and form of stimulation (Brodie and Blumberg, 2003; Kanthasamy et al., 2003). Some 
of the apoptotic inducers used in non-neuronal cells are etoposide, aplidin, mitomycin, and 
UV radiation.  Recently, using pharmacological and genetic tools, we characterized the role 
of proteolytic activation of PKCδ in neuronal apoptosis.  
Proapoptotic role of PKCδ in dopaminergic cell death: 
PKCs play an important role in CNS function and pathology (Messing et al., 1991; 
Aronowski et al., 2000; Dempsey et al., 2000; Schechtman and Mochly-Rosen, 2001; Raval 
et al., 2003). PKCδ has been implicated in cell differentiation, secretion, and in programmed 
cell death (Cross et al., 2000; Kikkawa et al., 2002; Kaul et al., 2003). PKCδ is expressed in 
brain tissues and its level increases with age (Goldberg and Steinberg, 1996). The regional 
distribution of PKCδ in the CNS has not been studied in detail.  Previous studies have 
shown PKCδ expression in the cerebellum, thalamus, septal nuclei, and purkinje cells in the 
posterior cerebellum (Barmack et al., 2000; Naik et al., 2000). We observed the highest level 
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of PKCδ expression in the substantia nigra as compared to other brain regions in both rat and 
mouse brain (Yang et al., 2004).   
Recently, we showed that caspase-3 dependent proteolytic cleavage of PKCδ 
mediates apoptotic cell death induced by various dopaminergic neurotoxins (MMT, Mn, 
dieldrin, MPP+ and 6-OHDA) and proteasomal inhibitors (MG-132) in immortalized 
mesencephalic clonal neuronal cells (N27), primary mesencephalic cultures, and in intact 
animals. We also noted that the oxidative stress inducer H2O2 can directly activate PKCδ via 
proteolytic cleavage.  Interestingly, neither translocation of PKCδ to the plasma membrane 
nor the cleavage of other isoforms including PKCα, PKCβI, and PKCβII were noted during 
dopaminergic toxins treatment, demonstrating the specificity of PKCδ proteolytic activation 
in the induction of apoptosis in dopaminergic neurons.  Pharmacological inhibitors directed 
against ROS, MPT pore, caspase-9, caspase-3, and non-receptor tyrosine kinases 
significantly blocked toxin induced proteolytic activation of PKCδ and dopaminergic cell 
death.  Subsequently, we also showed that overexpression of loss of function dominant 
negative mutant PKCδD327A (caspase-cleavage resistant), PKCδK376R (kinase inactive), and 
PKCδY311F (phosphorylation defective) proteins attenuate dopaminergic toxin induced 
apoptotic cell death (Kaul et al., 2003; Kitazawa et al., 2005; Anantharam et al., 2004; Kaul 
et al., 2005; Latchoumycandane et al., 2005). The unequivocal role of PKCδ in mediating 
neuronal apoptosis was demonstrated in RNAi studies, where suppression of PKCδ 
expression by small interfering RNA (siRNA) prevented MPTP and 6-OHDA induced 
dopaminergic degeneration in N27 cells, primary mesencephalic cultures, and in the 
substantia nigra of animals.   Very recently, we demonstrated that overexpression of the 
mitochondrial antiapoptotic protein Bcl-2 attenuates neurotoxin-induced PKCδ cleavage, 
indicating that mitochondrial-dependent proapoptotic factors can influence the proteolytic 
activation of PKCδ (Kitazawa et al., 2005).  In addition to the proapoptotic role, we also 
observed PKCδ amplified apoptotic signaling via positive feedback activation of the caspase 
cascade.  Thus, the dual role of PKCδ as a mediator and amplifier of apoptosis may be 
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important in dopaminergic degeneration observed in the pathogenesis of PD.  Thus, 
identifying PKCδ-interacting proteins may help elucidate the role of PKCδ in dopaminergic 
neurotransmission.    
Diversity of PKC functions: 
Recent studies have demonstrated distinct functions among PKC isoforms.  The 
similarity in enzymatic properties of the PKC catalytic domain alone cannot explain the 
diverse cellular functions of the different PKC isoforms.  Apart from different activation, 
only the subcellular distribution of the activated PKCs can explain the diverse functions. 
Functional interactions between PKCs and a wide range of cell signaling proteins enable 
PKCs to carry out a wide variety of different cellular tasks.  Studies have shown subcellular 
localization of PKCs in the cell changes dramatically upon cellular activation.  Activated 
PKCs can translocate to the different subcellular organelles, such as mitochondria, nucleus, 
plasma membrane, and ER, which is mediated by scaffold proteins termed receptor for 
activated c kinase or RACKs.  Translocation to different subcellular organelles enables 
PKCs to be in close proximity and regulate the activity of its substrates.  Translocation to 
various subcellular organelles also enables PKC to be regulated by other signaling proteins. 
Among the various PKC isoforms, only PKCδ has the greatest flexibility to affect multiple 
cellular functions because its subcellular localization is finely regulated by phosphorylation 
and proteolytic activation and may explain in part both the protective and detrimental 
function of PKCδ.  At a molecular level, the function of PKC interacting proteins can be 
classified into four different groups: a) Upstream activators; b) Intracellular compartments; c) 
Substrates;   d) Signaling proteins. Some of the protein-protein interactions that occur 
between PKCδ and proteins associated DA metabolism, DA synthesis, and DA 
neurotransmission are described below. 
Protein kinase C regulates tyrosine hydroxylase activity and phosphorylation 
Tyrosine hydroxylase (TH) is the initial and rate-limiting step in the biosynthesis of 
catecholamines such as dopamine and norepinephrine.  TH catalyzes the hydroxylation of 
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L-tyrosine to L-DOPA, which is then converted to dopamine (DA) and epinephrine by DOPA 
decarboxylase.  In addition to regulation by feedback inhibition by catecholamines, allosteric 
activation by heparin, phospholipids, polyanions, and RNA, the activity of this rate-limiting 
enzyme is also regulated by the phosphorylation-dephosphorylation reaction.  TH activation 
by phosphorylation is the primary mechanism responsible for the maintenance of DA levels in 
tissues after DA secretion. PKC can regulate TH activity at both transcriptional and 
post-translational levels in dopaminergic cell lines (Campbell et al., 1986).  Studies have 
shown PKC activator TPA can induce increases in TH enzymatic activity at the enzyme level, 
and TPA treatment can increase TH gene transcription in PC12 cells (Wolf and Roth, 1990).  
Recently, Lopez-Toledano et al. (2004) reported that TPA treatment promoted the generation 
of TH-positive neurons in neural stem cells, and the generation of TH-positive cells was 
suppressed in the presence of the PKC inhibitor staurosporine (Lopez-Toledano et al., 2004). 
Phosphorylation /dephosphorylation of TH represents an important mechanism in the 
regulation of the enzymatic activity. Phosphorylation mediated by protein kinases results in 
 
 
 
 
 
 
 
activation of TH.  The regulation of TH activity by phosphorylation in vitro has been 
extensively investigated (Haycock and Haycock, 1991). TH can be phosphorylated at serine 
residues at positions 8, 19, 31 and 40 present in the N-terminal half by a variety of protein 
kinases (Fig. 3). Studies have shown that both PKC as well PKA can directly phosphorylate 
TH at ser31 and ser40 and that phosphorylation by PKA plays the predominant role in vivo 
(Haycock, 1990). Purified protein kinase C can only phosphorylate and activate partially 
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purified TH at ser40 (Albert et al., 1984; Haycock and Haycock, 1991; Haycock and Wakade, 
1992). PKC as well as PKA phosphorylate TH at the same rate and similar kinetics.  
Studies have also shown phosphorylation by PKA results in activation of the TH 
enzymatic activity, whereas phosphorylation by PKC resulted in a marginal increase in TH 
activity (Funakoshi et al., 1991). Recently, we observed high levels of the PKC isoform 
PKCδ in the substantia nigra (SN) in murine and human brain samples. Confocal 
microscopic analysis revealed co-localization of PKCδ and TH in the substantia nigra of rat 
brain and postmortem human brain (Zhang et al., 2007). These results suggest that PKC-TH 
interactions may play a critical role in dopaminergic function and are currently under 
investigation in our laboratory.    
Protein kinase C modulates phosphorylation and trafficking of dopamine 
transporter  
The dopamine transporter (DAT) plays a key role in terminating dopaminergic 
neurotransmission by regulating the availability of DA in the synapse. The primary function 
of DAT is to reuptake DA into the presynaptic neurons after its release and thus clear DA 
from the synaptic space. The activity of DAT and its ability to clear DA is acutely controlled 
by PKC.  PKC mediated phosphorylation of DAT results in reduced transporter activity, 
suggesting PKC negatively modulates DAT activity (Huff et al., 1997; Zhang et al., 1998; Lin 
et al., 2003). DAT contains multiple potential ser/thr phosphorylation sites at the N terminus 
(Foster et al., 2002; Granas et al., 2003; Lin et al., 2003). The PKC activator TPA increased 
DAT phosphorylation and reduced its transport activity by affecting Vmax, as determined by 
[3H]DA uptake. Together, these data suggest that DAT phosphorylation through the PKC 
pathway can lead to decreased transporter function and expression (Huff et al., 1997; Zhu et 
al., 1997; Zhang et al., 1998; Lin et al., 2003).  Regulation of DAT by PKC is assumed to be 
due to direct phosphorylation of DAT protein by PKC, according to the existence of 
consensus amino acid sequences for PKC phosphorylation. But when all putative PKC 
phosphorylation sites are eliminated, in PKC null mutant hDAT, PKC activator and inhibitor 
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still affected regulation of DAT function, which suggests that PKC may regulate DAT 
function in an indirect way through a mediator protein or activation of a clathrin-mediated 
pathway (Chang et al., 2001). To determine which PKC isoforms are capable of regulating 
DAT activity, Doolen and Zahniser studied the effect of activating or inhibiting different PKC 
isoforms on DAT function in Xenopus laevis oocytes expressing human (h)DAT. Activators 
of both conventional PKCs and novel PKCs significantly inhibited DAT-associated transport 
currents, and this effect was reversed by pharmacological inhibitors directed against PKCα, β, 
γ and δ but not by PKCε translocation inhibitor. Their data suggest that TPA regulated DAT 
activity is primarily mediated by conventional PKCs and PKCδ (Doolen and Zahniser, 2002).  
In another study, PKCβ(II) was physically associated with DAT and was responsible for 
increased DA uptake into the rat striatum (Johnson et al., 2005). In addition to negatively 
regulating transporter activity of DAT, PKC also induces down regulation of DAT via the 
clathrin mediated endocytic pathway. Since PKC can down regulate 
phosphorylation-defective DAT mutants, PKC mediated down-regulation and endocytosis 
occur independent of phosphorylation, possibly via other DAT associated proteins.  Studies 
with PC12 cells stably transfected with human DAT cDNA revealed that TPA treatment 
decreased transporter capacity and the number of DAT molecules on the cell surface 
(Melikian and Buckley, 1999).  Immunostaining studies showed that [3H]DA uptake was 
reduced by PKC activation because of rapid sequestration/internalization of hDAT protein 
from the cell surface, while the increased DA uptake by PKC inhibition was associated with 
the recruitment of internalized or intracellular transporters to the plasma membrane (Pristupa 
et al., 1998).  Therefore, PKC activation accelerates DAT endocytosis, reduces recycling, 
and does not involve degradation (Melikian and Buckley, 1999; Loder and Melikian, 2003).  
Subsequently, a PKC-sensitive autonomous endocytic signal was identified in the C terminus 
of DAT.  The C-terminal residues 587−596 in the FREKLAYAIA region are necessary and 
sufficient to drive constitutive and protein kinase C-regulated DAT internalization in 
dopaminergic cells (Holton et al., 2005).  In COS7 cells expressing the truncated hDAT 
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lacking the first 22 N-terminal residues, PKC activation still induced transport function and 
internalization, suggesting that phosphorylation of hDAT was not critical for both 
receptor-mediated or PKC-mediated internalization of the hDAT (Granas et al., 2003).  Thus, 
PKC can negatively regulate DAT function by direct phosphorylation as well as by a 
combination of increased internalization and decreased recycling (Fig. 4).  Dysregulation of 
synaptic DA levels caused by altering DAT function is associated with many neurological 
disorders, including depression. 
 
 
 
 
 
 
 
 
 
 
Although the cellular and molecular mechanisms leading to PKC-DAT interactions are still 
unclear, the regulation of DAT activity by PKC is presumed to function as a mechanism for 
fine-tuning DA levels under diverse physiological conditions. 
PKCs and Dopamine receptor cell signaling: 
Dopamine receptors are a family of G-protein coupled receptors that are activated by 
dopamine and are classified into two subfamilies: the D1-receptor group (D1 and D5) and the 
D2-receptor group (D2, D3, and D4).   These receptors are highly expressed in the central 
nervous system and in the pituitary gland.  Upon binding to dopamine, D1 receptors 
stimulate adenylate cyclase activation via Gαs, which then activates PKA mediated signal 
transduction events.  Studies have also shown D1 receptor subtype coupling to other 
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heterotrimeric G proteins to Gαo and Gαq and D5 receptor subtype to Gαz.  D1 receptor 
activation has also been shown to result in the activation of MAP kinases such as ERK and 
JNK (Barbieri et al., 2004; Chen et al., 2004; Shishodia et al., 2004; Chan et al., 2005). In 
normotensive animals, dopamine, via D1-like receptors, mediates decreased sodium 
excretion transport in the renal proximal tubule via stimulation of PKC activity at 15 min; 
however, at 60 min there was a decrease in PKCδ and PKCζ  activities associated with an 
increase in sodium excretion (Nowicki et al., 2000). In this study, dopamine induced 
translocation of PKCα and PKCδ to the plasma membrane in the renal epithelial cell line as 
early as within 20 seconds of stimulation. The translocation was suggested to be an important 
event in the dopamine induced PKC mediated regulation of ion pumps, channels, and other 
transporters in renal cells. The antioxidant effect of Tempol (superoxidedismutase mimetic) 
in Zuker rats was mediated by decreased D1 receptor phosphorylation and reduced PKC 
activity (Marwaha et al., 2006).  Interaction between metabotropic glutamate receptors 
(mGluR1/5) and D1 receptor subclass via enhanced phosphorylation of ERK2 in striatal 
medium spiny neurons was mediated by PKC (Lania et al., 2003).  
Unlike the D1-receptors, activation of D2-receptor subtypes inhibits adenylcylase 
activity and cAMP production via Gαi/o.  Ethanol and other substances of abuse have been 
shown to increase the dopamine levels in the nucleus accumbens (Inoue et al., 2007). Ethanol 
and NPA D2 receptor agonists caused translocation and activation of PKCδ and PKCδ in the 
Chinese hamster kidney cells and in NG 108-15 to the perinucleus and cytoplasm, 
respectively (Yao et al., 2008). Activation of PKC caused the switching of coupling of D2 
receptors from inhibition of adenyl cyclase towards facilitation of arachidonic acid release by 
phosphorylating components of the receptor-Gαi/o protein complex. Therefore, PKC 
activation results in the amplification of D2 receptor signaling via the arachidonic acid 
release alongside the inhibition of adenylcylase (Di Marzo et al., 1993).  
In dopamine-producing PC12 cells, D2 receptor activation protects against 
H2O2-induced apoptotic cell death.  The anti-apoptotic effect of D2-receptors was mediated 
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by PI-3 kinase/protein kinase B (Akt) via c-Src dependent transactivation of epidermal 
growth factor receptor (EGFR).  In HeLa cells, D2 receptor mediated activation of NfκB via 
phosphorylation and activation of cSrc tyrosine kinase at Y418 (Yang et al., 2003). Further, 
TPA treatment resulted in a 3-fold increase in D2-receptor phosphorylation in D2-receptor 
transfected HEK293T cells.  Phosphorylation of D2 receptor on multiple serine/threonine 
sites results in the internalization of the receptor (Morris et al., 2007). Humans have two 
isoforms of D2 receptors – D2L (long form) and D2S (short form). In D2L and D2S 
transfected Ltk-fibroblast cells, TPA treatment blocked D2S-mediated increases in cytosolic 
free Ca2+, whereas D2L-mediated increases in cytosolic Ca2+ were only partially blocked, 
suggesting differential regulation by PKC (Morris et al., 2007). Therefore, PKCs can regulate 
the D1/D2 receptor activity, surface expression, and down-stream cell signaling.   
α-Synuclein 
α-Synuclein is a neuronal protein thought to be central in the pathogenesis of 
Parkinson's disease (PD) because it comprises the fibrillar core of Lewy bodies, one of the 
histologically defining lesions of PD, and because mutations in α-synuclein cause autosomal 
dominant PD. α-Synuclein is an abundant pre-synaptic protein belonging to the family of 
proteins that include α-, β, γ synuclein and synoretin ( Jakes et al., 1994; Goedert, 2001). 
Although the physiological role of α-synuclein is still unclear, it has been suggested to play a 
role in synaptic plasticity, memory development, neurotransmitter release, and axonal 
transport (George et al., 1995; Abeliovich et al., 2000; Jensen and Gai, 2001; Chen et al., 2002). 
Because of its open random coiled structure, α-synuclein has been suggested to also function 
as a chaperone (Weinreb et al., 1996) and shares physical and functional homology with the 
14-3-3 protein chaperone family (Ostrerova et al., 1999). Abnormal accumulation and 
aggregation of α-synuclein have been implicated in the dysfunction, degeneration, and 
ultimate death of dopaminergic neurons in PD (Spillantini and Goedert, 2000; Wakabayashi et 
al., 2002).  Recent studies have shown physical and/or functional interactions between 
α-synuclein and several proteins associated with DA metabolism and survival of dopaminergic 
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neurons.  These proteins include TH, 14-3-3, PP2A, PLD2, Fyn, Src, Parkin, DAT, ERK, 
PI3-Akt kinase, cytochrome C, cytochrome C oxidase (COX), BAD, calmodulin, histones, 
GSK3, and caspase-3. 
Recently, we demonstrated that 1-methyl-4-phenylpyridinium (MPP+) induces 
caspase-3-dependent proteolytic activation of PKCδ, which subsequently contributes to 
neuronal apoptotic cell death in mesencephalic dopaminergic neuronal cells (Kaul et al., 
2003; Yang et al., 2004).  Subsequently, we also showed physical and functional interaction 
between PKCδ, α-synuclein, and BAD in an in vitro model of Parkinson’s disease (Kaul et 
al., 2003; Kaul et al., 2005; Yang et al., 2004). In that study, we explored whether the 
α-synuclein-PKCδ interaction modulates MPP+-induced apoptotic cell death in 
mesencephalic dopaminergic neuronal cells (N27). Over-expression of wild-type human 
α-synuclein in N27 cells attenuated MPP+-induced cytotoxicity, mitochondrial cytochrome c 
release, caspase-3 activation, proteolytic activation of PKCδ, and DNA fragmentation 
without affecting ROS production. On the contrary, expression of the mutant human 
α-synucleinA53T did not attenuate, but rather exacerbated, the MPP+-induced PKCδ activation 
under similar conditions.  Similarly, wild-type human α-synuclein expression also rescued 
mesencephalic dopaminergic neuronal cells from MPP+-induced apoptotic cell death, while 
α-synucleinA53T exacerbated the MPP+-induced DNA fragmentation. 
Co-immunoprecipitation studies revealed that α-synuclein interacted with the pro-apoptotic 
proteins PKCδ (PKC isozyme) and BAD (Bcl-2 related), and their association is further 
strengthened after stimulation with MPP+.  Alternatively, no association was observed 
between α-synuclein and Bcl-2 or between α-synuclein and PKCα, suggesting that 
α-synuclein preferentially associates with the Bcl-2 or PKC family members.  We also 
observed that the interaction between PKCδ and α-synuclein does not involve direct 
phosphorylation.  On the other hand, physical association of α-synuclein with PKCδ 
prevents caspase-3 dependent proteolytic activation of PKCδ.  The putative contributions of 
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α-synuclein-PKCδ interactions to neurodegenerative processes in PD merit further 
investigation. 
14-3-3 proteins: 
14-3-3 proteins (28-33 kDa) are abundantly expressed in the brain and participate in 
controlling cell cycle, cell growth, differentiation, survival, cell adhesion, transcription, 
apoptosis, migration, and spreading.  14-3-3 Proteins have been identified as phosphoserine/ 
phosphothreonine-binding proteins and >200 binding partners have been identified to date.  
14-3-3 targets are found in all subcellular compartments which include transcription factors, 
biosynthetic enzymes, ion channels, cytoskeletal proteins, signaling molecules, apoptosis 
factors, and tumor suppressors.  14-3-3 binding has been shown to alter the subcellular 
localization, stability, phosphorylation state, activity and/or molecular interactions, and 
function as adaptor molecules to stimulate protein–protein interaction of target proteins.  
There are at least seven known members of the 14-3-3 family.  14-3-3 proteins have recently 
been implicated in several neurodegenerative disorders including ALS, Prion associated 
diseases, Alzheimer's, Huntington, and Parkinson's diseases. 
Immunohistochemical investigation of Lewy bodies showed intense positive 14-3-3 
staining in PD and DLBD post-mortem brains (Kawamoto et al., 2002). Recent studies 
indicate that only ε, γ, ζ and θ, but not β, η and σ 14-3-3 isotypes, colocalized with Lewy bodies 
in PD. In DA neurons, 14-3-3 play a critical role in DA synthesis and metabolism by binding to 
phospho-TH.  Binding of 14-3-3 proteins to TH is required for its optimal activation by 
phosphorylation, and prevention of TH dephosphorylation leads to a prolonged stimulation of 
TH activity (Ichimura et al., 1988). On the other hand, α-synuclein, one of the main 
components of Lewy bodies, binds to dephosphorylated TH and prevents phosphorylation, 
leading to prolonged inhibition of TH activity (Perez et al., 2002).   
Several PKCs, including PKCα, PKCβ, PKCε, PKCζ and PKCλ, have been 
demonstrated to bind to 14-3-3 proteins in an isoform-specific manner.  Very recently, a 
sphingosine-dependent protein kinase was shown to phosphorylate β-, η- and ζ- isoforms of 
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14-3-3 at positions ser60, ser59, and ser 58, respectively (Megidish et al., 1998).  The 
sphingosine-dependent protein kinase was later identified to be the proteolytically cleaved 
catalytic fragment of PKCδ. It is postulated that dimer formation of 14-3-3 proteins is required 
for binding to its target proteins. PKCδ phosphorylation of 14-3-3 inhibits 14-3-3 dimer 
formation and prevents it from binding to its partners. The 14-3-3 family of proteins has been 
shown to interact with several proteins associated with cell signaling and apoptotic cell death, 
including α-synuclein, BAD, BAX, histones, HDAC, PP2A, Stat, MAP kinases, heat shock 
proteins and ubiquitin proteasomal systems associated proteins.  We postulate that 
dopaminergic degeneration during PD phosphorylation of 14-3-3 proteins by proteolytically 
activated PKCδ may prevent 14-3-3 binding to TH, resulting in decreased DA synthesis, and 
also prevent 14-3-3 binding to BAD/BAX, allowing them to freely translocate to mitochondria 
to promote their proapoptic effect.  Although PKC-14-3-3 interactions have not been 
established in DA neurons in the nigro-striatal systems, the isotype-specific interaction of PKC 
isoforms with 14-3-3 isoforms may play a crucial role in the survival of dopaminergic neurons 
in healthy individuals as well as during dopaminergic degeneration observed in PD.  
Parkin:  
Mutations in the parkin gene were recently discovered to cause autosomal recessive 
juvenile Parkinsonism.  Parkin mutations have been recognized as the most common cause 
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of hereditary PD and a possible risk factor for idiopathic PD. The parkin gene comprises 12 
exons, codes for a 465-amino acid 52-kDa protein, and is most prominently expressed in 
muscle and throughout the brain.  Parkin functions in the ubiquitin-proteasome system as an 
E3 ubiquitin-protein ligase together with the E2 ubiquitin conjugating co-enzymes. Because 
this function appears to be defective in patients with parkin mutations, the exact molecular 
mechanisms by which parkin dysfunction causes PD remain to be elucidated.  
Immunohistochemical investigation of Lewy bodies showed intense positive parkin staining 
in PD and DLBD post-mortem brains (Nakamura et al., 2006). Recent studies indicate that 
parkin colocalized with α-synuclein in Lewy bodies (Choi et al., 2001).  Parkin 
overexpression was also shown to rescue dopaminergic neurons from oxidative 
stress-induced cell death.  Regulation of parkin activity by nitrosylation results in the 
inhibition of its ubiquitin ligase activity (Chung et al., 2004). Recently, parkin activity was 
also shown to be regulated by casein kinase-1, PKA, and PKC, resulting in decreased ligase 
activity (Sato et al., 2006).  Unfolded protein stress mediated by proteasomal inhibition or 
ER stress, but not oxidative stress, reduced the overall phosphorylation of parkin.  Therefore, 
regulation of parkin phosphorylation by PKC may contribute to the survival of dopaminergic 
neurons.  
Mitogen Activated Protein Kinases (MAPKs) 
Transduction pathways in eukaryotic cells integrate diverse extracellular signals, and 
regulate complex biological responses such as growth, differentiation, and death. One group 
of proline-directed Ser/Thr protein kinases, the mitogen-activated protein kinases (MAPKs), 
plays a central role in these signaling pathways. MAPKs are members of a three-kinase 
phosphorylated system composed of the MAPK, MAPK kinase (MKK), and MAPK kinase 
kinase (MKKK).  MKKKs phosphorylate and activate MKKs, which in turn phosphorylate 
and activate MAPKs.   The extracellular signal regulated kinases (ERKs), c-Jun N-terminal 
kinases (JNKs), and the p38 kinases are MAPKs family members. Several MAP kinases have 
been implicated in neurodegenerative disorders, in particular the c-Jun N-terminal kinase 
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(JNK) pathway in Parkinson's disease.  In mice, adenoviral gene transfer of the JNK binding 
domain of JNK-interacting protein-1 (a scaffold protein and inhibitor of JNK) inhibited this 
cascade downstream of MKK4 phosphorylation, and blocked JNK, c-Jun, and caspase 
activation, as well as the death of dopaminergic neurons and the loss of catecholamines in the 
striatum (Xia et al., 2001).  Direct blockade of JNK with specific inhibitor SP-600125 
protects dopaminergic neurons both from MPP+-induced neuronal apoptosis in vitro and in 
the MPTP Parkinson's disease model. Immunohistochemical investigations revealed the 
presence of all three MAPKs, ERK, JNK and P38 α-synuclein, in Lewy bodies of PD and 
DLBD post-mortem brains (Ferrer et al., 2001). Some of the MAP kinase family members 
have also been shown to physically and functionally interact with α-synuclein. JNK 
inhibitors have been or are currently being tested in clinical trials to decrease the progression 
of PD.  
PKC isoforms, including PKCα, PKCδ, and PKCε, regulate activity of ERK, JNK, and p38 
kinases directly or via upstream MAP kinases, RAS, RAC and the RAF pathway. Inhibition 
or depletion of PKCδ protects cells from apoptotic cell death mediated via these MAP kinase 
pathways (García-Fernández et al., 2002).  Some studies have shown a physical and 
functional interaction between PKCδ and several MAP kinase family members, including 
stress-activated protein kinase, RAC, MEKK1, and MEKK4 (Bogoyevitch et al., 1995; Clerk 
et al., 1998).   Therefore, PKCδ-MAP kinase interactions may be critical to DA 
homeostasis and dopaminergic neurotransmission. 
Non-receptor tyrosine kinases (NTKs) 
Protein-tyrosine phosphorylation by receptor and non-receptor tyrosine kinases is 
thought to be important in regulating synaptic function and plasticity. Unlike receptor 
tyrosine kinases, non-receptor tyrosine kinases are ubiquitously expressed in all metazoan 
cells and are oncogenic once they are activated. Non-receptor tyrosine kinases were first 
discovered in Rous Sarcoma virus; therefore, they are also referred to as Src tyrosine kinases.  
Molecular cloning and biochemical analysis have revealed the existence of nine  members: 
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Src, Fyn, Yes, Fgr, Lyn, Hck, Blk, and Yrk.. Src tyrosine kinases mediate cell signaling in 
cell growth, differentiation, and proliferation (Brown and Cooper, 1996).   Several 
members of the Src tyrosine kinases (Src, Fyn, Lyn, c-Abl, PYK2, Lck, and growth factor 
receptors) have been shown to regulate the PKCδ activity (Li et al., 1994).  Regulation of 
PKCδ activity by tyrosine phosphorylation is particularly important because PKCδ is most 
efficiently tyrosine-phosphorylated when compared to other PKC isoforms.  Further, PKCδ 
has also been shown to phosphorylate Src and Fyn tyrosine kinases.  
Co-immunoprecipitation studies revealed PKCδ to physically associate with several Src 
tyrosine kinases and regulate their activity (Shanmugam et al., 1998). Immunohistochemical 
investigations also revealed colocalization PKCδ with Src tyrosine kinases (Betty et al., 
2001). Studies have also shown Src kinase family members such as Fyn and Src to 
phosphorylate α-synuclein (Ellis et al., 2001). Recently, it was shown that activation of 
Pyk2/RAFTK1 and Pyk2/RAFTK, a non receptor protein-tyrosine kinase that is expressed to 
a high degree in human brain, inhibited α-synuclein phosphorylation in response to cell stress 
(Nakamura et al., 2002).  In addition, Dunah et al. (2004) reported that dopamine receptor 
(D1)-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors required Fyn 
protein tyrosine kinase.  Thus, functional interactions between PKCδ, TH, α-synuclein, 
NMDA receptors, and NTKs may be crucial for normal DA metabolism and 
neurotransmission. 
Heat Shock Proteins (HSP) 
HSPs are chaperone proteins which function to assist a nascent polypeptide chain to 
attain a functional conformation as a new protein and then to assist the protein’s arrival at the 
site in the cell where the protein carries out its functions. It has become increasingly clear 
that disruption of chaperoning mechanisms contributes to aging and disease. Deficiencies and 
defects in HSPs affect a wide range of neurological disorders including PD. HSPs  are 
encoded in genes that are inducible by heat shock and are classified into high-molecular-mass 
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Hsp (≥100 kD), Hsp90 (81 to 99 kD), Hsp70 (65 to 80 kD), Hsp60 (55 to 64 kD), Hsp40 (35 
to 54 kD), and small Hsp (≤34 kD).  
Immunohistochemical investigations revealed colocalization of Hsp70 and Hsp25 
with α-synuclein in the Lewy bodies of PD and DLBD post-mortem brains (Uryu et al., 
2002).  PCR screening of DNA samples from 274 PD patients and 183 controls revealed an 
A to C mutation at position -110 in the 5' promoter region of Hsp70, suggesting this 
functional polymorphism may render susceptibility to PD (Wu et al., 2004). Recently, Hsp70 
was shown to attenuate alpha-synuclein-induced apoptotic cell death in cell culture and 
animal models of Parkinson's disease (Dedmon et al., 2005).  Adenoviral-mediated Hsp70 
gene transfer inhibited MPTP-induced nigrostriatal degeneration in an animal model of PD 
(Dong et al., 2005).  Recently, Hsp27 was shown to inhibit 6-OHDA-induced apoptosis in 
PC12 cells (Gorman et al., 2005). In this study, 6-OHDA induced the heat shock response, 
leading to increased levels of Hsp25 and Hsp70.  Prior heat shock or overexpression of 
Hsp27 (human homologue of Hsp25) delayed cytochrome C release and caspase activation, 
and reduced the level of apoptosis caused by 6-OHDA, suggesting increased Hsp25 
expression is associated with cell survival. Thus, both Hsp70 and Hsp25 may play a critical 
role in the survival of DA neurons.  
Recently, Lee at al. (2005) demonstrated HSP25 inhibits PKCδ-mediated cell death 
through direct interaction.  Direct binding of HSP25 to the PKCδ V5 region (aa 606-676) 
prevents PKCδ translocation and activation.  To release this inhibitory effect, PKCδ 
phosphorylates Hsp25 at Ser-15 and Ser-86. Phosphorylation of Hsp25 at these residues 
releases it from bound PKCδ.  In another study, PKCδ-Hsp70 interaction was shown to play 
a critical role in cardioprotection in the rat heart (Honma et al., 2002).  PKCδ activation led 
to the phosphorylation and translocation of heat-shock factor 1 (HSF1), and thus promoted 
expression of Hsp72 protein, leading to cardioprotection.  Since Hsp70 and Hsp25 are both 
present in Lewy bodies, PKCδ-HSP interactions may be critical to the pathophysiology 
observed in PD. 
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RACKs:  
The newly discovered class of PKC anchoring proteins called Receptors for Activated 
C-Kinase (RACKs) and caveolins help target the PKC isozymes to the different organelles 
within the cell and facilitate the interactions between the individual PKCs and their substrates 
(Schechtman and Mochly-Rosen, 2001; Chen et al., 2002b).  In 1995, Mochly-Rosen was 
first to propose the name RACK for PKC isozyme-selective anchoring proteins. Because 
RACK proteins can act as scaffolds to bring multiple proteins together in signaling 
complexes, they confer PKC isozymes the specificity of interaction with their substrates.  
RACKs were one of the first identified binding partners for PKCs, but many proteins have 
since been shown to associate physically with PKCs. These PKC-interacting proteins 
(C-KIPs) are classified into four categories. a) Proteins that target PKC to its upstream 
activators. A major function of C-KIPs is to enable the regulation of individual PKC 
isoforms by immediate upstream regulators such as DAG. b) Proteins that direct PKC to 
intracellular compartments. A feature of PKC signaling is that the kinases translocate 
between cellular compartments such as the cytosol, nucleus, mitochondria, ER and 
cytoskeleton. c) Substrates of PKC.  Many C-KIPs are also substrates of PKC (termed 
substrates that interact with C-kinase). Scaffolding proteins such as RACKs and receptors for 
inactive C-kinase also fall into this category because they bring together PKC and its 
substrates. d) Other signaling proteins. A RACK protein that specifically interacts with PKCδ 
but not with other PKC isoforms has recently been identified (Chakraborti  et al., 2005). 
Therefore, RACK-PKCδ interactions probably play a crucial role in the survival of 
dopaminergic neurons and thus merit further investigation. 
Summary: PKCδ is a serine/threonine kinase that plays a key role in growth 
regulation and tissue remodeling. We observed that PKCδ is highly expressed in nigral 
dopaminergic neurons and co-localizes with TH (Zhang et al., 2007). PKCδ negatively 
regulates TH by the PKCδ-PP2A-TH pathway, PKCδ phosphorylates PP2Ac to enhance its 
activity and thereby reduces TH-ser40 phosphorylation and TH activity and ultimately 
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dopamine synthesis. The exact nature of the physical association and dynamic regulation of 
TH, PKCδ, and PP2A are yet to be characterized; however, recent literature provides some 
information regarding this interaction.  PKCδ, TH, or PP2A have been recently shown to 
physically associate with each other, as well as with other putative chaperone proteins such 
as α-synuclein and 14-3-3 (Ostrerova et al., 1999; Kleppe et al., 2001; Srivastava et al., 2002; 
Kjarland et al., 2006).  Recently, Peng et al. (Peng et al., 2005) demonstrated that a 
functional interaction between α-synuclein and PP2A can regulate TH phosphorylation and 
TH activity.  Srivastava et al. reported a physical interaction between PKCδ and PP2A in 
NIH3T3 cells, and that dephosphorylation of PKCδ by PP2A results in its inactivation 
(Srivastava et al., 2002). In our recent study, we showed that α-synuclein interacts with 
PKCδ and regulates its activity following neurotoxic insults (Kaul et al., 2005). Therefore, in 
the dopaminergic system, the physical and functional association between PKCδ, TH, and 
PP2A could be facilitated and/or regulated by chaperone proteins such as α-synuclein (Kaul 
et al., 2005; Peng et al., 2005) and 14-3-3 (Ostrerova et al., 1999; Kleppe et al., 2001; 
Kjarland et al., 2006). Nevertheless, further studies are required in both in vitro and in vivo 
model systems to elucidate the dynamics of physical and functional regulation of PKCδ and 
PP2A in regulation of TH activity. Regulation of TH activity and DA levels is critical for 
normal dopaminergic neurotransmission in the CNS.  Excessive DA production may not 
only alter neurotransmission, but may also contribute to neuronal cell death through 
increased oxidative stress (Hoyt et al., 1997; Luo et al., 1998). In this regard, we wish to 
point out that PKCδ can be activated by at least two independent mechanisms in neuronal 
cells.  These include membrane translocation and caspase-3-dependent proteolytic cleavage 
(Kikkawa et al., 2002; Brodie and Blumberg, 2003; Kanthasamy et al., 2003).  Of the two 
activation mechanisms, PKCδ activated by membrane translocation following tonic 
stimulation by lipid activators, contributes to cell survival and proliferation (Kikkawa et al., 
2002; Kanthasamy et al., 2003; Jackson and Foster, 2004).  As demonstrated in our recent 
studies, another form of activation is caspase-3-dependent proteolytic cleavage of native 
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PKCδ into regulatory and catalytic fragments, resulting in persistent activation during 
exposure to neurotoxic agents such as MPP+, MMT, manganese, or dieldrin (Anantharam et 
al., 2002; Kaul et al., 2003; Latchoumycandane et al., 2005).  This form of proteolytic 
activation contributes to apoptotic cell death of dopaminergic neurons (Kanthasamy et al., 
2003).  The lipid activator TPA induced membrane translocation of native PKCδ, but did 
not induce apoptotic cell death in dopaminergic cell lines (unpublished observations).  
Furthermore, recent studies from our lab and others have shown that, unlike the native 74 
kDa PKCδ, the 41 kDa catalytically active PKCδ fragment, upon proteolytic cleavage, is 
targeted to various sub-cellular organelles including the mitochondria (Majumder et al., 2000) 
and nucleus (DeVries et al., 2002) to activate apoptotic cell death signaling molecules.  
These results suggest that native and cleaved PKCδ have different substrate profiles. 
Activation of PKC causes a decrease in DAT-mediated activity and cell surface 
expression. The activity of biogenic amine and amino acid neurotransmitters is limited by 
presynaptic and astrocytic Na+-dependent transport systems. Their functional importance is 
underscored by the observation that these transporters are the targets of broad classes of 
psychotherapeutic agents, including antidepressants and stimulants. The clearance of 
extracellular dopamine is apparently mediated by a single gene product. The activity and cell 
surface expression of the dopamine transporter (DAT) are decreased in response to PKC 
activation. In a series of studies, activation of PKC was shown to acutely decrease DAT 
activity and increase transporter trafficking of neurotransmitter transporters phosphorylation 
(Huff et al., 1997). Several different groups have reported similar effects of PKC on DAT 
activity and have provided compelling evidence that this effect is associated with 
internalization of the transporter protein in different cellular systems including Xenopus 
oocytes (Zhu et al., 1997; Pristupa et al., 1998; Daniels and Amara 1999; Melikian and 
Buckley 1999). The ultimate fate of internalized transporter, whether it is targeted for 
degradation or recycling to the plasma membrane, may be influenced by factors that have not 
yet been identified. PKC phosphorylates the D2 dopamine receptor (DAR) on multiple sites 
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within two domains of the third intracellular loop. This PKC-mediated phosphorylation of 
the D2 DAR was demonstrated to promote both functional desensitization and internalization 
of the receptor protein via a β-arrestin- and dynamin-dependent pathway. PKC can mediate 
phosphorylation of the D2 DAR, producing novel functional effects. This regulatory event 
appears to be specific for the βI isoform of PKC, although additional isoforms remain to be 
tested.   
Puzzles and future directions:  
PKC-mediated regulation of TH, DAT, dopamine receptor, and other important 
proteins in dopaminergic cells may have important implications in neurological dopaminergic 
system disorders, such as Parkinson’s disease. But most studies investigating the protein 
kinase C family have focused on general PKC, with little data generated on the different PKC 
isoforms, such as PKCδ. A detailed understanding of the cellular actions of individual PKC 
isoforms ultimately will require knowledge of their distinct cellular substrates. PKCδ 
substrates traditionally have been identified using pharmacological strategies (with activators 
or inhibitors) or molecular strategies (involving targeted deletion or overexpression of 
individual PKC isoforms or translocation modifier peptides). Each of these approaches is 
accompanied by its own distinct set of problems. For example, PMA may not strictly report 
PKC actions, since high-affinity DAG/PMA-binding C1 domains have been identified in 
proteins that lack kinase domains (and are unrelated to PKC). The chimaerins (a family of 
Rac GTPase activating proteins), RasGRPs (Ras/Rap1 exchange factors), and Munc13 
isoforms (scaffolding proteins involved in exocytosis) are examples of proteins that bind 
PMA with nanomolar affinity and translocate to membranes in response to PMA. The 
interpretation of studies with PMA can be confounded further by cross-talk between PKCs 
and other members of the extended phorbol ester binding protein family. For example, recent 
studies identified RasGRP3 (a guanine nucleotide exchange factor for Ras) as a binding 
partner and substrate for PKCδ (Brodie et al., 2003). These proteins co-localize to similar 
subcellular compartments and interact functionally (in an as yet poorly understood manner) 
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at the level of downstream signaling pathways such as ERK. Studies with PKC inhibitors can 
be even more problematic, since many commonly used PKC inhibitors lack the requisite 
specificity for PKC. For example, chelerythrine (which has been used widely as a general 
PKC inhibitor) induces apoptosis through a mitochondrial mechanism that is unrelated to 
PKC inhibition; chelerythrine is also reported to inhibit interactions of Bcl-XL with BH3 
(Bcl-2 homology domain 3)-containing proteins such as Bax (Clerk et al., 2001; Chan et al., 
2003; Yamamoto et al., 2001). Rottlerin (which has been touted to be a selective PKCδ 
inhibitor) uncouples mitochondrial respiration from oxidative phosphorylation and exerts 
inhibitory actions in PKCδ−/− cells; some studies even challenge the efficacy of rottlerin as 
an in vitro PKCδ inhibitor (Soltoff et al., 2001; Leitges et al., 2001). Finally, even Ro318220 
and GF109203X (agents considered to be relatively selective PKC inhibitors) are reported to 
inhibit RSK (p90 ribosomal S6 kinase) and p70 S6 kinase (Alessi et al., 1997). These caveats 
emphasize that studies using PKC inhibitors as tools to investigate PKC function must be 
interpreted with caution, and that newer strategies to identify PKCδ targets are imperative. A 
novel chemical genetic approach developed by Shokat and colleagues (Shah et al., 2003) 
represents a very exciting methodological breakthrough that holds tremendous promise for 
the identification of endogenous PKC substrates in future studies. Their approach involves 
engineering the ATP-binding site in a kinase of interest so that it accepts a structurally 
modified γ -32P-labelled ATP analogue with a bulky substitution attached at the N6 position 
[for example N6-(benzyl)ATP or N6-(phenethyl)ATP]. Since the chemically modified γ 
-32P-labelled ATP analogue binds only the mutated enzyme’s active site (which carries an 
alanine or glycine in place of a conserved bulky residue), only unique substrates of the kinase 
of interest are labeled in in vivo cells. This strategy has been used to identify substrates of 
JNK, CDK2 (cyclin-dependent kinase 2), and v-Src. This viable strategy can identify the 
distinct substrates of allosterically activated PKCδ in membranes as well as 
tyrosine-phosphorylated PKCδ in the soluble fractions of cells exposed to oxidant stress. 
Understanding the mechanisms that contribute to the regulation of dopamine function 
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by PKCδ and finding more PKCδ substrate protein has the potential to impact many different 
areas of neuroscience research and drug use. PKCδ may become a target of future drugs 
therapeutic for different brain diseases. As this relatively young field continues to mature, the 
mechanisms of this regulation and the impact of these diverse types of regulation on normal 
and abnormal brain function will be elucidated. 
 
 
Background and Literature Review II 
Neuroprotective strategies in a Parkinson’s disease animal model 
 
Parkinson’s disease (PD) is a major neurodegenerative disorder characterized by substantial 
loss of dopaminergic neurons in the substantia nigra, resulting in irreversible motor 
symptoms consisting mainly of tremors, bradykinesia, and rigidity.  The etiology of 
Parkinson’s disease is not known. Nevertheless, a significant body of biochemical data from 
human brain autopsy studies and from animal models points to an ongoing process of 
oxidative stress in the substantia nigra, which could initiate dopaminergic neurodegeneration. 
Although the pathology and clinical symptoms of PD are well defined, the cellular and 
molecular mechanisms underlying the selective degeneration of dopaminergic neurons 
remain elusive. Lack of such fundamental knowledge has severely hindered the development 
of neuroprotective strategies to circumvent the chronic progression of this debilitating 
neurodegenerative disorder. Much of our knowledge about dopaminergic neurodegeneration 
has come from studies employing two neurotoxins that produce animal models and 
Parkinsonism syndrome in rodents, primates, and other species. Both neurotoxins, namely 
6-hydroxydopamine (6-OHDA) （ Kostrzewa et al., 1974) and MPTP 
(N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) (Burns et al.,1983; Chiuehet al.,1993) cause 
the degeneration of nigro-striatal dopaminergic neurons, with the subsequent loss of striatal 
dopamine (Table 1). Earlier studies with 6-OHDA indicate that this neurotoxin is a highly 
reactive substance, which is readily autoxidised and oxidatively deaminated by monoamine 
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oxidase to give rise to hydrogen peroxide and reactive oxygen species (ROS) (Cohen et al., 
1974). This neurotoxin may exert its neurodegenerative action via OS (Glinka et al., 1996). 
The consequence of OS is the initiation of ROS generation, followed by brain membrane 
lipid peroxidation. The possibility that an endogenous toxin similar to a neurotoxin, such as 
6-OHDA, is formed in the brain and involved in the neurodegeneration process has been 
envisioned (Kostrzewa et al., 1974).  
Between 1979 and 1982, a severe and irreversible parkinsonian syndrome was 
diagnosed among young drug addicts in California. They have symptoms of bradykinesia, 
rigidity, and resting tremor closely resembled idiopathic Parkinson’s disease and these 
symptoms can be relieved by dopaminergic substitution therapy, as in typical Parkinson’s 
disease. Subsequently, MPTP, a meperidine analog, was recognized to be present as a 
by-product in designer drug preparations and to have caused the nigral degeneration 
underlying this new disorder. MPTP can cross the blood-brain barrier, and be converted to 
MPP+ in glial cells by monoamine oxidase B, and be taken up by catecholaminergic neurons 
via the dopamine reuptake system (dopamine transporter, DAT). Thus, specific MAO B 
inhibitors or catecholamine reuptake inhibitors are able to protect against MPTP toxicity. 
MPP+ is concentrated in the mitochondria according to the electrochemical gradient. Inside 
mitochondria, it inhibits the complex I of the respiratory chain, leading to ATP depletion and, 
eventually, to cell death of dopaminergic neurons (Zigmond and Stricker, 1989). It’s 
interesting that here also is a decrease in complex I activity in brain and other tissues in 
Parkinson’s disease. Apart from mitochondrial dysfunction, extramitochondrial damage by 
MPTP is suggested by the fact that cells without electron transport chain activity (Rho 0) still 
seem to be susceptible to MPP+ (Przedborski and Jackson-Lewis, 1998; Soldner et al., 1999). 
This finding was disputed, though, by others (Fall and Bennett, 1999). In the following years, 
it became evident that MPTP represents a highly useful tool to study dopaminergic 
degeneration modeling Parkinson’s disease in various species, including rodents and 
non-human primates (Burns et al., 1983; Heikkila et al., 1984).  
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Here are increasing controversies about the MPTP animal model. As shown in table 1, 
although MPTP model mimics PD patients, here are still some imperfections in MPTP model. 
First, in MPTP treated rodents the persistence of gross behavioral and motor features strongly 
depends on the dosing regimen. People found that it needs several years for the 
neurodegeneration happening in PD patients, but in MPTP animal model, this process occurs 
in several days. Second, In MPTP-treated animals, nigral cell death is paralleled by death in 
other catecholaminergic cell groups, such as the ventral tegmental area and locus coeruleus 
on a minor scale as in Parkinson’s disease (Seniuk et al., 1990). Third, lewy bodies, which 
are the characteristic of PD haven’t been observed in MPTP animal models (Forno et al., 
1988). Safety considerations in handling MPTP are important (Przedborski et al., 2001). 
Table 1 Deficiency of MPTP model 
  PD MPTP animal model 
 Within a few days after MPTP treatment 
 Acute treatment (20mg/kg,i.p.,each 2h*4 doses) 
 Subchronic treatment(30mg/kg,i.p.,each 24h*5 days)
Time for 
neurodegeneration 
occurring 
 
 
Slow progress, over 
several years 
Chronic treatment (40mg/kg,s.c.,each 24h*30 days) 
Neurochemistry 
changes 
 Dopamine deficiency Dopamine deficiency 
 Cell degeneration 
mostly in substantia 
nigra 
Cell degeneration in substantia nigra, ventral 
tegmental area and locus coeruleus 
Histology 
changes 
 Lewy bodies found in 
substantia nigra 
Lewy bodies not found 
Behavior changes  Muscle rigidity, 
tremor, bradykinesia, 
akinesia 
Tremor, bradykinesia only seen in acute MPTP 
treated animals 
The discovery of MPTP and its neurodegenerative property gave the notion that an 
environmental toxin similar to it might be responsible for the onset of PD. However, no 
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similar toxin as MPTP has been identified as synthetic substance so far, either in the 
environment or in the brain. MPTP, similarly to 6- OHDA, is thought to initiate its 
dopaminergic neurotoxicity via metabolism catalyzed by monoamine oxidase (MAO), giving 
rise to its reactive metabolite MPP+. The latter is thought to begin the neurodegeneration 
process via ROS induced by OS and inhibition of mitochondrial complex I (Chiueh et al., 
1992), as it produces sustained dopamine oxidation, hydroxyl radical formation, and 
membrane lipid peroxidation (Chiueh et al., 1992). Furthermore, both toxins induce an 
inflammatory process that results in proliferation of reactive microglia in the SNPC (McGeer 
et al., 1988). 
Table 2 Oxidative stress in 6-OHDA and MPTP-induced nigrostriatal degeneration 
 6-OHDA MPTP 
Biochemical variables which increase Reactive 
microglia proliferation 
McGeer 1989 McGeer et al. 1988 
Iron release Lode et al. 1990 Akiyama et al. 1996 
Lan and Jiang 1997 
Lipid peroxidation Kumar et al. 1995 
Ogawa et al. 1994 
Jenner 1998  
Youdim et al. 1993 
Generation of reactive oxygen species Perumal et al. 1989 Jenner 1998 
Biochemical indices which decrease 
Reduced glutathione (GSH) Ratio of GSH to 
oxidized 
Perumal et al. 1989 
Pearce et al. 1997 
Perumal et al. 1989 
Tohgi et al. 1995 
Calcium binding proteins Gerfen et al. 1987  German et al. 1992 
Iacopino et al. 1992 
Mitochondrial complex I (NADPH oxidase ) activity Glinka et al. 1995 Mizuno et al. 1988 
It is assumed that the induction of the inflammatory process is related to reactive 
microglia because of its ability to generate substantial amounts of ROS. Similar in 
parkinsonian brains, where a considerable increase in the inflammatory cytokines interleukin 
(IL)-1b, IL-2, IL-6, and tumor necrosis factor (TNF)-a (Mogi et al., 1994) was observed. It is 
not known whether oxidative stress is a primary or secondary event. Oxidative stress induced 
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by MPTP has been used in animal models to investigate the neurodegenerative process to 
facilitate the development of antioxidant, neuroprotective drugs (Johannessen et al., 1986). It 
is apparent that radical scavengers, iron chelators, dopamine agonists, nitric oxide synthase 
inhibitors, and certain calcium channel antagonists provide neuroprotection against such 
toxins if given prior to the insult in these animal models. Furthermore, an inflammatory 
process was found from human and animal studies, which can express itself as proliferation 
of activated microglia in the substantia nigra, activation and translocation of transcription 
factors and neurotrophic factor (NF), and kappa-b and elevation of cytotoxic cytokines, 
tumor necrosis factor (TNF)-a, interleukin (IL)-1b, and IL-6 (McGeer et al., 1997; 
Kurkowska et al., 1999; Kim et al., 2000; Knott et al., 2000). Both radical scavengers and 
iron chelators prevent lipopolysaccharide (LPS) and iron-induced activation of NF kappa-b. 
If an inflammatory response is involved in Parkinson’s disease, antioxidants and the newly 
developed, non-steroidal, anti-inflammatory drugs such as cyclo-oxygenase (COX2) 
inhibitors would be considered as a form of treatment. However, there has been little or no 
success in the clinical treatment of neurodegenerative diseases (for example, Parkinson’s 
disease, ischemia, etc.) in which neurons die, while in animal models the same drugs provide 
neuroprotection. This may indicate that either the animal models employed do not reflect the 
events in neurodegenerative diseases, or that because neuronal death involves a cascade of 
events, a single neuroprotective drug is not effective. Thus, consideration should be given to 
multi-neuroprotective drug therapy in Parkinson’s disease, similar to the approach taken in 
AIDS and cancer therapy. 
The treatment of Parkinson’s disease can be both rewarding and challenging. 
Unfortunately, no proven “neuroprotective” agents have been identified, and treatment 
remains symptomatic only. Treatment options for Parkinson’s disease have greatly expanded 
in recent years. Most PD treatment strategies are on pharmacologic agents, but exercise and 
lifestyle changes have been shown to be helpful as well. When medications are no longer 
able to provide adequate relief, neurosurgical options in the form of deep brain stimulation of 
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the subthalamic nucleus or the internal segment of the globus pallidus are playing an 
increasingly important role in symptomatic treatment. Pharmacological treatments, such as 
levodopa, dopamine receptor agonists, antioxidants, anti-oxidative stress, anticholinergic 
medications, monoamine oxidase B inhibitors, and the catechol-O-methyl transferase 
inhibitors, remain the mainstay of therapeutic intervention and are reviewed. Despite the 
great efficacy of levodopa, “levodopa-sparing strategies” in early Parkinson’s disease are 
emphasized in order to delay the development of difficult-to-manage motor fluctuations and 
dyskinesias. In the paragraphs that follow, a review of currently available 
pharmacotherapeutic treatment options for the Parkinson’s animal models will be presented. 
Dopamine receptor agonist 
It is generally believed that treatment with dopamine receptor agonists is symptomatic 
rather than curative, these drugs normally are used as adjunctive therapy for treatment of PD., 
and does not stop or delay the progression of neuronal degeneration. However, recent studies 
showed that several DA agonists of the DA D2–receptor family (including D2, D3 and 
D4-subtypes) possess neuroprotective properties in different in vitro and in vivo experimental 
PD models (Grilli et al., 1999; Le et al., 2000; Uberti D, Abramova et al., 2002; Piccioni et 
al., 2002; Uberti et al., 2004; Fujita et al., 2006). 
Apomorphine has been introduced in the treatment of late-stage Parkinson's disease 
(PD). The disadvantage of a short half-life of apomorphine is now overcome by the use of a 
continuous subcutaneous (s.c.) self-delivering system. (R)-Apomorphine (5-10 mg/kg, s.c.) 
pretreatment in C57BL mice protects against MPTP (24 mg/kg, i.p.) induced loss of 
nigro-striatal dopamine neurons, as indicated by striatal dopamine content, tyrosine 
hydroxylase content, and tyrosine hydroxylase activity (Grünblatt et al., 1999). Apomorphine 
was continuously infused in mice by means of a s.c. minipump that delivered the drug at a 
rate of 3.15 mg/kg/day. At 40 h following a 30 mg/kg MPTP injection 30% DA loss was 
prevented and striatal dopaminergic terminals were rescued (Battaglia et al., 2002). 
Pramipexole (SND 919; 2-amino-4,5,6,7-tetrahydro-6-propyl- amino- benzthiazole- 
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dihydrochloride) is a potent and selective dopamine D2/D3 receptor agonist. 
Co-administration of 1.0 mg/kg Pramipexole (s.c.) and 30 mg/kg MPTP to mice, followed by 
24 and 48 h of additional Pramipexole treatment, significantly attenuated MPTP-induced 
striatal DA loss, with a 50% protection (Ramirez et al., 2003). Pramipexole treatment also 
significantly attenuated the loss of tyrosine hydroxylase immunoreactive neurons (TH-IR) 
within the substantia nigra pars compacta (SNc) in both young and aged animals. Low dose 
Pramipexole (0.1 mg/kg/day*5days) down regulates the dopamine transporter via the D3 
receptor (Joyce et al., 2004). Another dopamine agonist, bromocriptine(10 mg/kg i.p.), 
blocked ·OH formation caused by MPTP (30 mg/kg i.p.). Bromocriptine blocked MPTP as 
well as 6-OHDA-induced behavioral dysfunction as well as glutathione and dopamine 
depletion, indicating its potent neuroprotective action (Archer et al., 1994; Ogawa et al., 
1994). One study checked the combined effect of bromocriptine (BRC) and Hypericum 
perforatum extract (HPE), which is a natural oxidant, and got more than 40% protection 
against MPTP induced dopamine loss (Mohanasundaria et al., 2006). SKF-38393 (10 mg/kg), 
a dopamine receptor agonist, blocked the MPTP-induced depletion of glutathione and 
attenuated MPTP-induced depletion of dopamine (a 40% protection) (Muralikrishnan et al., 
2001).  
MAO inhibitor 
The antiparkinsonian drug l-selegiline (l-deprenyl), an irreversible MAO-B inhibitor, 
was the first neuroprotective agent to prevent MPTP-induced Parkinsonism in mice and 
non-human primates. The mechanism of this process has been explained as l-selegiline 
inhibition of MAO-B, to prevent metabolism of the neurotoxin to the reactive metabolite, 
MPP+, and the formation of hydrogen peroxide. This explanation appears to be too simple, as 
selegiline was shown to prevent, as well as to rescue, cultured nigral neurons from the 
induced oxidative damage caused by the reactive metabolite MPP+. Selegiline can rescue 
neurons after they have sustained lethal damage and the rescue is independent of MAO-B 
inhibition. C57BL mice were treated with MPTP and then treated with selegiline 72 h after 
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the MPTP treatment to allow for complete conversion of MPTP to MPP+ and for maximal 
dSNn damage induced by MPP+. The delayed selegiline treatment rescued approximately 
69% of the dSNns that had not died by the time the treatment began (the neurons died in the 
saline control group) (Tatton et al., 1993). (R)-[(N-Propargyl-(3R) aminoindan-5-yl) ethyl 
methyl carbamate] (TV3326) is a novel cholinesterase and brain-selective monoamine 
oxidase (MAO)-A/-B inhibitor. Chronic treatment (150 mol/kg i.p) in mice gave 90% 
protection against striatal dopamine depletion induced by MPTP and prevented the reduction 
in striatal tyrosine hydroxylase activity, like selective B and non-selective MAO inhibitors. 
TV3326 preferentially inhibits MAO-B in the striatum and hippocampus, and the degree of 
MAO-B inhibition correlates with the prevention of MPTP-induced dopamine depletion 
(Sagi et al., 2003). MAO-B inhibitors, such as L-deprenyl, prevent MPTP-toxicity in 
different species, and have been used in Parkinson therapy (Wiener et al., 1989; Nakashima 
et al., 1991; Othblat et al., 1998; Castagnoli et al., 1999; Tatton et al., 1999; RSteyn et al., 
2001).  However, it is metabolized to (-)-methamphetamine, and new MAO-B inhibitors 
without a structural amphetaminic moiety are needed. (Perez et al., 2003) reported a novel 
non-amphetamine-like MAO-B inhibitor, PF 9601N or N-(2-propynyl)-2- 
(5-benzyloxy-indolyl) methylamine. This attenuates the MPTP-induced striatal dopamine 
depletion in young-adult and adult-old C57/BL mice, using different schedules of 
administration. The intraperitoneal (i.p.) co-administration to young-adult C57/BL6 mice of 
MPTP (30 mg/kg) and different concentrations of PF 9601N or L-deprenyl (29.5-0.357 
micromol/kg) showed a dose-dependent protective effect against striatal dopamine depletion.  
Lower doses of PF 9601N (1.5 micromol/kg) were necessary to get almost total protection, 
without any change in the DOPAC and HVA content, when administered 2 h before MPTP 
(30 mg/kg), whereas partial protection (45%) against dopamine depletion was observed in the 
case of L-deprenyl. When adult-old (8-10 months) C57/BL6 mice were used, MPTP (25 
mg/kg) administration induced 25 days later irreversible dopamine depletion. Under these 
conditions, chronic administration with 0.15 micromol/kg of PF 9601N, before the toxin, 
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every 24 h for 10 days, rendered almost total protection against dopamine depletion, whereas 
L-deprenyl yielded only 50% protection of the dopamine content, assayed under the same 
conditions. It is worth remarking that in both cases MAO-B was not affected. These results 
indicate that PF 9601N attenuates MPTP neurotoxicity in vivo better than L-deprenyl through 
different mechanisms, with special relevance to the protective effect, independent of MAO-B 
inhibition, observed in the irreversibly MPTP-lesioned adult-old mice. 
Anti-oxidative stress 
Recent investigations in animal models and in post-mortem human brain tissues have 
demonstrated that apoptosis is an important mode of cell death in nigral dopaminergic 
degeneration (Przedborski et al., 1998; Jellinger et al., 2000; Hartmann et al., 2001; 
Kanthasamy et al., 2003; Tatton et al., 2003). Oxidative damage has been unambiguously 
identified as contributing to dopaminergic cell death in Parkinson’s disease and in the MPTP 
model. Increases in markers of oxidative stress, such as malondialdehyde, protein carbonyls, 8- 
hydroxy-2-deoxyguanosine, and lipid peroxides were noted in PD substantia nigra, but also in 
other brain regions (Jenner et al., 1998). Morphological hallmarks encompass 
internucleosomal DNA cleavage, chromatin margination and condensation, preservation of 
membrane integrity and of cellular organelles (mitochondria, endoplasmic reticulum), 
membrane blebbing and cellular shrinkage as well as the formation of membrane-enclosed 
apoptotic bodies. Typically, there is a lack of inflammatory changes around apoptotic cells as 
opposed to necrosis (Mattson et al., 2000). A method of showing apoptotic cell death relies on 
the demonstration of caspase cleavage. Two major pathways leading to caspase activation 
have been characterized (Kaufmann and Hengartner, 2001). One involves the activation of 
death receptors on the cell surface, e.g., Fas/CD95 or TNFa. They share a common motif, the 
death domain, necessary for the binding of cytoplasmic adaptor molecules, e.g., FADD or 
TRADD. Through involvement of a common death effector domain, the prodomain of 
procaspase-8 is bound, bringing about the autocatalytic activation of the enzyme. This, in turn, 
leads to the activation of downstream effector caspases, directly or via a mitochondrial 
 38
pathway as an amplification step (Fig. 1). The mitochondrial pathway involves the release of 
cytochrome C from mitochondria, forming a ternary complex with procaspase-9 and with the 
scaffolding protein Apaf-1 and procaspase-9. Along with cytochrome C, other proapoptotic 
effectors, such as Smac/Diablo or apoptosis-inducing factor (AIF), are released from 
mitochondria into the cytosol. In the ternary complex, the so-called apoptosome, caspase-9 
activation can take place. Again, in further steps effector caspases, such as caspase-3, are 
activated (Fig. 1) and are responsible for the cleavage of at least 200 protein substrates 
involved in the degenerative process. 
Minocycline, a semisynthetic tetracycline, has neuroprotective effects in an MPTP 
mouse model of Parkinson's disease. The neuroprotective effect of minocycline is associated 
with marked reductions in inducible NO synthase (iNOS) and caspase 1 expression. 
Minocycline at 90 and 120 mg/kg significantly protects TH-positive neurons from death 
induced by MPTP exposure, and minocycline pretreatment had a similar “protective” effect on 
striatal dopamine levels (120mg/kg minocycline showed 60% protection) after acute MPTP 
administration (Du et al., 2001). 
 
 
 
 
 
 
 
 
 
 
Figure 1. Pathways implicated in MPTP-mediated toxicity 
(Eberhardt and Schulz, 2003) 
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Additional studies in primary mesencephalic cultures provided evidence that caspase 
inhibition by zVAD-fmk rescued the tyrosine hydroxylase-positive somata, but not their 
neurites and synapses from MPP+ and 6-hydroxydopamine-induced toxicity (Eberhardt et al., 
2000). A novel peptidyl broad-spectrum caspase inhibitor, Q-VD-OPH, which offers 
improvements in potency, stability, and toxicity over zVAD-fmk, showed significant 
protection against MPTP, 3-nitropropionic acid (3NP), and malonate toxicities. 20 mg/kg 
daily Q-VD-OPH significantly reduced 30% dopamine depletion in striatum produced by 
MPTP administration and prevented 50% of MPTP-induced loss of dopaminergic neurons in 
the substantia nigra. Western blots performed on tissues from the midbrain showed that 
Q-VD-OPH inhibited increases of the active forms of caspase-9 and caspase-8, as well as the 
caspase-8-mediated proapoptotic protein Bid induced by MPTP (Yang et al., 2004). 
Reportedly neuronal nitric oxide synthase (nNOS) inhibitor, 7-nitroindazole, can protect 
against MPTP neurotoxicity in mice. 50mg/kg 7-nitroindazole almost completely protected 
against both dopamine depletions and tyrosine hydroxylase (TH) positive neuron decreases in 
the mouse brain in an acute MPTP model (i.p. four times with 10 mg/kg MPTP at 1-h 
intervals) (Watanabe et al., 2004). Bis-ethylthiomethyl analog of K-252a, 
CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 
MPTP-mediated loss of nigrostriatal dopaminergic neurons in vivo (Saporito et al., 1999). 
The neuronal survival properties of CEP-1347/KT-7515 may be related to its ability to inhibit 
the activation of c-jun N-terminal kinase, a key kinase in some forms of stress-induced 
neuronal death and perhaps apoptosis (Ham et al., 1995; Xia et al., 1995; Maroney et al., 
1998). In the low dose MPTP model (20 mg/kg), CEP-1347/KT-7515 (0.3 mg/kg/day) 
attenuated the MPTP-mediated loss of striatal dopaminergic terminals by 50%. In the high 
MPTP dose model (40 mg/kg), CEP-1347/KT-7515 ameliorated the loss of dopaminergic cell 
bodies by 50% and partially preserved striatal dopaminergic terminals. CEP-1347/KT-7515 
did not inhibit monoamine oxidase B or the dopamine transporter, suggesting that the 
neuroprotective effects of CEP-1347/KT-7515 occur downstream of the metabolic conversion 
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of MPTP to MPP+ and accumulation of MPP+ into dopaminergic neurons (Saporito et al., 
1999). 
Recent studies from our laboratory demonstrated that the protein kinase C (PKC) 
delta isoform is an oxidative stress-sensitive kinase and a key mediator of apoptotic cell 
death in PD models (Kaul et al., 2003; Yang et al., 2004). In an attempt to translate the 
mechanistic studies to a neuroprotective strategy targeting PKC delta, we systematically 
characterized the neuroprotective effect of the PKC delta inhibitor rottlerin. Administration 
of rottlerin, either intraperitoneally or orally, to C57 black mice showed significant protection 
against MPTP-induced locomotor deficits and striatal depletion of dopamine and its 
metabolite 3,4-dihydroxyphenylacetic acid. Notably, rottlerin post-treatment was effective 
even when MPTP-induced depletion of dopamine and its metabolites was greater than 60%, 
demonstrating its neurorescue potential. Furthermore, the dose of rottlerin used in 
neuroprotective studies effectively attenuated the MPTP-induced PKC delta kinase activity. 
Importantly, stereological analysis of nigral neurons revealed rottlerin treatment significantly 
protected against MPTP-induced TH-positive neuronal loss in the substantia nigra compacta 
(Fig. 2) (Zhang et al., 2007). 
 
 
 
 
 
 
 
 
Figure 2. Stereological evaluation of neuroprotective effect of rottlerin on number and 
morphology of SNpc neurons in brains of MPTP-treated mice 
(Zhang et al., 2007) 
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Antioxidants, iron chelators and neurotrophic factors 
Melatonin, N-acetyl-5-methoxytryptamine, is an effective free radical scavenger and 
antioxidant (Reiter et al., 2000). Moreover, melatonin significantly inhibits the generation 
of ·OH in the brain following hypoxic or ischemic stimulation in vivo and in vitro (Li et al., 
1997). The neuroprotective role of melatonin is apparent in terms of its antioxidant effect as 
previously reported. Although melatonin prevents some pathological changes induced by 
MPTP in brain (Acuna-Castroviejo et al., 1997; Jin et al., 1998), studies investing protection 
against dopamine loss are not promising. Green tea containing high levels of 
(-)-epigallocatechin 3-gallate (EGCG) showed protective effects in a PD animal model 
(Levites et al., 2001; Choi et al., 2002; Mandel et al., 2004). Both tea and the oral 
administration of EGCG prevented the loss of tyrosine hydroxylase (TH)-positive cells in the 
substantia nigra (SN) and of TH activity in the striatum. 25 mg/kg of EGCG preserved 40% 
striatal levels of dopamine and its metabolites compared with the MPTP treatment group (20 
mg/kg, twice/day *5days). Both tea and EGCG decreased expression of nNOS in the 
substantia nigra (Choi et al., 2002). Moderate elevation of brain VE is not adequate for 
protecting DA-containing neurons against the toxic actions of a high dose of MPTP (20 mg 
kg-1, i.p. x 3, 2 h intervals) (Gong et al., 1991). 
Iron has been shown to accumulate at sites where neurons degenerate in 
neurodegenerative diseases like Parkinson's disease. Iron is thought to participate or initiate 
oxidative stress via generation of reactive oxygen species (ROS), such as hydroxyl radical. 
Iron chelators are neuroprotective and prevent 6-hydroxydoapmine and MPTP dopaminergic 
neurotoxicity in rats and mice (Youdim et al., 2004, Kooncumchoo et al., 2006, Youdim et al., 
1999, Kaur et al., 2003). In an iron-loaded (carbonyl iron, 25 g iron/kg diet) MPTP (30mg/kg, 
i.p.)-treated mouse model, desferrioxamine inhibits the iron accumulation and thus reverses 
the increase in oxidized glutathione (GSSG), oxidized to reduced glutathione ratios, .OH and 
lipid peroxidation levels. The striatal dopamine concentration was elevated to normal value. 
Pretreatment with the bioavailable metal chelator clioquinol (CQ) (30 mg/kg, p.o., 8 weeks) 
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protected against MPTP-mediated oxidative stress and dopaminergic cell loss in an acute 
MPTP treatment model, with 50% protection against dopamine loss (Kaur et al., 2003). 
Several lines of evidence also suggest that steroids have neuroprotective properties. 
17β-Estradiol was shown to protect neurons in vitro against death from a variety of stressors 
(Behl et al., 1995; Green et al., 1997). Hence, it could act as a free-radical scavenger or also 
have a direct modulatory effect on glutamate receptors (Weaver et al., 1997). Administration 
of 17β-estradiol to C57Bl/6 MPTP mice prevented depletion of striatal DA concentrations 
(Dluzen et al., 1996; Miller et al., 1998; Callier et al., 2000) and the glial fribrillary acid protein 
elevation induced by the neurotoxin (Miller et al., 1998). In C57Bl/6 MPTP mice, treatments 
with 17β-estradiol, progesterone, or raloxifene, a selective estrogen receptor modulator 
(SERM), prevent the depletion of striatal DA concentrations induced by MPTP by more than 
50%, whereas 17β-estradiol (the isomer with weak estrogenic activity on estrogen receptors) 
does not (Grandbois et al., 2000). 
Adenosine receptor antagonists 
Adenosine is a ubiquitous neuromodulator in the central nervous system. Its major role 
in the central nervous system is to modulate neurotransmitter release, the postsynaptic 
components, and also the nonsynaptic components such as glial cell signaling. Adenosine 
exerts these diverse physiological actions through activation of specific G protein-coupled 
receptors termed A1, A2A, A2B, and A3 (Fredholm et al., 1994). Adenosine A2A receptors 
are specifically localized in the striatum (Svenningsson et al., 1999), where they are 
coexpressed with dopamine D2 receptors in the GABAergic striatopallidal neurons; in contrast, 
there are no A2A receptors in the neurons projecting from the striatum to the substantia nigra 
that express D1 receptors (Ferre et al., 1997). Stimulation of adenosine A2A receptors 
decreases the binding affinity of D2 receptors (Ferré et al., 1991), and it elicits effects opposite 
of D2 receptor activation at the level of second-messenger systems and early gene expression 
(Svenningsson et al., 1999). These data suggest that antagonistic adenosine-dopamine 
interactions may regulate basal ganglia activity and that they could explain the depressant and 
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stimulating effects of adenosine A2A receptor agonists and antagonists on motor behavior 
(Ferre et al., 1997). Adenosine receptor antagonists, including caffeine and related 
methylxanthines, produce motor stimulant effects, which seem to be related to an action on 
A2A, rather than A1, receptors (Fredholm et al., 1999). Caffeine may attenuate MPTP 
neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor 
antagonism (Chen et al., 2002; Xu et al., 2002; Schwarzschild et al., 2003). And estrogen can 
prevent neuroprotection by caffeine in the mouse MPTP model of Parkinson's disease (Xu et 
al., 2006). The A2A-selective antagonist KW-6002 (istradefylline) exhibits antiparkinsonian 
activities in experimental models of PD (Kanda et al., 1998; Shiozaki et al., 1999; Koga et al., 
2000; Chen et al., 2001; Pierri et al., 2005), and is in clinical development. More recently, 
other adenosine A2A antagonists, SCH-420814 and BIIB014/V2006, have entered clinical 
development as antiparkinsonian drugs. These findings support a role for A2A receptors as 
neuromodulators of dopaminergic function, and they suggest that they may play an important 
role in movement disorders such as PD. In addition, antagonism of adenosine A2A receptors 
exerts dual actions on motor dysfunction and neurodegenerative processes in animal models of 
PD (Ikeda et al., 2002). Consistent with its pharmacology, A2A receptor knockout mice are 
resistant to both motor impairment and neurochemical changes relevant to neurodegenerative 
disorders such as PD (Ledent et al., 1997; Chen et al., 2001). Hence, adenosine A2A receptor 
antagonists may represent a novel therapeutic approach to pathologies characterized by 
neurodegenerative events, since they both reverse motor impairment and are neuroprotective. 
A novel adenosine A1 and A2A dual antagonist, 5-[5-amino-3-(4-fluorophenyl) 
pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), dose-dependently improved the 
reduction of striatal DA content by MPTP administration (Mihara et al., 2007). The 
percentages of recovery of DA content from the vehicle-treated control level were 7.09, 21.11, 
38.78, and 60.41 at doses of 0.01, 0.032, 0.1, and 0.32 mg/kg, respectively, with statistical 
significance at doses of 0.1 mg/kg and higher. The specific adenosine A2A antagonist 
8-(E)-2-(3,4-dimethoxyphenyl) 
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ethenyl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione (KW-6002; istradefylline) 
similarly restored the striatal DA content reduced by MPTP treatment in a dose-dependent 
manner. The percentages of recovery in DA contents at doses of 0.1, 0.32, 1, and 3.2 mg/kg 
were 22.91, 28.37, 38.79, and 42.45%, respectively (Mihara et al., 2007). 
Anticholinergics and dopamine uptake blockers 
MPTP in mice induces a decrease in dopamine and an increase in acetylcholine in the 
neostriatum. Both responses to MPTP can be blocked by prior treatment with atropine or 
trihexyphenidyl (Hadjiconstantinou et al., 1985). Pretreatment with 
3-(10,11,-dihydro-5H-dibenzo-[a,d]-cycloheptan-5-ylidene)-1-ethyl- 2- methylpyrrolidine 
(piroheptine), an anticholinergic drug which also inhibits dopamine uptake, completely 
prevented loss of striatal dopamine in MPTP-treated mice. Trihexyphenidyl partially protected 
against the neurotoxicity of MPTP. However, clomipramine, a selective 5-hydroxytryptamine 
uptake inhibitor, did not prevent the loss of striatal dopamine. Piroheptine is another agent 
which was found to prevent MPTP neurotoxicity (Saitoh et al., 1988). Dopamine uptake 
blockers protect against the dopamine depleting effect of MPTP in the mouse striatum;， a 
series of DA uptake blockers was tested for their ability to prevent this effect of MPTP. The 
agents tested (amfonelic acid, benztropine, bupropion and mazindol) completely protected 
against DA depletion in the mouse striatum when given before DA-depleting doses of MPTP 
were administered, whereas atropine and trihexyphenidyl (which were employed for 
comparative purposes) did not. DA uptake blocking agents appear to represent a second 
general class of compounds, monoamine oxidase inhibitors being the first, which protect 
against the biologic effects of MPTP in the mouse (Ricaurte et al., 1985). 
Anti-inflammatory aspirin, salicylic acid 
Anti-inflammatory drugs such as salicylic acid and acetylsalicylic acid (ASA) were 
protective against MPTP-induced striatal dopamine depletion in mice (Aubin et al., 1998; 
Ferger et al., 1999). Chuieh and others have demonstrated that MPTP results in the formation 
of the highly toxic hydroxyl radical in vivo. Hydroxyl radical formation was monitored in 
 45
dialysis studies by the salicylate detection method (Chiueh et al., 1993; Obata and Chiueh, 
1992). Hydroxyl radicals react with salicylate to form 2,3- and 2,5-dihydroxybenzoic acid 
(DHBA). MPTP increases the formation of both 2,3- and 2,5-DHBA in vivo. If hydroxyl 
radicals are interacting with salicylate, then of course salicylate is also mopping up hydroxyl 
radicals. If indeed these are the agents through which MPTP exerts its neurotoxicity, Aubin et 
al. (1998) found that salicylate totally protects against the neurotoxic effects of MPTP and that 
this property is shared by acetylsalicylate (aspirin) and a lysine salt formulation of aspirin, 
Aspegic, but not by other cyclooxygenase inhibitors. The neurotoxic effects of the 
dopamine-selective neurotoxin MPTP (15 mg/kg, s.c.), in mice, were totally prevented by 
systemic administration of salicylate (ED5O = 40 mg/kg, i.p.), aspirin (ED50 = 60 mg/kg, i.p.), 
or the soluble lysine salt of aspirin, Aspegic (ED50 = 80 mg/kg, i.p.) (Aubin et al., 1998). As 
many pathophysiological conditions induce COX-2 (Masferrer et al., 1992; Herschman, 1996), 
the impact of COX-2 seems to be higher in PD than that of the constitutive isoenzyme COX-1. 
Overexpression of neuronal COX-2 in mice potentiated excitotoxicity, suggesting a possible 
role of COX-2 in neurodegenerative diseases (Kelley et al., 1999). Additionally, recent results 
show evidence of chronic inflammation in humans who were exposed to MPTP up to 14 years 
ago (Langston et al., 1999). Different pathways lead to the activation of COX-2. TNF-alpha 
activates COX-2 via the JNK pathway (Westwick et al., 1994; Adams et al., 1996) and via 
induction of NF-kB (Yamamoto et al., 1998). NF-kB is a transcription factor for COX-2 and 
iNOS (Baeuerle and Baichwal, 1997) and was found to be enhanced 70-fold in parkinsonian 
brains (Hunot et al., 1997). Inductors for NF-kB were, besides others, ROS and 
pro-inflammatory cytokines (Baeuerle and Baichwal, 1997). MPTP/ MPP1 administration 
enhanced ROS production (Adams et al., 1993; Sriram et al., 1997; Ferger et al., 2000) as well 
as iNOS expression (Liberatore et al., 1999), which is able to enhance COX-2 activity 
(Nogawa et al., 1998). Different mechanisms involved in MPTP toxicity and probably in the 
pathophysiology of PD could be able to activate COX-2. Teismann et al. showed that 
dopamine depletion induced by a single administration of MPTP (30 mg/kg) was significantly 
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attenuated to 37.1% and 38.6% of saline control values by acetylsalicylic acid (50 and 100 
mg/kg) and to 36% and 40% by meloxicam (7.5 and 50 mg/kg), respectively (Teismann et al., 
2001). 
Conclusion: The principle of utilizing levodopa-sparing strategies to delay the 
development of motor fluctuations and minimize dyskinesias has had a major impact on 
maintaining long-term symptomatic control with medications in Parkinson’s disease. It is now 
well documented that, when appropriate, dopamine receptor agonists combined with MAO-B 
inhibitors, amantadine, and anticholinergic drugs provide excellent symptomatic relief for a 
number of years before the utilization of levodopa is required. The MPTP model still 
constitutes the best characterized toxin paradigm for Parkinson’s disease, faithfully replicating 
most of its clinical and pathological hallmarks. Many lines of evidence point to a significant 
contribution of apoptosis to cell death after application of MPP in cell culture or MPTP in vivo. 
This holds true for apoptotic DNA strand breaks, activation of the JNK pathway and caspases, 
induction of Par-4 protein, and the protection conferred by interference with p53, Apaf-1, or 
Bax signaling. In MPTP models, intervention in upstream events in apoptosis, e.g., inhibition 
of the JNK pathway, provides morphological and functional rescue. In contrast, inhibition of 
the propagation and execution phase of apoptosis, e.g., by inhibition of caspases, blocks or 
delays cell death but may not recover neuronal function. At this stage, the combination of an 
anti-apoptotic together with a neurorestorative therapy may be promising. Here is a list of 
neuroprotective reagents in table 3. 
Table 3  List of neuroprotective reagents 
Properties Drugs Doses % of DA 
recovery 
References 
Apomorphine 3 mg/kg, s.c. 30% Battaglia et al., 2002 
Pramipexole 1.0 mg/kg, s.c. 50% Ramirez et al., 2003 
Bromocriptine  10 mg/kg, i.p. 40% Mohanasundaria et al., 2006 
DA receptor agonist
SKF-38393 10 mg/kg, i.p. 40% Muralikrishnan et al., 2001 
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Table 3(continued)    
Properties Drugs Doses % of DA 
recovery 
References 
Selegiline 10 mg/kg, i.p 90% Takahata et al., 2003 
TV3326 150μM /kg, i.p 90% Sagi et al., 2003 
L-deprenyl 1.5 μM/kg, i.p. 45% Perez et al., 2003 
MAO inhibitor 
PF 9601N 0.15μM/kg, i.p. 99% Perez et al., 2003 
Minocycline 120mg/kg, i.p. 60% Du et al., 2001 
Q-VD-OPH 20 mg/kg, i.p. 30% Yang et al., 2004 
7-nitroindazole 50mg/kg, i.p. 99% Watanabe et al., 2004 
CEP-1347 0.3 mg/kg, i.p. 50% Saporito et al., 1999 
Melatonin 15 mg/kg, i.p. 25% Li et al., 2002 
Anti-oxidative stress
17b-Estradiol 2 mg/ daily, s.c. 90% Callier et al., 2000 
EGCG 25 mg/kg, i.p. 40% Choi et al., 2002 
Vitamine E 7g/kg diet 100% Lan et al., 1997 
Antioxidants  
Coenzyme Q 1600 mg/kg diet 45% Cleren et al., 2008 
Clioquinol 30 mg/kg, p.o 50% Kaur et al., 2003 
Cytisine 2.0 mg/kg, s.c. 50% Ferger et al., 1998 
Iron chelators 
Desferrioxamine 250 mg/kg, i.p. 100% Lan et al., 1997 
3-Hydroxymorphinan 24 mg/kg, i.p. 90% Zhang et al., 2006 
Caffeine 20 mg/kg, i.p. 40% Xu  et al., 2002 
Neurotrophic 
LY404187 0.5 mg/kg s.c. 25% O'Neill et al., 2004 
ASP5854 0.32 mg/kg 60% Mihara et al., 2007 Adenosine receptor 
antagonists Istradefylline 3.2 mg/kg 42% Mihara et al., 2007 
salicylic acid 40 mg/kg, i.p 99% Aubin et al., 1998 
Meloxicam 50 mg/kg 40% Teismann et al., 2001 
Aspirin 60 mg/kg, i.p 99% Aubin et al., 1998 
Anti-inflammatory  
Dextromethorphan 25 mg/kg, i.p 50% Vaglini et al., 2003 
 
Puzzles and future directions: The current therapeutic approach to the treatment of 
PD is symptomatic, and the most commonly used treatment is dopamine replacement therapy 
with levodopa or dopamine receptor agonists (bromocriptine, lisuride, pergolide and 
 48
apomorphine) or increasing the availability of brain dopamine by administering inhibitors of 
dopamine metabolic enzymes (MAO-A and -B and catechol O-methyltransferase). If 
neuroprotective therapy is to be realized in PD, a much better understanding of the biochemical 
pathology of the ongoing progressive dopaminergic degeneration is required. 
Intriguingly, in humans a presymptomatic phase of 5 years duration before overt 
parkinsonian features appear has been estimated from functional imaging and pathological 
studies. In a normal population a nigral cell loss of 4.4% is assumed to occur, while in PD 
patients the loss may be up to 10-fold higher (Dunnett et al., 1999). The therapeutic challenge 
might lie in the identification of the proper time-point for treatment onset, and optimally at a 
presymptomatic stage. Toxin models of Parkinsonism will probably help clarify this point. 
Furthermore, future novel therapeutic targets might be tested in the MPTP model, such as 
telomerase (Mattson et al., 2000), Smac/Diablo overexpression, and inhibitors of proapoptotic 
members of the Bcl-2 family. 
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CHAPTER II: PROTEIN KINASE C-DELTA NEGATIVELY REGULATES 
TYROSINE HYDROXYLASE ACTIVITY AND DOPAMINE SYNTHESIS BY 
ENHANCING PROTEIN PHOSPHATASE-2A ACTIVITY IN DOPAMINERGIC 
NEURONS 
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Abstract 
Tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis, can be 
regulated by phosphorylation at multiple serine residues including serine-40.  In the present 
study, we report a novel interaction between a key member of the novel PKC family, 
PKC-delta (PKCδ), and TH, in which the kinase modulates dopamine synthesis by negatively 
regulating TH activity via protein phosphatase 2A (PP2A).  We observed that PKCδ is 
highly expressed in nigral dopaminergic neurons and co-localizes with TH.  Interestingly, 
suppression of PKCδ activity with the kinase inhibitor rottlerin, PKCδ-siRNA or with PKCδ 
dominant negative mutant effectively increased a number of key biochemical events in the 
dopamine pathway, including TH-ser40 phosphorylation, TH enzymatic activity, and 
dopamine synthesis in neuronal cell culture models.  Additionally, we found that PKCδ not 
only physically associates with the PP2A catalytic subunit (PP2Ac) but also phosphorylates 
the phosphatase to increase its activity.  Notably, inhibition of PKCδ reduced the 
dephosphorylation activity of PP2A and thereby increased TH-ser40 phosphorylation, TH 
activity and dopamine synthesis.  To further validate our findings, we used the PKCδ 
knockout (PKCδ -/-) mouse model.  Consistent with other results, we found greater 
TH-ser40 phosphorylation and reduced PP2A activity in the substantia nigra of PKCδ -/- 
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mice than in wild-type mice.  Importantly, this was accompanied by an increased dopamine 
level in the striatum of PKCδ -/- mice.  Collectively, these results suggest that PKCδ 
phosphorylates PP2Ac to enhance its activity and thereby reduces TH-ser40 phosphorylation 
and TH activity and ultimately dopamine synthesis. 
 
Introduction 
Tyrosine hydroxylase (TH) is a rate-limiting enzyme in the biosynthesis of 
catecholamines and catalyzes the first step of a biochemical synthetic pathway in which 
L-tyrosine is converted to L-3,4-dihydroxyphenylalanine (L-dopa).  Phosphorylation and 
dephosphorylation of TH represent important post-translational regulatory mechanisms of the 
enzymatic activity that mainly determine the amount of catecholamine synthesis.  A number 
of phosphorylation sites have been identified in TH, and phosphorylation of TH greatly 
influences the enzyme activity (Lee et al., 1989).  Phosphorylation of TH at amino-terminal 
serine (Ser) amino sites at Ser8, Ser19, Ser31, and Ser40 leads to activation of TH.  A 
number of protein kinases have been shown to phosphorylate these serine residues to varying 
degrees.  For example, THser19 is phosphorylated by CaMKII, TH-ser40 by Protein kinase 
A (PKA), Protein kinase G, MSK, Protein kinase C (PKC), and TH-ser31 by ERK1/ERK2 
kinases and indirectly by PKC (Haycock, 1990).  Among these serine phosphorylation sites, 
TH-ser40 is a major residue that positively regulates the TH activity in vivo (Campbell et al., 
1986; Wu et al., 1992).  The phosphorylation state of TH can also be regulated by 
dephosphorylation reactions mediated by phosphatases.  Haavik et al. demonstrated that 
phosphatase 2A (PP2A) is the major serine/threonine phosphatase that dephosphorylates TH, 
resulting in reduced TH activity (Haavik et al., 1989).   
The PKC family consists of more than 12 isoforms and is subdivided into three major 
subfamilies, which include conventional PKC (α, βI, βII, γ), novel PKC (δ, ε, µ, η, θ), and 
atypical PKC (τ, λ, ζ) (Gschwendt, 1999; Dempsey et al., 2000; Maher, 2001; Kanthasamy et 
al., 2003).  PKCδ, a key member of the novel PKC family, plays a role in a variety of cell 
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functions including cell differentiation, proliferation and secretion.  Our recent studies 
demonstrate that PKCδ is an oxidative stress-sensitive kinase, and activation of this kinase 
via caspase-3 dependent proteolysis induces apoptotic cell death in cell culture models of 
Parkinson’s disease (Kanthasamy et al., 2003; Kaul et al., 2003; Yang et al., 2004; 
Latchoumycandane et al., 2005). General PKCs can phosphorylate TH-ser40 and TH-ser31 
(Albert et al., 1984; McTigue et al., 1985; Tachikawa et al., 1987; Cahill et al., 1989; 
Haycock et al., 1992; Bunn and Saunders, 1995; Bobrovskaya et al., 1998), however, direct 
phosphorylation of TH by PKA and not by PKC results in activation of the enzymatic activity 
(Funakoshi et al., 1991).  The role of PKC isoforms in the regulation of TH activity is not 
well studied.  Following the characterization of a key proapoptotic role of PKCδ in 
dopaminergic neuronal cell death during neurotoxic insults (Kanthasamy et al., 2003; Kaul et 
al., 2003; Yang et al., 2004; Kitazawa et al., 2005), we further examined in the present study 
whether PKCδ has any physiological role in regulating dopamine synthesis.  Herein, we 
report a novel functional interaction between PKCδ and TH in which PKCδ negatively 
regulates TH activity and dopamine synthesis by enhancing PP2A activity. 
 
Materials and Methods 
Chemicals.  Rottlerin, recombinant PKCδ protein, NSD-1015, okadaic acid, dibutyryl 
cAMP, protease cocktail, ATP, protein-A-sepharose, protein-G-sepharose and anti-β-actin 
antibody were obtained from Sigma-Aldrich (St. Louis, MO); purified PP2A and PP2Ac 
enzyme was purchased from Upstate (Chicago, IL).  Mouse tyrosine hydroxylase antibody, 
PhosphoTH-ser40 and ser31 antibodies were purchased from Chemicon (Temecula, CA); the 
rabbit polyclonal antibody for tyrosine hydroxylase was obtained from Calbiochem 
Bioscience, Inc. (King of Prussia, PA).  Rabbit PKCδ antibody was purchased from Santa 
Cruz Biotechnology, Inc. (Santa Cruz, CA); mouse PKCδ antibody and PP2Ac antibody 
were from BD Biosciences (San Jose, CA).  Anti-rabbit and anti-mouse secondary 
antibodies and the ECL chemiluminescence kit were purchased from Amersham Pharmacia 
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Biotech (Piscataway, NJ).  Alexa 488 conjugated anti-rabbit/mouse, Cy3 conjugated 
anti-rabbit/mouse antibody and Hoechst 33342 were purchased from Molecular Probes, Inc. 
(Eugene, OR).  [γ-32P]ATP was purchased from Perkin Elmer Life Science Products 
(Boston, MA).  Serine/Threonine phosphatase assay kit was purchased from Promega; 
AMAXA® NucleofectorTM kit was from Amaxa (AMAXA GmbH, Germany).  The 
Bradford protein assay kit was purchased from Bio-Rad Laboratories (Hercules, CA).  
RPMI, fetal bovine serum, L-glutamine, penicillin, and streptomycin were purchased from 
Invitrogen (Gaithersburg, MD). 
 
Animal studies. Six to 8-week-old C57/BL/6 mice and PKCδ knockout mice weighing 
25-30 g were housed in standard conditions: constant temperature (22 ± 1°C), humidity 
(relative, 30%), and a 12-h light/dark cycle with free access to food and water.  PKCδ 
knockout animals were kindly provided by Dr. Keiichi Nakayama’s Laboratory (Division of 
Cell Biology, Department of Molecular and Cellular Biology, Medical Institute of 
Bioregulation, Kyushu University, Fukuoka, Japan).  We obtained a pair of male and female 
heterozygous PKCδ (+/-) C57 black mice from Dr. Nakayama’s laboratory and established a 
breeding colony in our animal facility.  We then genotyped animals in our colony as per the 
protocol described previously (Miyamoto et al., 2002).  Briefly, genomic DNA was isolated 
from tails of 3-4 week old mice and then subjected to PCR followed by electrophoresis.  
The genotype of the animals was confirmed using the molecular size of PCR products:  
PKCδ naïve (+/+): 900 bp; PKCδ (+/-): 900 and 600 bp; and PKCδ knockout (-/-): 600 bp.  
The animals and protocol procedures were approved and supervised by the Committee on 
Animal Care (COAC) at Iowa State University. 
 
Cell culture models.  PC12 and differentiated N27 cells were cultured as described earlier 
(Adams et al., 1996; Anantharam et al., 2002; Kaul et al., 2003).  Briefly, cells were grown 
in RPMI 1640 medium containing 10% fetal bovine serum, 2 mM L-glutamine, 50 units of 
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penicillin, and 50 µg/ml streptomycin.  Cells were maintained in a humidified atmosphere of 
5% CO2 at 37°C.  N27 cells were differentiated with 2 mM dibutyryl cAMP for 3-5 days 
and then used for experiments described below.  Primary mesencephalic neuronal cultures 
were prepared from the ventral mesencephalon of gestational 16-18-day-old mice embryos as 
described previously (Yang et al., 2004).  Mesencephalic tissues were dissected and 
maintained in ice-cold Ca2+-free HBSS and then dissociated in HBSS solution containing 
trypsin-EDTA (0.25%) for 20 min at 37°C.  The dissociated cells were then plated at equal 
density (0.5 × 106 cells) in 30-mm-diameter tissue culture wells precoated with poly-D-lysine 
(1 mg/ml).  Cultures were maintained in a chemically defined medium consisting of 
neurobasal medium fortified with B-27 supplements, L-glutamine (500 μM), penicillin (100 
IU/ml), and streptomycin (100 μg/ml) (Life Technologies).  The cells were maintained in a 
humidified CO2 incubator (5% CO2, 37°C) for 24 hr and then treated with cytosine 
arabinoside (10 μM) for 24 hr to inhibit glial cell proliferation.  Half of the culture medium 
was replaced every 2 days.  Approximately 6-7-day-old cultures were used for experiments. 
 
Transfection of PKCδK376R gene in N27 cells and primary mesencephalic neurons.  
Plasmid pPKCδK376R-V5 encodes the loss of function PKCδ-V5 epitope tagged mutant 
protein; K376R refers to the mutation of the lysine residue at position 376 to arginine in the 
catalytic site, resulting in inactivation of the kinase.  Plasmid pLacZ-V5 encodes the 
β-galactosidase protein alone with a V5-epitope and is used as a vector control.  N27 cells 
stably expressing PKCδK376R-V5 (herein referred to as PKCδ-DN cells) and LacZ 
alone-expressing cells (LacZ cells) were cultured as described previously (Kitazawa et al., 
2005).  PKCδ-DN or LacZ expressing N27 cells were identified by immunostaining of the 
C-terminal V5 epitope on expressed proteins and were differentiated with 2 mM dibutyryl 
cAMP prior to experiments.  PKCδ-DN and LacZ were also transiently expressed in mouse 
primary mesencephalic neurons using an AMAXA® NucleofectorTM kit (AMAXA GmbH, 
Germany).  As described above, primary mesencephalic neurons were prepared from the 
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midbrain of 16-18-day-old mice embryos.  After digestion with trypsin-EDTA-HBSS, the 
primary neurons were homogenously resuspended with transfection buffer provided with the 
kit to a final concentration of 4-5 x 106 neurons/100 μl and mixed with 2 μg plasmid DNA 
encoding either PKCδ-DN-V5 or LacZ-V5.  Electroporation was carried out with an 
AMAXA® NucleofectorTM instrument as per the manufacturer's protocol.  The transfected 
neurons were then transferred to 24-well plates containing poly-D-lysine and laminin coated 
cover slips.  After 24 hr, the primary neurons were fixed and used for immunocytochemistry.  
Transfection efficiency was >75% as determined by immunostaining of V5- expression.   
 
Design, synthesis and transfection of siRNA.  Small interfering RNAs (siRNAs) were 
prepared by an in vitro transcription method as described previously (Yang et al., 2004).  
Initially, siRNA target sites specific to rat PKCδ mRNA (gi: 18959249), as determined by blast 
analysis, were chosen.  One nonspecific siRNA (NS-siRNA) was also chosen based on 
random sequence.  For each siRNA, sense and antisense templates were designed based on 
each target sequence and partial T7 promoter sequence (Donze and Picard, 2002): for 
PKCδ-siRNA, sense, 5'-AACTGTTTGTGAATTTGCCTTCCTGT CTC-3'; antisense, 
5'-AAAAGGCAAATTCACAAACAGCCTGTCTC-3'; for NS-siRNA, sense, 
5'-AATTCTCACACTTCGGAGAACCTGTCTC-3'; antisense, 5'-AAGTTCTCCG 
AAGTGTGAGAACCTGTCTC-3'.  All template oligonucleotides were chemically 
synthesized and PAGE purified.  In vitro transcription, annealing, and purification of siRNA 
duplexes were performed using the protocol supplied with the silencer siRNA construction kit 
(Ambion).  Briefly, approximately 2 μg of each single-strand (ss) transcription template was 
first annealed with the T7 promoter and filled in by Klenow DNA polymerase to form 
double-strand transcription templates.  For preparation of each siRNA duplex, transcription 
reactions were first performed with separated antisense and sense templates using the T7 RNA 
polymerase provided with the kit and then annealed to form siRNA duplexes.  Then, the 
siRNA duplex was treated with DNase and RNase to remove the extra nucleotides of 
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transcribed siRNA to meet the structural 3′UU overhang and 5′ phosphate requirement 
(Elbashir et al., 2001).  N27 cells (50–70% confluence) and primary mesencephalic neurons 
were transfected with siRNA duplexes by using an AMAXA® NucleofectorTM kit (AMAXA 
GmbH, Germany) as described in our recent publication (Yang et al., 2004).  
 
Treatment paradigm.  PC12 cells, differentiated N27 dopaminergic cells and primary 
mesencephalic neurons were exposed to 1-10 μM rottlerin for the duration of the experiment.  
DMSO (0.01%) was used as vehicle control.  PKCδ-DN- and Lac Z-expressing N27 cells 
were only treated with 0.01% DMSO.  For measurement of TH activity in rottlerin-treated 
cultures, cells were exposed to 2 mM NSD-1015 for 1 hr prior to rottlerin treatment.  
Untreated or vehicle-treated cells were used as control samples.  We derived the 
concentrations of rottlerin and okadaic acid used in this study based on previously published 
literature.  Rottlerin inhibits PKCδ kinase activity with a Ki of 3-6 μM, while PKCα, β, γ, ε 
and λ  Ki values are at least 5-10 times higher (Gschwendt, 1999; Davies et al., 2000; Way 
et al., 2000; Soltoff, 2001).  In our previous study, we showed 3-10μM rottlerin 
dose-dependently attenuated kinase activity to a greater extent (Anantharam et al., 2002).  
We used 5 μM rottlerin in the study, which was lower than Ki values of other PKC isoforms.  
Additionally, we employed various genetic approaches such as RNAi, dominant negative 
mutant and knockout approaches to validate the results obtained with rottlerin treatment.   
We used 2 µM okadaic acid to completely inhibit PP2A activity in dopaminergic cells, since 
previous studies demonstrated IC50 ranges from 0.1-1 μM for PP2A activity in cell culture 
models (Favre et al., 1997; Schonthal, 1998).  
 
Western blotting.  Cell and brain lysates containing equal amounts of protein were loaded 
in each lane and separated on a 10-12% SDS-PAGE gel as described previously (Kaul et al., 
2003).  After the separation, proteins were transferred to nitrocellulose membrane, and 
nonspecific binding sites were blocked by treating with 5% nonfat dry milk powder.  The 
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membranes were then treated with primary antibodies directed against PKCδ (rabbit 
polyclonal or mouse monoclonal for PKCδ knockout studies, 1:2000 dilution), TH (rabbit 
polyclonal or mouse monoclonal, 1:1000), phospho TH-ser40 (rabbit polyclonal, 1:1000), 
phospho TH-ser31 TH (rabbit polyclonal, 1:1000), or PP2Ac (mouse monoclonal, 1:1000).  
The primary antibody treatments were followed by treatment with secondary 
HRP-conjugated anti-rabbit or anti-mouse IgG (1:2000) for 1 hr at RT.  Secondary 
antibody-bound proteins were detected using Amersham's ECL chemiluminescence kit.  To 
confirm equal protein loading, blots were reprobed with a β-actin antibody (1:5000 dilution).  
Western blot images were captured with a Kodak 2000 MM imaging system and data were 
analyzed using 1D Kodak imaging analysis software.  
 
Co-immunoprecipitation.  Immunoprecipitation studies were conducted to determine the 
association properties between PKCδ, TH and PP2A and were performed as described in our 
recent publications (Kaul et al., 2005).  Briefly, PC12, N27 cells or substantia nigral tissue 
from PKCδ (+/+) or PKCδ (-/-) mouse brain were washed with ice-cold Ca2+-free PBS saline 
and resuspended in a lysis buffer [25 mM HEPES (pH 7.5), 20 mM β-glycerophosphate, 0.1 
mM sodium orthovanadate, 0.1% Triton X-100, 0.3 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 
0.5 mM DTT, 10 mM NaF, and protease inhibitor cocktail].  The suspension was kept on ice 
for 30 min and then centrifuged at 10,000 × g for 5 min.  The supernatants were collected 
and used for immunoprecipitation.  Extracts containing ~200 μg total protein were 
immunoprecipitated overnight at 4°C with 5-20 μg of anti-PKCδ (rabbit polyclonal), anti-TH 
(mouse monoclonal), anti-PP2Ac (mouse monoclonal) antibodies, rabbit IgG or mouse IgG.  
Mouse monoclonal anti-PKCδ antibody was used for PKCδ (-/-) brain tissue. 50μg PKCδ 
blocking peptide was used to neutralize PKCδ antibody by incubating for one hr and used as 
a negative control.  The immunoprecipitates were then adsorbed onto Protein A or G 
sepharose for 1 hr at 4°C.  The sepharose-bound antigen–antibody complexes were washed 
three times with PBS to remove unbound proteins.  For association studies, samples were 
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mixed with 2X SDS PAGE loading buffer, boiled for 5 min, and then proteins were separated 
on SDS-PAGE and subjected to Western blot as described earlier.  
 
32P-Phosphorylation assays.  To determine whether PKCδ can directly phosphorylate PP2A, 
we used recombinant PKCδ in in vitro phosphorylation assays.  Immunoprecipitations were 
performed as described earlier (Kaul et al., 2003).  Briefly, PP2Ac was immunoprecipitated 
from N27 cell lysates using mouse monoclonal PP2Ac antibody.  The samples were then 
incubated with protein G sepharose, and the immunoprecipitates and recombinant PP2Ac 
were used in in vitro phosphorylation assays.  Recombinant PKCδ  was resuspended in 2X 
kinase buffer [40 mM Tris (pH 7.4), 20 mM MgCl2, 20 μM ATP, 2.5 mM CaCl2] and the 
reaction was started by adding 20 μl of reaction buffer containing immunoprecipitated or 
recombinant PP2Ac and 5 μCi of [γ-32P] ATP (4500 Ci/mM).  To inhibit PKCδ, 
recombinant PKCδ protein was preincubated with 5μM rottlerin for 15 min before the 
reaction.  After incubation for 10 min at 30°C, the reaction was terminated by addition of 
2X SDS-gel loading buffer and separated by SDS-PAGE.  PP2Ac and histone H1 
phosphorylated bands were detected using a Personal Molecular Imager (FX model, BioRad 
Labs) and quantified with Quantity One 4.2.0 software.  Histone H1 substrate was used as a 
positive control for PKCδ kinase activity. 
 
PP2A assay.  To determine PP2A phosphatase activity, we used the Serine/Threonine 
phosphatase assay kit from Promega.  In cell free assay, 20 ng of recombinant PP2A enzyme 
in PP2A reaction buffer (250 mM imidazole, pH 7.2, 1 mM EGTA, 0.1% β-mercaptoethanol, 
5 μl peptide substrate, 0.5 mg/ml BSA) was incubated with 20 ng of recombinant PKCδ 
protein in the presence or absence of 5 μM rottlerin. 2 μM okadaic acid was used as a 
positive control.  Reaction was started by adding PKCδ reaction buffer containing 40 mM 
Tris, pH 7.4, 20 mM MgCl2, 20 μM ATP, 2.5 mM CaCl2, 50 μg/ml phosphatidylserine, and 
4.0 μM dioleoylglycerol.  After 1 hr incubation, molybdate dye (2X vol) was added to the 
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reaction mixture.   For in vivo PP2A activity measurement, N27 cells and substantia nigral 
tissue from mouse brain were homogenized in lysis buffer (25 mM Tris-HCl, 10 mM 
β-mercaptoethanol, 2 mM EDTA, protease inhibitor) supplied with the kit.  After 
centrifugation, the supernatants were used for measurement of PP2 activity by incubating 
equal volumes of the substrate and PP2A reaction buffer for 1 hr.  PP2A activity was 
determined by measuring the amount of free phosphate generated in a reaction by measuring 
the absorbance of a molybdate:malachite green: phosphate complex at  600 nm using a 
Spectramax plate reader (Molecular Devices).  The effective range for the detection of 
phosphate released in this assay is 100–4,000 pmol of phosphate. 
 
Tyrosine hydroxylase activity.  TH enzyme activity was measured by the modified method 
of Hayashi et al (Hayashi et al., 1988) in which DOPA levels are quantified as an index of TH 
activity after inhibition of DOPA decarboxylase with the decarboxylase inhibitor NSD-1015 
(Hayashi et al., 1988).  Briefly, cells were incubated with Krebs-HEPES buffer (pH 7.4) 
containing 2 mM NSD-1015 at 37°C for 30 min, and then subjected to the treatment 
paradigm as described earlier.  After treatment, cells were collected and resuspended in 
antioxidant solution, sonicated, centrifuged, and DOPA levels in the supernatants were 
measured by HPLC detection as described below.   
 
Measurements of DA and its metabolites.  DA and DOPAC levels in PC12, N27 cells and 
in brain striatal tissues were determined by high-performance liquid chromatography with 
electrochemical detection (HPLC-EC); samples were prepared as described previously 
(Kitazawa et al., 2001; Sun et al., 2006).  Briefly, neurotransmitters were extracted from 
samples using 0.1 M perchloric acid containing 0.05% Na2EDTA and 0.1% Na2S2O5.  The 
extracts were filtered in 0.22 micron spin tubes and 20 μl of the samples was loaded for 
analysis.  DA and DOPAC were separated isocratically by a reversed-phase column with a 
flow rate of 0.7 ml/min.  An HPLC system (ESA Inc., Bedford, MA) with an ESA 
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automatic sampler (model 542) was used for these experiments.  The electrochemical 
detection (EC) system consisted of an ESA coulochem model 5100A with a microanalysis 
cell model 5014A and a guard cell model 5020 (ESA Inc., Bedford, MA).  The peak areas of 
standard DA and DOPAC were compared with that of samples.  The DA and DOPAC levels 
in the samples were measured and expressed as ng/mg protein, and retention times for DA 
and DOPAC were 5.8-7.7 min and 4.7-5.5 min, respectively.  
Immunohistochemical staining of brain slices.  Mice were perfused with 4% 
paraformaldehyde following anesthesia with ketamine, and then the brain was cut on a 
microtome into 20-µm sections.  Sections from SNpc were treated for immunofluorescence 
staining.  Brain sections were first blocked with 5% normal goat serum containing 0.4% BSA 
and 0.2% Triton-X 100 in PBS for 20 min, then incubated with antibodies directed against 
PKCδ (rabbit polyclonal, 1:500 dilution) and TH (mouse monoclonal, 1:500 dilution) 
overnight at 4°C followed by incubation with either Alexa 488-conjugated (green, 1:1000) or 
Cy3-conjugated (red, 1:1000) secondary antibody for 1 hr at RT.  Secondary antibody 
treatments were followed by incubation with Hoechst 33342 (10 μg/ml) for 3 min at room 
temperature to stain the nucleus.  Then the slices were mounted on a slide and viewed under a 
Nikon inverted fluorescence microscope (Model TE-2000U); images were captured with a 
SPOT digital camera (Diagnostic Instruments, Sterling Heights, MI). 
Immunocytochemical staining in cell cultures.  Immunostaining of PKCδ, TH, 
P-TH-ser40 and P-TH-ser31 were performed in PC12, N27 and primary mesencephalic 
neurons.  Cells were grown on poly-L-Lysine-coated glass cover slips.  After treatment, 
the cells were fixed with 4% paraformaldehyde and processed for immunocytochemical 
staining.  First, non-specific sites were blocked with 5% normal goat serum containing 0.4% 
BSA and 0.2% Triton-X 100 in PBS for 20 min.  Cells and primary neurons were then 
incubated with antibodies directed against PKCδ (mouse monoclonal, 1:500 dilution), TH 
(rabbit polyclonal, 1:500 dilution), and P-TH-ser40 (rabbit polyclonal, 1:500 dilution) 
overnight at 4°C followed by incubation with either Alexa 488-conjugated (green, 1:1000) or 
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Cy3-conjugated (red, 1:1000) secondary antibody for 1 hr at RT.  Secondary antibody 
treatments were followed by incubation with Hoechst 33342 (10 μg/ml) for 3 min at room 
temperature to stain the nucleus.  Then the cover slips containing stained cells were washed 
with PBS, mounted on a slide, and viewed under a Nikon inverted fluorescence microscope 
(Model TE-2000U); images were captured with a SPOT digital camera (Diagnostic 
Instruments, Sterling Heights, MI). 
 
Data analysis.  Data analysis was performed using Prism 4.0 software (GraphPad Software, 
San Diego, CA).  Data were first analyzed using one-way ANOVA and then Bonferroni's 
post-test was performed to compare all treatment groups, and differences with p<0.05 were 
considered significant. 
 
Results 
PKCδ physically associates with TH. First we examined the level of PKCδ 
expression in nigral dopaminergic neurons.  Double immunostaining of mouse nigral tissues 
with PKCδ and TH showed a strong co-localization of these proteins (Fig. 1A).  To further 
confirm their possible interaction, we performed co-immunoprecipitation and reverse 
immunoprecipitation studies.  As shown in Fig. 1B, immunoprecipitation with PKCδ 
antibody followed by immunoblotting with TH antibody showed a clear association of TH 
with PKCδ in mouse substantia nigral lysate (Fig. 1B).  In reverse immunoprecipitation 
analysis, TH antibody was used for immunoprecipitation and PKCδ antibody was used for 
immunoblotting.  The right panel of Fig. 1B shows a PKCδ band in TH immunoprecipitates 
from mouse brain, indicating an association between these two proteins.  Rabbit IgG and 
mouse IgG immunoprecipitates were used as negative controls.  These results clearly 
indicate that PKCδ physically associates with TH in the dopaminergic neuronal system. 
To further determine the functional relationship between PKCδ and TH, we used a 
PC12 model, which has been used extensively for post-translational regulation of TH 
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(Haycock, 1989, 1990). First we performed immunoprecipitation studies to verify that PKCδ 
interacts with TH in this cell model.  Similar to nigral tissue, immunoprecipitation and 
reverse immunoprecipitation studies showed a clear association and interaction between 
PKCδ and TH (Fig. 1C).  These results not only confirmed the PKCδ and TH interaction in 
dopamine producing cells, but also indicated the usefulness of PC12 cells for examining the 
role of PKCδ in the regulation of TH function.  
 
PKCδ inhibition enhances TH activity. Since PKCδ colocalized with TH, we 
examined whether PKCδ has any influence on TH activity.  As a first step, we determined 
TH activity under conditions of PKCδ inhibition using various doses of the PKCδ specific 
inhibitor rottlerin.  TH activity was measured by determining DOPA levels following 
inhibition of DOPA decarboxylase with the enzyme inhibitor NSD-1015, as described in the 
methods section.   PC12 cells were exposed to 2 mM NSD-1015 for 1 hr prior to treatment 
with the PKCδ-specific inhibitor rottlerin for 3 hr.  We used 1-10 μM rottlerin in the present 
study because we previously showed this dose range effectively inhibits PKCδ activity 
(Anantharam et al., 2002).  As shown in Fig. 2, rottlerin treatment significantly increased 
intracellular DOPA levels, indicating increased TH activity following PKCδ inhibition.   
Treatment with 1 μM, 5 μM and 10 μM rottlerin increased TH activity to 2091.09±80, 
3045±75 and 2067±44 pg DOPA/106 cells/hr, respectively, compared with the control level of 
1519±91 pg DOPA/106 cells/hr. Together, these results suggest that inhibition of PKCδ 
activation results in increased TH activity.  
 
Effect of PKCδ inhibition on TH phosphorylation. Since inhibition of PKCδ 
resulted in enhanced TH activity, we examined whether PKCδ has any effect on the 
phosphorylation status of TH.  It is well established that TH activity can be regulated by 
phosphorylation of multiple serine residues (Campbell et al., 1986; Mitchell et al., 1990), and 
serine phosphorylation at positions 31 and 40 has been suggested to play a key role in TH 
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activation and increased dopamine biosynthesis (Haycock, 1990).  We measured the extent 
of TH-ser31 and TH-ser40 phosphorylation in immunoblots using phosphospecific antibodies 
directed against TH-ser31 and TH-ser40.  As shown in Fig. 3A, the level of TH-ser40 
phosphorylation was significantly enhanced in rottlerin-treated cells (5 μM rottlerin for 3 hr), 
whereas the level of TH-ser31 phosphorylation was unaltered.  Similarly, the level of total 
TH and PKCδ were unaltered in rottlerin-treated PC12 cells as compared to 0.01% DMSO 
control-treated cells, indicating that rottlerin treatment does not alter the expression of TH and 
PKCδ.  Nitrocellulose membranes were reprobed with β-actin antibody and the density of 
the 43 kDa β-actin band was identical in all lanes, confirming equal protein loading.  
Densitometric analysis of the 60 kDa P-TH-ser40 band in Fig. 3A revealed a 3-fold increase in 
phosphorylation as compared to vehicle-treated cells, whereas there was no increase in protein 
levels of P-TH-ser31 and TH. TH-ser40 phosphorylation was also confirmed in 
immunofluorescence measurements.  After treatment with 5 μM rottlerin for 3 hr, PC12 cells 
were fixed and processed for immunofluorescence staining of P-TH-ser40 using Alex 488 
secondary antibody.  An increase in bright green immunofluorescence positive cells was 
observed in rottlerin-treated cells (Fig. 3B), but only a weak staining was observed in 
vehicle-treated cells, indicating that PKCδ inhibition results in increased phosphorylation of 
TH-ser40.  No staining was observed in cells stained with Alexa 488 alone.  Cell count 
analysis of images using Metamorph image analysis revealed that rottlerin treatment induced 
the increase in P-TH-ser40 stained cells by 333% compared to vehicle-treated cells.  These 
results demonstrate that PKCδ inhibition results in enhanced TH phosphorylation specifically 
at ser40. 
 
Effect of loss of function PKCδ mutant on TH activity and DA synthesis in 
mesencephalic dopaminergic neuronal cells. Although PC12 cells are a good model to 
study TH function, they are non-neuronal cells derived from adrenal pheochromocytoma.  
Therefore, to further determine whether PKCδ alters TH activity in neuronal cells, we used 
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immortalized rat mesencephalic dopaminergic neuronal cells (N27 cells), which are a 
homogenous population of TH-positive neuronal cells that synthesize and release dopamine 
upon differentiation (Clarkson et al., 1999; Zhou et al., 2000).  Also, the N27 dopaminergic 
cell line is easily transfectable and convenient for establishing stable cell lines compared to 
hard-to-transfect PC12 cells.  In recent years, this neuronal cell line has been recognized by 
many investigators, including us, as a highly useful cell culture model for studying 
degenerative mechanisms in Parkinson’s disease (Clarkson et al., 1999; Kaul et al., 2003; 
Miranda et al., 2004; Kaul et al., 2005; Peng et al., 2005).   
First, we examined whether PKCδ interacts with TH in N27 dopaminergic cells in a 
manner similar to that observed in PC12 cells and mouse nigral tissue (Fig. 4A).  As shown 
in Fig. 4A, double immunostaining studies with differentiated N27 cells showed 
co-localization of PKCδ with TH and P-TH-ser40, further supporting the previous results of 
association of PKCδ with TH observed in PC12 cells.  Next, we examined whether PKCδ 
inhibition would alter TH activity and dopamine in N27 cells.  For these studies, we used 
genetic approaches in addition to PKCδ pharmacological inhibitor studies.  We utilized N27 
cells stably expressing a loss of function PKCδ dominant negative mutant (PKCδ-DN) 
established in our laboratory (Kaul et al., 2003; Kitazawa et al., 2005).  N27 cells were 
exposed to 2 mM NSD-1015 for 1 hr prior to a 3 hr treatment with the PKCδ-specific 
inhibitor rottlerin (5 μM) or 0.01% DMSO, and then measured the DOPA levels as a measure 
of TH activity.  We also measured DOPA levels in PKCδ-DN expressing N27 cells and 
Lac-Z-expressing N27 cells (vector control).  As shown in Fig. 4B, DOPA levels were 
significantly higher in rottlerin-treated cells compared to vehicle-treated cells, and were in 
agreement with the data obtained in PC12 cells (see Fig. 2).  Also, TH activity was 
significantly higher in PKCδ-DN mutant-expressing cells as compared to LacZ-expressing 
cells (Fig. 4B).  The TH activity was 1231±120 and 3025±267 pg DOPA/106 cells/hr in 
vehicle- and rottlerin-treated cells, and 1483±146 and 2539±307 pg DOPA/106 cells/hr in 
LacZ- and PKCδ-DN-expressing cells, respectively (Fig. 4B).   
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Increase in TH activity should result in increase in dopamine synthesis and therefore, 
we measured the levels of cellular dopamine (DA) by HPLC in N27 cells expressing 
PKCδ-DN and in rottlerin-treated N27 cells.  Vehicle-treated N27 cells and 
Lac-Z-expressing N27 cells were used as controls.  Steady-state DA levels were 
significantly increased in rottlerin-treated and PKCδ-DN mutant-expressing N27 cells 
compared to vehicle-treated and LacZ-expressing cells, respectively (Fig. 4C).  The DA 
level in rottlerin treated-cells was 2748±209 ng/mg protein compared to 754±73 ng/mg 
protein in vehicle-treated N27 cells, a 3.7-fold increase.  Similarly, DA levels in PKCδ-DN 
mutant-expressing cells were 4806±373 ng/mg protein compared to 1015±73 ng/mg protein 
in LacZ-expressing cells, a 4.8-fold increase (Fig. 4C).   Thus, both inhibition of baseline 
PKCδ activity with rottlerin and loss of function PKCδ-DN mutant increased DA levels in 
the dopaminergic cells.  To determine whether increased DA levels in the rottlerin-treated 
and PKCδ-DN-expressing cells were due to enhanced TH activity or due to reduced 
degradation of DA to its major metabolite dihydroxyphenyl acetic acid (DOPAC) by 
monoamine oxidase (MAO), we measured DOPAC levels.  As shown in Fig. 4D, DOPAC 
levels were also significantly increased by 4-fold in rottlerin-treated cells and by 3-fold in 
PKCδ-DN-expressing cells, compared to the vehicle-treated and LacZ-expressing N27 cells, 
indicating that the dopamine degradation pathway is not altered during rottlerin treatment.  
Together, these data suggest that PKCδ inhibition increases DA synthesis in dopaminergic 
neuronal cells as a result of increased TH activation.  
 
PKCδ negatively modulates TH-ser40 phosphorylation. Since TH activity and 
dopamine synthesis were enhanced in N27 cells expressing PKCδ-DN and in rottlerin-treated 
N27 cells, we further examined whether PKCδ inhibition increases the phosphorylation 
status of TH in N27 dopaminergic neuronal cells.  As shown in Fig. 5A, the levels of 
TH-ser40 phosphorylation were significantly enhanced in rottlerin-treated N27 cells, whereas 
the level of TH-ser31 phosphorylation was not altered compared to vehicle-treated cells.  
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Also, the level of total TH was unaltered in rottlerin-treated N27 cells.  Similarly, the 
TH-ser40 phosphorylation level was also significantly enhanced in PKCδ-DN-expressing 
cells compared to LacZ-expressing cells, whereas TH-ser31 phosphorylation and total TH 
levels were unaltered.  Nitrocellulose membranes were reprobed with β-actin antibody and 
the density of the 43 kDa β-actin band was identical in all lanes, confirming equal protein 
loading.  Densitometric analysis of the P-TH-ser40 (60 kDa) band revealed a 3-4-fold 
increase in rottlerin-treated and PKCδ-DN-expressing cells, compared to DMSO and 
LacZ-expressing cells. We also confirmed TH-ser40 phosphorylation by immunofluorescence 
measurements in N27 cells.  N27 cells stably expressing PKCδ-DN-V5 and LacZ-V5 were 
fixed and double immunostained for antibodies directed against P-TH-ser40 and V5-epitope in 
PKCδ-DN-V5 and LacZ-V5 constructs.  Primary antibody staining was followed by 
Cy3-labeled secondary antibody against TH-ser40 and Alexa 488-labeled secondary antibody 
against the V5-epitopes. As shown in Fig. 5B, a bright red immunofluorescence staining was 
observed in PKCδ-DN expressing cells as compared to a very weak staining in Lac-Z 
expressing cells, suggesting that PKCδ inhibition resulted in enhanced phosphorylation of 
TH at ser40.  Both the LacZ- and PKCδ-DN-expressing cells were stained for vector fusion 
protein V5 (Green), demonstrating the expression level of the constructs.  Analysis of 
fluorescent intensity for TH-ser40 immunostaining revealed a 2.5-fold increase in 
PKCδ-DN-expressing cells as compared to Lac-Z-expressing cells (Fig. 5B).  Collectively, 
these results demonstrate that PKCδ inhibition results in enhanced TH phosphorylation at 
ser40 in N27 dopaminergic neuronal cells.  
To further confirm the regulatory role of PKCδ in TH phosphorylation in the 
dopaminergic system, we examined the effect of PKCδ inhibition on TH-ser40 
phosphorylation in primary dopaminergic neurons obtained from the ventral mesencephalon 
of E16-18 mouse embryos.  Primary mesencephalic cultures were transfected with plasmids 
coding for the loss of function PKCδ-DN mutant and LacZ using the Amaxa nucleofector 
system.  24 hr post-transfection, primary neurons were processed for immunohistochemical 
 66
analysis using TH-ser40 and V5-epitope antibodies in PKCδ-DN mutant and LacZ cells.  As 
shown in Fig. 5C, immunochemical staining revealed that the extent of TH-ser40 
phosphorylation was significantly enhanced in primary neurons transfected with the 
PKCδ-DN mutant compared to LacZ transfected primary neurons. V5 staining was used for 
identification of transfected cells.  Fluorescent intensity analysis of TH-ser40 
immunostaining showed about 2.5 times more fluorescence in primary neurons expressing the 
PKCδ-DN mutant as compared to Lac-Z expressing neurons.  These results confirm that 
PKCδ negatively modulates TH-ser40 phosphorylation in primary dopaminergic neurons.  
 
Enhanced TH-ser40 phosphorylation and DA synthesis in PKCδ 
siRNA-transfected dopaminergic neuronal cells. To further substantiate the regulatory role 
of TH activity and DA synthesis by PKCδ, we used an RNA interference (RNAi) approach.  
We recently developed PKCδ siRNAs that specifically suppress PKCδ expression, but not 
the expression of PKCε, a novel isoform most closely and phylogenetically related to PKCδ 
(Yang et al., 2004).  The siRNAs also did not produce any cytotoxic effect in N27 
dopaminergic cells.  In this experiment we measured TH-ser40 phosphorylation, and DA 
and DOPAC levels following siRNA mediated suppression of PKCδ expression in N27 cells.  
Figure 6A shows a significant suppression of endogenous PKCδ expression in PKCδ 
siRNA-transfected cells as compared to non-specific siRNA (NS-siRNA) transfected N27 
cells.  A 60% reduction in PKCδ expression was observed in PKCδ-siRNA transfected cells 
as measured by Western blot analysis.  Importantly, TH-ser40 phosphorylation levels were 
also significantly higher in PKCδ-siRNA-transfected cells as compared to NS-siRNA 
transfected N27 cells, whereas the total TH levels were similar in both PKCδ-siRNA and 
NS-siRNA transfected cells (Fig. 6A).  Densitometric analysis of P-TH-ser40 (60 kDa band) 
revealed a 2-fold increase in PKCδ-siRNA transfected cells compared to NS-siRNA 
transfected N27 cells.  Reprobing of the nitrocellulose membranes with β-actin antibody 
showed the density of the 43 kDa β-actin band to be identical in all lanes, confirming equal 
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protein loading.  Next, we measured DA and DOPAC levels in siRNA transfected N27 cells 
by HPLC.  As shown in Fig. 6B, DA and DOPAC levels were significantly higher in 
PKC-siRNA transfected cells compared to NS-siRNA- transfected N27 cells.  A 45% 
increase in the DA level and a 2-fold increase in DOPAC were noted in 
PKCδ-siRNA-transfected cells as compared to NS-siRNA-transfected N27 cells.  Together, 
these data further substantiate that PKCδ negatively regulates TH-ser40 phosphorylation and 
DA synthesis in dopaminergic neuronal cells. 
 
Increased TH-ser40 phosphorylation in primary mesencephalic dopaminergic 
neurons from PKCδ knockout (-/-) mice. We also extended the TH phosphorylation studies 
to primary mesencephalic dopaminergic neurons derived from naïve and PKCδ knockout (-/-) 
E16-18 mouse embryos (Miyamoto et al., 2002).  The level of TH-ser40 phosphorylation in 
nigral dopaminergic neurons in PKCδ (+/+) and PKCδ (-/-) mice was compared by 
immunostaining.  The baseline TH-ser40 phosphorylation levels were significantly higher in 
untreated primary neurons obtained from PKCδ (-/-) mice compared to untreated PKCδ (+/+) 
mice (Fig. 7).  Fluorescent intensity measurements revealed that the TH-ser40 level was 
3-fold higher in PKCδ (-/-) dopaminergic neurons as compared to PKCδ (+/+) mesencephalic 
neurons.  In addition to the knockout studies, we tested the effect of the PKCδ inhibitor, 
rottlerin, on TH-ser40 phosphorylation in the PKCδ (+/+) primary neuronal cultures.  The 
cultures were treated with 5 μM rottlerin for 3 hr and then the level of TH-ser40 
phosphorylation was measured.  As shown in Fig. 7, rottlerin treatment increased TH-ser40 
phosphorylation in PKCδ (+/+) primary dopaminergic neurons. The fluorescent intensity was 
increased 2-fold in rottlerin-treated dopaminergic neurons as compared to dopaminergic 
neurons.  Together, these results confirm that suppression of PKCδ increases TH-ser40 
phosphorylation in dopaminergic neurons.   
 
Effect of PP2A inhibition on TH activity and TH-ser40 phosphorylation. The 
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increased TH-ser40 phosphorylation resulting from PKCδ inhibition suggested that PKCδ 
may affect dephosphorylation of TH under normal conditions. Previous studies have 
demonstrated that protein phosphatase 2A (PP2A) is a major serine phosphatase that 
mediates the dephosphorylation of TH, in particular TH-ser40, resulting in the inactivation of 
TH (Vrana and Roskoski, 1983; Haavik et al., 1989). Since both of these proteins negatively 
regulate TH, we hypothesize that PKCδ may work through PP2A to reduce 
dephosphorylation of TH-ser40 and TH activity.  This would explain why inhibition of 
PKCδ increases TH-ser 40 phosphorylation, TH activity and dopamine synthesis. 
 In order to test this novel hypothesis, we first examined whether PP2A regulates TH 
activity and TH-ser40 phosphorylation in our dopaminergic model system.  N27 cells were 
incubated with the PP2A inhibitor okadaic acid (2μM) for 2 hr, and then TH-ser40 
phosphorylation and TH activity were measured.  As shown in Fig. 8A, Western blot 
analysis revealed an increase in baseline TH-ser40 phosphorylation levels in okadaic 
acid-treated cells as compared to untreated cells.  The levels of total TH were similar in 
okadaic acid-treated and untreated cells, suggesting that increase in the TH-ser40 
phosphorylation level is not due to increased TH expression.  We also measured TH activity 
as well as dopamine content in okadaic acid-treated cells.  HPLC measurement revealed a 
significant increase in TH activity (Fig. 8B) and DA level (Fig. 8C) in okadaic acid–treated 
cells.  TH activity was increased from 826±64 DOPA pg/106 cells/hr in control cells to 
1434±21 DOPA pg/106 cells/hr in okadaic acid-treated cells. The dopamine levels increased 
from 997±30 ng/mg protein in untreated cells to 1421±10 ng/mg protein in okadaic 
acid-treated cells. Together, these results suggest that PP2A regulates TH activity and 
dopamine synthesis in dopaminergic neurons.  
 
Association and phosphorylation of PP2A by PKCδ. To determine the interaction 
between PKCδ and PP2A, we first examined whether PP2A is physically associated with 
PKCδ.  Immunoprecipitation studies were conducted in cell culture as well as in mouse 
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substantia nigral tissue lysate to determine the possible association. Immunoprecipitation 
studies revealed PP2Ac immunoreactivity in PKCδ immunoprecipitates from PKCδ (+/+) 
mouse substantia nigra lysates (Fig. 9A) and N27 cell lysates (Fig. 9C).  Similarly, in 
reverse immunoprecipitation analysis, the PP2Ac immunoprecipitates showed PKCδ 
immunoreactivity.  The nigral lysate from PKCδ (-/-) mice was used as a negative control.  
No PP2Ac immunoreactivity was observed in PKCδ immunoprecipitates from PKCδ (-/-) 
mouse substantia nigra lysates (Fig. 9B), demonstrating the specificity of 
immunoprecipitation studies. In addition, immunoprecipitated samples using preadsorbed 
PKCδ antibody with blocking peptide showed substantially reduced immunoreactivity to 
PP2Ac, indicating the specificity of PKCδ antibody used in the study.  Rabbit IgG and 
mouse IgG immunoprecipitates were used as additional negative controls in these 
experiments.  Collectively, these results indicate a physical association between PP2Ac and 
PKCδ in a dopaminergic cell line as well as in substantia nigra.   
Next we determined whether physical association of PP2Ac with PKCδ involves 
direct phosphorylation of PP2Ac by PKCδ.  We performed phosphorylation studies using 
immunoprecipitated PP2Ac from N27 cells and pure recombinant PP2Ac protein as substrate.  
As shown in Fig. 9D, both immunoprecipitated and recombinant PP2Ac were effectively 
phosphorylated by recombinant pure PKCδ as determined by 32P-in vitro kinase assays (Fig. 
9D, lanes 1 and 3).  Histone H1 was used as a positive control substrate in phosphorylation 
assays (Fig. 9D, lane 5). To further confirm that PKCδ directly phosphorylates PP2Ac, and 
not another PP2Ac-associated kinase, recombinant PKCδ was preincubated with rottlerin for 
15 minutes prior to the addition of 32P-ATP in in vitro kinase assays.  Rottlerin strongly 
reduced direct phosphorylation of immunoprecipitated and recombinant PP2Ac by PKCδ  
(Fig. 9D, lanes 2 and 4).  In the positive control, incubation with rottlerin also blocked the 
direct phosphorylation of histone by PKCδ (Fig. 9D, lane 6).  Immunoprecipitated and 
recombinant PP2Ac samples incubated with 32P-ATP without PKCδ were used as negative 
controls (Fig. 9D, lanes 7 and 8). A weak band was observed in PP2Ac immunoprecipitates 
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which may be attributed to the endogenously associated PKCδ (Fig. 9D, lane 7).  
Collectively, these data indicate that PKCδ associates with and phosphorylates PP2Ac. 
Since PP2Ac can be phosphorylated by PKCδ, we examined whether PKCδ 
phosphorylation activates or inactivates PP2A enzyme activity.  We first checked the 
possibility in a cell free system.  Purified PP2A was incubated with recombinant PKCδ 
protein in the presence or absence of rottlerin, and PP2A phosphatase activity was 
determined. The PP2A inhibitor okadaic acid was used as a positive control.  As shown in 
Fig. 10A, incubation of PP2A with PKCδ strongly enhanced PP2A activity, which was 
attenuated by rottlerin. For the in vivo studies, we determined PP2A phosphatase activity in 
rottlerin-treated N27 cells and in N27 cells expressing the loss of function PKCδ-DN mutant.  
PP2A activity was significantly reduced in rottlerin-treated cells as compared to 
vehicle-treated N27 cells (Fig. 10B).  Similarly, PP2A activity was also significantly 
reduced in PKCδ-DN-mutant-expressing cells compared to LacZ-expressing N27 cells (Fig. 
10B), indicating that suppression of PKCδ kinase activity reduces the enzymatic activity of 
endogenous PP2A.  However, total PP2A level was unchanged in rottlerin-treated or 
PKCδ-DN cells (Fig. 10C), indicating that the decreased PP2A activity is not due to reduced 
PP2A protein levels.  Taken together with the phosphorylation studies, these data suggest 
that PKCδ phosphorylates PP2Ac and enhances PP2A activity. 
 
Regulation of PP2A activity, TH-ser40 phosphorylation, and DA synthesis in 
PKCδ (-/-) knockout animals. Further validation of the role of PKCδ in the regulation of 
TH activity and DA synthesis was sought by extending these studies to PKCδ (-/-) knockout 
animals.  As shown in Fig. 11A, lack of PKCδ expression in PKCδ (-/-) animals was 
confirmed in Western blots; 74 kDa native PKCδ protein was present only in the brain lysates 
from PKCδ (+/+) mice, but not from the PKCδ (-/-) mice.  Next we examined TH-ser40 
phosphorylation status in PKCδ (-/-) animals. Determination of TH-ser40 phosphorylation in 
substantia nigra brain tissue revealed a significantly higher level in PKCδ (-/-) animals 
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compared to PKCδ (+/+) animals, whereas the total TH levels were similar in the substantia 
nigra of these animals (Fig. 11A). The density of the 43 kDa β-actin band was identical in all 
lanes, indicating equal protein loading.   
To determine whether PKCδ influences PP2A activity in vivo, we compared PP2A 
enzyme activity in the substantia nigra of PKCδ (+/+) and PKCδ (-/-) animals.  PP2A 
activity in the substantia nigra lysates from PKCδ (-/-) mice was significantly lower than in 
PKCδ (+/+) mice (Fig. 11B), supporting our findings from cell culture studies that PKCδ 
positively influences PP2A activity in nigral neurons. 
We also compared DA and DOPAC levels between PKCδ (-/-) animals and PKCδ 
(+/+) animals.  HPLC analysis revealed that striatal DA and DOPAC levels were 
significantly higher in the striatum of PKCδ (-/-) animals compared to PKCδ (+/+) animals 
(Fig. 11C).  DA levels were determined to be 311.7±24.88 ng/mg protein in PKCδ (-/-) 
compared to 190±14.24 ng/mg protein in PKCδ (+/+) animals, an increase of 60%.  
Similarly, striatal DOPAC levels were estimated to be 83.64±12.02 ng/mg protein in PKCδ 
(-/-) compared to 59.41±8.697 ng/mg protein in PKCδ (+/+) animals, an increase of 40%.  
Together, these in vivo data further demonstrate that PKCδ negatively regulates TH activity, 
resulting in reduced TH phosphorylation and DA synthesis.  
 
Discussion 
In the present study, we systematically characterized the regulation of TH by a 
member of the novel class of the protein kinase C family, PKCδ, and demonstrated that (i) 
PKCδ is highly expressed in nigral dopaminergic neurons, (ii) suppression of PKCδ activity 
by kinase inhibitors, dominant negative mutants or RNAi-mediated knockdown increases 
TH-ser40 phosphorylation, TH activity, and dopamine levels (iii) PKCδ phosphorylates 
PP2A to promote dephosphorylation of TH-ser40, and inhibition of PKCδ attenuates PP2A 
activity, resulting in elevated TH-ser40 phosphorylation, TH activity, and dopamine levels, 
and finally (iv) TH activity and dopamine levels are enhanced in PKCδ (-/-) knockout 
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animals.  These results were obtained using both cellular and molecular biological 
approaches in multiple cell culture models including PC12 cells, N27 mesencephalic 
dopaminergic cells and primary mesencephalic neurons, as well as in animal models, 
including a knockout model.  Collectively, to our knowledge, this is the first report 
describing a negative regulation of the rate-limiting enzyme of the dopamine synthetic 
pathway, TH, by PKCδ via modulation of PP2A activity.   
Phosphorylation is a key post-translational mechanism to regulate TH activity. 
Phosphorylation of serine residues at 8, 19, 31 and 40 can activate TH, resulting in enhanced 
dopamine synthesis (Campbell et al., 1986; Haycock, 1990; Mitchell et al., 1990; Lindgren et 
al., 2001; McCulloch et al., 2001; Dunkley et al., 2004).  A number of kinases, including 
PKC, PKA, CaMPK-II, and MAPkinase, have been shown to phosphorylate one or more of 
these sites to increase TH activity, depending on the cell type.  Since we found a high 
expression of PKCδ in nigral dopaminergic neurons (Fig.1), we initially hypothesized that 
PKCδ might phosphorylate TH to increase its activity.  In order to test this hypothesis, we 
used the PKCδ inhibitor rottlerin to inhibit the kinase and anticipated that inhibition of PKCδ 
would result in inhibition of TH activity.  Surprisingly, we observed a dose-dependent 
increase in TH activity and dopamine levels in cells treated with the PKCδ inhibitor rottlerin.  
To further confirm this observation, PKCδ-dominant negative mutant and siRNAs were used 
for PKCδ inhibition, which also caused increased TH activity and dopamine levels in 
dopaminergic cells.  Determination of TH-ser40 phosphorylation under conditions of PKCδ 
inhibition further revealed an enhanced TH-ser40 phosphorylation with no significant change 
in phosphorylation of TH-ser31.  Of the different phosphorylation sites, Ser40 is the major 
regulatory site contributing to increased TH activity and dopamine synthesis in vivo 
(Meligeni et al., 1982; Waymire et al., 1991; Daubner et al., 1992; Wu et al., 1992; 
McCulloch et al., 2001).  Studies using PC12 cells either responsive or non-responsive to 
cAMP stimuli demonstrated that PKA is an important kinase in TH-ser40 phosphorylation 
(Wilson et al., 1996; Salvatore et al., 2001).  Recently, Kobori et al. reported that GDNF 
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increases TH-ser31 and TH-ser40 phosphorylation, which contributes to enhanced dopamine 
synthesis in mesencephalic cultures (Kobori et al., 2004).  Taken together, phosphorylation 
of the serine residues also appears to depend on cell types and stimuli.  
General PKC increases ser-40 phosphorylation and TH activity (Cahill et al., 1989; 
Haycock, 1990; Haycock and Haycock, 1991; Waymire et al., 1991; Haycock, 1993; 
Bobrovskaya et al., 1998), however, the effect of PKC subtypes has never been explored.  
At the present time, 12 different isoforms of PKC have been identified and grouped into three 
major classes (Gschwendt, 1999; Dempsey et al., 2000; Maher, 2001; Kanthasamy et al., 
2003).  The conventional class of PKC isoforms PKC α, βI, βII, and γ require DAG and 
Ca2+ for activation, the novel PKC isoforms, PKCδ, ε, µ, η, and θ require only DAG but not 
Ca2+ for activation, and the atypical PKCs, PKC τ, λ, and ζ require neither Ca2+ nor DAG for 
activation.  The isoform-specific physiological functions of each subtype of PKCs are yet to 
be characterized in CNS.  The recently available, more specific pharmacological inhibitors, 
genetic mutants and siRNAs specific for subtypes of isoforms are extremely useful in 
characterizing functional significance of PKC isoforms.  Our results of enhanced TH 
activity by pharmacological inhibitors and siRNA in three different cell culture models 
clearly demonstrate that PKCδ can negatively regulate TH activity.  
An increase in TH-ser40 phosphorylation is normally mediated by either activation of 
a kinase responsible for the serine phosphorylation, or by blocking the activity of the 
phosphatase responsible for dephosphorylation of ser40.  Since we found an increase in 
TH-ser40 phosphorylation and TH activity under the condition of PKCδ inhibition 
(pharmacological inhibitor, dominant negative mutant, siRNA studies; Figs. 2-6), we 
hypothesized that PKCδ attenuates TH function by enhancing phosphatase activity.  Haavik 
et al. demonstrated that PP2A is the major serine/threonine phosphatase that regulates greater 
than 90% of the dephosphorylation of TH at Ser40 (Haavik et al., 1989).  In their study, 
okadaic acid treatment dramatically increased TH phosphorylation and TH activity, 
establishing PP2A as an important regulator of both TH activity and Ser40 phosphorylation.  
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Recently, Leal et al. (Leal et al., 2002) demonstrated that PP2A dephosphorylated TH-ser40 
at twice the rate compared to TH-ser31 and TH-ser19, suggesting a preferential 
dephosphorylation of TH-ser40 by PP2A.  Additionally, Lindgren et al. (Lindgren et al., 
2001) showed that PP2A inhibitor treatment in rat striatal slices did not increase TH 
phosphorylation at Ser31, whereas TH-ser40 phosphorylation was readily increased, 
indicating that the TH-ser40 site may be highly regulated by 
phosphorylation/dephosphorylation reactions as compared to TH-ser31.  Furthermore, 
among these three phosphorylated serine residues, TH-ser40 mainly contributed to tyrosine 
hydroxylase activation and dopamine synthesis in vivo (Ramsey et al., 1996).  Thus, 
consistent with previous studies, our results indicate TH ser40 is predominantly regulated by 
phosphorylation/dephosphorylation.   
An active PP2A enzyme consists of a heterotrimer of the structural A subunit, a 
catalytic C subunit, and a regulatory B subunit (Dobrowsky and Hannun, 1993; Sontag et al., 
1995; McCright et al., 1996; Ruvolo et al., 2002). The exact nature of the physical 
association and dynamic regulation of TH, PKCδ and PP2A are yet to be characterized; 
however, recent literature provides some information regarding this interaction.  PKCδ, TH 
or PP2A have been recently shown to physically associate with each other, as well as other 
putative chaperone proteins such as α-synuclein and 14-3-3 (Ostrerova et al., 1999; Kleppe et 
al., 2001; Srivastava et al., 2002; Kjarland et al., 2006).  Recently, Peng et al. (Peng et al., 
2005) demonstrated that a functional interaction between α-synuclein and PP2A can regulate 
TH phosphorylation and TH activity.  Srivastava et al. reported a physical interaction 
between PKCδ and PP2A in NIH3T3 cells, and that dephosphorylation of PKCδ by PP2A 
results in its inactivation (Srivastava et al., 2002). In our recent study, we showed that 
α-synuclein interacts with PKCδ and regulates its activity following neurotoxic insults (Kaul 
et al., 2005). Therefore, in the dopaminergic system, the physical and functional association 
between PKCδ, TH and PP2A could be facilitated and/or regulated by chaperone proteins 
such as α-synuclein (Kaul et al., 2005; Peng et al., 2005) and 14-3-3 (Ostrerova et al., 1999; 
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Kleppe et al., 2001; Kjarland et al., 2006). Nevertheless, further studies are required in both 
in vitro and in vivo model systems to elucidate the dynamics of physical and functional 
regulation of PKCδ and PP2A in regulation of TH activity. 
In the present study, we show that PKCδ and PP2Ac physically associate in 
dopaminergic neuronal cell lysates as well as in mouse brain substantia nigra lysates.  This 
interaction of PKCδ with PP2Ac may stimulate PP2A activity.  To determine whether the 
physical association is accompanied by a functional interaction, we measured PP2A activity 
under conditions where PKCδ activity was inhibited.  We found that PP2A activity was 
significantly decreased, without altering the PP2A protein levels, by the PKCδ inhibitor 
rottlerin.  Basal PP2A enzymatic activity was also significantly reduced in dopaminergic 
cells stably expressing loss of function kinase inactive PKCδ-DN mutant compared to LacZ 
cells.  Furthermore, substantia nigra of PKCδ (-/-) mice showed significantly lower basal 
PP2A activity compared to naïve animals, indicating that PKCδ can augment PP2A activity.  
Additionally, in vitro kinase assays also revealed that PKCδ can phosphorylate PP2Ac.  
Taken together, these data suggest that physical association accompanied by PP2Ac 
phosphorylation by PKCδ, results in PP2A activation.  PP2A activity can be effectively 
regulated by phosphorylation.  Many studies have shown that phosphorylation of PP2A at 
Tyr307 reduces its activity (Chen et al., 1992), indicating that Tyr307 is a key negative 
regulatory phosphorylation site.  PP2A could also be phosphorylated at serine/threonine 
sites (Guo and Damuni, 1993), but the specific PKC isoforms involved in the PP2A 
phosphorylation at various sites of PP2A are yet to be characterized.  Following the 
observation that PKCδ can phosphorylate PP2Ac to increase activity, we further examined 
whether enhanced PP2A activity reduces TH-ser40 phosphorylation and TH activity.  
Treatment with the PP2A inhibitor okadaic acid increased the TH-ser40 level and enhanced 
TH activity, suggesting that PP2A effectively regulates TH activity and ser40 
phosphorylation. Our results are in agreement with a recent study showing attenuation of TH 
activity and TH-ser40 phosphorylation by PP2A (Peng et al., 2005).  Collectively, our data 
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on PKCδ and PP2A suggest that PKCδ negatively regulates TH-ser40 phosphorylation and 
TH activity via increased PP2A activity by direct phosphorylation of PP2A.   
Regulation of TH activity and DA levels is critical for normal dopaminergic 
neurotransmission in the CNS.  Excessive DA production may not only alter 
neurotransmission, but may also contribute to neuronal cell death through increased oxidative 
stress (Hoyt et al., 1997; Luo et al., 1998). In this regard, we wish to point out that PKCδ can 
be activated by at least two independent mechanisms in neuronal cells.  These include 
membrane translocation and caspase-3-dependent proteolytic cleavage (Kikkawa et al., 2002; 
Brodie and Blumberg, 2003; Kanthasamy et al., 2003).  Of the two activation mechanisms, 
PKCδ activated by membrane translocation following tonic stimulation by lipid activators 
contributes to cell survival and proliferation (Kikkawa et al., 2002; Kanthasamy et al., 2003; 
Jackson and Foster, 2004).  As demonstrated in our recent studies, another form of 
activation is caspase-3-dependent proteolytic cleavage of native PKCδ into regulatory and 
catalytic fragments resulting in persistent activation during exposure to neurotoxic agents 
such as MPP+, MMT, manganese or dieldrin (Anantharam et al., 2002; Kaul et al., 2003; 
Latchoumycandane et al., 2005).  This form of proteolytic activation contributes to 
apoptotic cell death of dopaminergic neurons (Kanthasamy et al., 2003).  In the case of a 
lipid activator, TPA induced membrane translocation of native PKCδ, but did not induce 
apoptotic cell death in dopaminergic cell lines (unpublished observations).  Furthermore, 
recent studies from our lab and others have shown that unlike the native 74 kDa PKCδ, the 
41 kDa catalytically active PKCδ fragment, upon proteolytic cleavage, is targeted to various 
sub-cellular organelles including the mitochondria (Majumder et al., 2000) and nucleus 
(DeVries et al., 2002) to activate apoptotic cell death signaling molecules.  These results 
suggest that native and cleaved PKCδ have different substrate profiles.  In this study, we 
examined the effect of native intact PKCδ on PP2A activity and TH regulation under normal 
conditions, but we did not study the effect of neurotoxicant-induced proteolytically activated 
PKCδ.  Apparently, a high expression of PKCδ in nigral dopaminergic neurons has dual 
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functions. In normal situations, PKCδ phosphorylates PP2A to increase the phosphastase 
activity, resulting in enhanced dephosphorylation of TH-ser40, which eventually leads to 
decreased TH activity and DA synthesis (summarized in Supplemental Fig. 1).  This 
negative regulation may be important for maintaining optimal dopamine levels. In addition to 
the function of regulating dopamine synthesis, under the condition of enhanced oxidative 
stress induced by neurotoxic insults, PKCδ serves as a key downstream proapoptotic effector 
of caspase-3, resulting in proteolytic activation of the kinase which contributes to cell death 
(Anantharam et al., 2002; Kanthasamy et al., 2003; Kaul et al., 2003; Yang et al., 2004).   
In conclusion, we provide novel evidence that PKCδ negatively regulates TH activity 
and DA synthesis via activation of PP2A, and we suggest that PKCδ-mediated regulation of 
TH may have important implications in neurological dopaminergic system disorders, such as 
Parkinson’s disease.   
 
References 
Adams FS, La Rosa FG, Kumar S, Edwards-Prasad J, Kentroti S, Vernadakis A, Freed CR, 
Prasad KN (1996) Characterization and transplantation of two neuronal cell lines with 
dopaminergic properties. Neurochem Res 21:619-627. 
Albert KA, Wu WC, Nairn AC, Greengard P (1984) Inhibition by calmodulin of 
calcium/phospholipid-dependent protein phosphorylation. Proc Natl Acad Sci U S A 
81:3622-3625. 
Anantharam V, Kitazawa M, Wagner J, Kaul S, Kanthasamy AG (2002) Caspase-3-dependent 
proteolytic cleavage of protein kinase Cdelta is essential for oxidative stress-mediated 
dopaminergic cell death after exposure to methylcyclopentadienyl manganese 
tricarbonyl. J Neurosci 22:1738-1751. 
Bobrovskaya L, Cheah TB, Bunn SJ, Dunkley PR (1998) Tyrosine hydroxylase in bovine 
adrenal chromaffin cells: angiotensin II-stimulated activity and phosphorylation of 
Ser19, Ser31, and Ser40. J Neurochem 70:2565-2573. 
 78
Brodie C, Blumberg PM (2003) Regulation of cell apoptosis by protein kinase c delta. 
Apoptosis 8:19-27. 
Bunn SJ, Saunders HI (1995) Staurosporine inhibits inositol phosphate formation in bovine 
adrenal medullary cells. Eur J Pharmacol 290:227-236. 
Cahill AL, Horwitz J, Perlman RL (1989) Phosphorylation of tyrosine hydroxylase in protein 
kinase C-deficient PC12 cells. Neuroscience 30:811-818. 
Campbell DG, Hardie DG, Vulliet PR (1986) Identification of four phosphorylation sites in 
the N-terminal region of tyrosine hydroxylase. J Biol Chem 261:10489-10492. 
Chen J, Martin BL, Brautigan DL (1992) Regulation of protein serine-threonine phosphatase 
type-2A by tyrosine phosphorylation. Science 257:1261-1264. 
Clarkson ED, Edwards-Prasad J, Freed CR, Prasad KN (1999) Immortalized dopamine 
neurons: A model to study neurotoxicity and neuroprotection. Proc Soc Exp Biol Med 
222:157-163. 
Daubner SC, Lauriano C, Haycock JW, Fitzpatrick PF (1992) Site-directed mutagenesis of 
serine 40 of rat tyrosine hydroxylase. Effects of dopamine and cAMP-dependent 
phosphorylation on enzyme activity. J Biol Chem 267:12639-12646. 
Davies SP, Reddy H, Caivano M, Cohen P (2000) Specificity and mechanism of action of 
some commonly used protein kinase inhibitors. Biochem J 351:95-105. 
Dempsey EC, Newton AC, Mochly-Rosen D, Fields AP, Reyland ME, Insel PA, Messing RO 
(2000) Protein kinase C isozymes and the regulation of diverse cell responses. Am J 
Physiol Lung Cell Mol Physiol 279:L429-438. 
DeVries TA, Neville MC, Reyland ME (2002) Nuclear import of PKCdelta is required for 
apoptosis: identification of a novel nuclear import sequence. Embo J 21:6050-6060. 
Dobrowsky RT, Hannun YA (1993) Ceramide-activated protein phosphatase: partial 
purification and relationship to protein phosphatase 2A. Adv Lipid Res 25:91-104. 
Donze O, Picard D (2002) RNA interference in mammalian cells using siRNAs synthesized 
with T7 RNA polymerase. Nucleic Acids Res 30:e46. 
 79
Dunkley PR, Bobrovskaya L, Graham ME, von Nagy-Felsobuki EI, Dickson PW (2004) 
Tyrosine hydroxylase phosphorylation: regulation and consequences. J Neurochem 
91:1025-1043. 
Elbashir SM, Lendeckel W, Tuschl T (2001) RNA interference is mediated by 21- and 
22-nucleotide RNAs. Genes Dev 15:188-200. 
Favre B, Turowski P, Hemmings BA (1997) Differential inhibition and posttranslational 
modification of protein phosphatase 1 and 2A in MCF7 cells treated with calyculin-A, 
okadaic acid, and tautomycin. J Biol Chem 272:13856-13863. 
Funakoshi H, Okuno S, Fujisawa H (1991) Different effects on activity caused by 
phosphorylation of tyrosine hydroxylase at serine 40 by three multifunctional protein 
kinases. J Biol Chem 266:15614-15620. 
Gschwendt M (1999) Protein kinase C delta. Eur J Biochem 259:555-564. 
Guo H, Damuni Z (1993) Autophosphorylation-activated protein kinase phosphorylates and 
inactivates protein phosphatase 2A. Proc Natl Acad Sci U S A 90:2500-2504. 
Haavik J, Schelling DL, Campbell DG, Andersson KK, Flatmark T, Cohen P (1989) 
Identification of protein phosphatase 2A as the major tyrosine hydroxylase phosphatase 
in adrenal medulla and corpus striatum: evidence from the effects of okadaic acid. FEBS 
Lett 251:36-42. 
Hayashi Y, Miwa S, Lee K, Koshimura K, Kamel A, Hamahata K, Fujiwara M (1988) A 
nonisotopic method for determination of the in vivo activities of tyrosine hydroxylase in 
the rat adrenal gland. Anal Biochem 168:176-183. 
Haycock JW (1989) Quantitation of tyrosine hydroxylase, protein levels: spot 
immunolabeling with an affinity-purified antibody. Anal Biochem 181:259-266. 
Haycock JW (1990) Phosphorylation of tyrosine hydroxylase in situ at serine 8, 19, 31, and 
40. J Biol Chem 265:11682-11691. 
Haycock JW (1993) Multiple signaling pathways in bovine chromaffin cells regulate tyrosine 
hydroxylase phosphorylation at Ser19, Ser31, and Ser40. Neurochem Res 18:15-26. 
 80
Haycock JW, Haycock DA (1991) Tyrosine hydroxylase in rat brain dopaminergic nerve 
terminals. Multiple-site phosphorylation in vivo and in synaptosomes. J Biol Chem 
266:5650-5657. 
Haycock JW, Ahn NG, Cobb MH, Krebs EG (1992) ERK1 and ERK2, two 
microtubule-associated protein 2 kinases, mediate the phosphorylation of tyrosine 
hydroxylase at serine-31 in situ. Proc Natl Acad Sci U S A 89:2365-2369. 
Hoyt KR, Reynolds IJ, Hastings TG (1997) Mechanisms of dopamine-induced cell death in 
cultured rat forebrain neurons: interactions with and differences from glutamate-induced 
cell death. Exp Neurol 143:269-281. 
Jackson DN, Foster DA (2004) The enigmatic protein kinase Cdelta: complex roles in cell 
proliferation and survival. Faseb J 18:627-636. 
Kanthasamy AG, Kitazawa M, Kaul S, Yang Y, Lahiri DK, Anantharam V, Kanthasamy A 
(2003) Proteolytic activation of proapoptotic kinase PKCdelta is regulated by 
overexpression of Bcl-2: implications for oxidative stress and environmental factors in 
Parkinson's disease. Ann N Y Acad Sci 1010:683-686. 
Kaul S, Anantharam V, Kanthasamy A, Kanthasamy AG (2005) Wild-type alpha-synuclein 
interacts with pro-apoptotic proteins PKCdelta and BAD to protect dopaminergic 
neuronal cells against MPP+-induced apoptotic cell death. Brain Res Mol Brain Res 
139:137-152. 
Kaul S, Kanthasamy A, Kitazawa M, Anantharam V, Kanthasamy AG (2003) Caspase-3 
dependent proteolytic activation of protein kinase C delta mediates and regulates 
1-methyl-4-phenylpyridinium (MPP+)-induced apoptotic cell death in dopaminergic 
cells: relevance to oxidative stress in dopaminergic degeneration. Eur J Neurosci 
18:1387-1401. 
Kikkawa U, Matsuzaki H, Yamamoto T (2002) Protein kinase C delta (PKC delta): activation 
mechanisms and functions. J Biochem (Tokyo) 132:831-839. 
Kitazawa M, Anantharam V, Kanthasamy AG (2001) Dieldrin-induced oxidative stress and 
 81
neurochemical changes contribute to apoptopic cell death in dopaminergic cells. Free 
Radic Biol Med 31:1473-1485. 
Kitazawa M, Anantharam V, Yang Y, Hirata Y, Kanthasamy A, Kanthasamy AG (2005) 
Activation of protein kinase C delta by proteolytic cleavage contributes to 
manganese-induced apoptosis in dopaminergic cells: protective role of Bcl-2. Biochem 
Pharmacol 69:133-146. 
Kjarland E, Keen TJ, Kleppe R (2006) Does isoform diversity explain functional differences 
in the 14-3-3 protein family? Curr Pharm Biotechnol 7:217-223. 
Kleppe R, Toska K, Haavik J (2001) Interaction of phosphorylated tyrosine hydroxylase with 
14-3-3 proteins: evidence for a phosphoserine 40-dependent association. J Neurochem 
77:1097-1107. 
Kobori N, Waymire JC, Haycock JW, Clifton GL, Dash PK (2004) Enhancement of tyrosine 
hydroxylase phosphorylation and activity by glial cell line-derived neurotrophic factor. J 
Biol Chem 279:2182-2191. 
Latchoumycandane C, Anantharam V, Kitazawa M, Yang Y, Kanthasamy A, Kanthasamy AG 
(2005) Protein kinase Cdelta is a key downstream mediator of manganese-induced 
apoptosis in dopaminergic neuronal cells. J Pharmacol Exp Ther 313:46-55. 
Leal RB, Sim AT, Goncalves CA, Dunkley PR (2002) Tyrosine hydroxylase 
dephosphorylation by protein phosphatase 2A in bovine adrenal chromaffin cells. 
Neurochem Res 27:207-213. 
Lee KY, Lew JY, Tang D, Schlesinger DH, Deutch AY, Goldstein M (1989) Antibodies to a 
synthetic peptide corresponding to a Ser-40-containing segment of tyrosine hydroxylase: 
activation and immunohistochemical localization of tyrosine hydroxylase. J Neurochem 
53:1238-1244. 
Lindgren N, Xu ZQ, Herrera-Marschitz M, Haycock J, Hokfelt T, Fisone G (2001) Dopamine 
D(2) receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat 
striatum. Eur J Neurosci 13:773-780. 
 82
Luo Y, Umegaki H, Wang X, Abe R, Roth GS (1998) Dopamine induces apoptosis through 
an oxidation-involved SAPK/JNK activation pathway. J Biol Chem 273:3756-3764. 
Maher P (2001) How protein kinase C activation protects nerve cells from oxidative 
stress-induced cell death. J Neurosci 21:2929-2938. 
Majumder PK, Pandey P, Sun X, Cheng K, Datta R, Saxena S, Kharbanda S, Kufe D (2000) 
Mitochondrial translocation of protein kinase C delta in phorbol ester-induced 
cytochrome c release and apoptosis. J Biol Chem 275:21793-21796. 
McCright B, Rivers AM, Audlin S, Virshup DM (1996) The B56 family of protein 
phosphatase 2A (PP2A) regulatory subunits encodes differentiation-induced 
phosphoproteins that target PP2A to both nucleus and cytoplasm. J Biol Chem 
271:22081-22089. 
McCulloch RI, Daubner SC, Fitzpatrick PF (2001) Effects of substitution at serine 40 of 
tyrosine hydroxylase on catecholamine binding. Biochemistry 40:7273-7278. 
McTigue M, Cremins J, Halegoua S (1985) Nerve growth factor and other agents mediate 
phosphorylation and activation of tyrosine hydroxylase. A convergence of multiple 
kinase activities. J Biol Chem 260:9047-9056. 
Meligeni JA, Haycock JW, Bennett WF, Waymire JC (1982) Phosphorylation and activation 
of tyrosine hydroxylase mediate the cAMP-induced increase in catecholamine 
biosynthesis in adrenal chromaffin cells. J Biol Chem 257:12632-12640. 
Miranda M, Sorkina T, Grammatopoulos TN, Zawada WM, Sorkin A (2004) Multiple 
molecular determinants in the carboxyl terminus regulate dopamine transporter export 
from endoplasmic reticulum. J Biol Chem 279:30760-30770. 
Mitchell JP, Hardie DG, Vulliet PR (1990) Site-specific phosphorylation of tyrosine 
hydroxylase after KCl depolarization and nerve growth factor treatment of PC12 cells. J 
Biol Chem 265:22358-22364. 
Miyamoto A, Nakayama K, Imaki H, Hirose S, Jiang Y, Abe M, Tsukiyama T, Nagahama H, 
Ohno S, Hatakeyama S, Nakayama KI (2002) Increased proliferation of B cells and 
 83
auto-immunity in mice lacking protein kinase Cdelta. Nature 416:865-869. 
Ostrerova N, Petrucelli L, Farrer M, Mehta N, Choi P, Hardy J, Wolozin B (1999) 
alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J 
Neurosci 19:5782-5791. 
Peng X, Tehranian R, Dietrich P, Stefanis L, Perez RG (2005) Alpha-synuclein activation of 
protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic 
cells. J Cell Sci 118:3523-3530. 
Ramsey AJ, Hillas PJ, Fitzpatrick PF (1996) Characterization of the active site iron in 
tyrosine hydroxylase. Redox states of the iron. J Biol Chem 271:24395-24400. 
Ruvolo PP, Clark W, Mumby M, Gao F, May WS (2002) A functional role for the B56 
alpha-subunit of protein phosphatase 2A in ceramide-mediated regulation of Bcl2 
phosphorylation status and function. J Biol Chem 277:22847-22852. 
Salvatore MF, Waymire JC, Haycock JW (2001) Depolarization-stimulated catecholamine 
biosynthesis: involvement of protein kinases and tyrosine hydroxylase phosphorylation 
sites in situ. J Neurochem 79:349-360. 
Schonthal AH (1998) Role of PP2A in intracellular signal transduction pathways. Front 
Biosci 3:D1262-1273. 
Soltoff SP (2001) Rottlerin is a mitochondrial uncoupler that decreases cellular ATP levels 
and indirectly blocks protein kinase Cdelta tyrosine phosphorylation. J Biol Chem 
276:37986-37992. 
Sontag E, Nunbhakdi-Craig V, Bloom GS, Mumby MC (1995) A novel pool of protein 
phosphatase 2A is associated with microtubules and is regulated during the cell cycle. J 
Cell Biol 128:1131-1144. 
Srivastava J, Goris J, Dilworth SM, Parker PJ (2002) Dephosphorylation of PKCdelta by 
protein phosphatase 2Ac and its inhibition by nucleotides. FEBS Lett 516:265-269. 
Sun F, Anantharam V, Zhang D, Latchoumycandane C, Kanthasamy A, Kanthasamy AG 
(2006) Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture 
 84
and animal models. Neurotoxicology 27:807-815. 
Tachikawa E, Tank AW, Weiner DH, Mosimann WF, Yanagihara N, Weiner N (1987) 
Tyrosine hydroxylase is activated and phosphorylated on different sites in rat 
pheochromocytoma PC12 cells treated with phorbol ester and forskolin. J Neurochem 
48:1366-1376. 
Vrana KE, Roskoski R, Jr. (1983) Tyrosine hydroxylase inactivation following 
cAMP-dependent phosphorylation activation. J Neurochem 40:1692-1700. 
Way KJ, Chou E, King GL (2000) Identification of PKC-isoform-specific biological actions 
using pharmacological approaches. Trends Pharmacol Sci 21:181-187. 
Waymire JC, Craviso GL, Lichteig K, Johnston JP, Baldwin C, Zigmond RE (1991) 
Vasoactive intestinal peptide stimulates catecholamine biosynthesis in isolated adrenal 
chromaffin cells: evidence for a cyclic AMP-dependent phosphorylation and activation 
of tyrosine hydroxylase. J Neurochem 57:1313-1324. 
Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, 
Shannak K, Haycock JW, Kish SJ (1996) Striatal dopamine nerve terminal markers in 
human, chronic methamphetamine users. Nat Med 2:699-703. 
Wu J, Filer D, Friedhoff AJ, Goldstein M (1992) Site-directed mutagenesis of tyrosine 
hydroxylase. Role of serine 40 in catalysis. J Biol Chem 267:25754-25758. 
Yang Y, Kaul S, Zhang D, Anantharam V, Kanthasamy AG (2004) Suppression of 
caspase-3-dependent proteolytic activation of protein kinase C delta by small interfering 
RNA prevents MPP+-induced dopaminergic degeneration. Mol Cell Neurosci 
25:406-421. 
Zhou W, Hurlbert MS, Schaack J, Prasad KN, Freed CR (2000) Overexpression of human 
alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized 
mesencephalon-derived cells. Brain Res 866:33-43. 
 
 85
FIGURE 1. 
 
Figure 1.  PKCδ associates with TH in mouse brain and PC12 cells. A, 
Immunohistochemical analysis. Mouse brain was cut to 20 μm thickness at the level of the 
substantia nigra and stained with PKCδ polyclonal Ab (1:500 dilution) and TH monoclonal 
Ab (1:500 dilution), followed by incubation with either Alexa 488-conjugated (green, 1:1000) 
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or Cy3-conjugated (red, 1:1000) secondary antibody.  Hoechst 33342 (10 μg/ml) was used 
to stain the nucleus. TH as red, PKCδ as green, nucleus as blue are shown. B, PKCδ (74 kDa) 
co-immunoprecipitated with TH in mouse substantia nigra.  PKCδ was 
immunoprecipitated (IP) from mouse substantia nigra lysates by using PKCδ polyclonal Ab 
(1:100) and immunoblotted (IB) with anti-TH (1:100). In reverse immunoprecipitation 
studies, TH was immunoprecipitated with mouse monoclonal anti-TH antibody (1:100) and 
immunoblotted with PKCδ.  TH (60 kDa) co-immunoprecipitated with PKCδ in mouse 
substantia nigra.  Similarly, PKCδ (74 kDa) co-immunoprecipitated with TH in mouse 
substantia nigra.  C, PKCδ also co-immunoprecipitated with TH in PC12 cells,  PKCδ 
was immunoprecipitated (IP) from PC12 cell lysates by using PKCδ polyclonal Ab (1:100) 
and immunoblotted (IB) with anti-TH (1:100). In reverse immunoprecipitation studies, TH 
was immunoprecipitated with mouse monoclonal anti-TH antibody (1:100) and 
immunoblotted with PKCδ.  TH (60 kDa) co-immunoprecipitated with PKCδ in PC12 cell 
lysates.  Similarly, PKCδ (74 kDa) co-immunoprecipitated with TH in PC12 cell lysates.  
Rabbit IgG and mouse IgG were used as negative controls.  IP: immunoprecipitated samples; 
IB: immunoblots 
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FIGURE 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  PKCδ inhibition enhances TH activity.  PC12 cells were incubated with the 
DOPA decarboxylase inhibitor NSD-1015 (2 mM) for 1 hr prior to treatment with the PKCδ 
inhibitor rottlerin (1-10 μM).  0.01% DMSO was used as vehicle control.  After 3 hr 
rottlerin treatment, cells were lysed and extracts were used for determining L-DOPA levels 
by HPLC.  Rottlerin treatment increased L-DOPA levels, indicating enhanced TH activity. 
The data represent mean + SEM of six to eight individual measurements.  Asterisks 
(*p<0.05 and **p<0.01) indicate significant differences between rottlerin-treated cells and 
control cells. 
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FIGURE 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  PKCδ inhibition enhances TH-ser40 phosphorylation.  A, Western blot 
analysis, PC12 cells were exposed to rottlerin (5 μM) or 0.01% DMS0 (vehicle control) for 3 
hr.  Cell extracts were prepared and separated by SDS-polyacrylamide gel electrophoresis 
and transferred to nitrocellulose membrane. Phospho-specific antibodies directed against 
P-TH-ser40 and P-TH-ser31, and antibodies directed against TH and PKCδ were used for 
immunoblotting. To confirm equal protein loading in each lane, the membranes were 
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reprobed with β-actin antibody. The immunoblots were visualized using the Amersham’s 
ECL detection agents. Densitometric analysis of 60 kDa TH and P-TH-ser40 and P-TH-ser31 
bands represents the mean ± SEM from three separate experiments (**p < 0.01).  B, 
Immunocytochemistry: PC12 cells were grown on poly-L-lysine coated cover slips and 
then exposed to either 5 μM rottlerin or 0.01% DMS0 for 3 hr. After treatment, the cells were 
fixed and immunostained for P-TH-ser40 followed by staining with Alexa 488-conjugated 
antibody (green), as described in the methods section.  For a negative control, cells were 
also immunostained with Alexa 488 without primary antibody staining.  Immunostained 
cells were mounted and viewed under a Nikon TE2000 fluorescence microscope and images 
were captured with a SPOT digital camera. For in situ quantitative analysis of P-TH-ser40 
levels, fluorescence immunoreactivity in cells was measured from six different areas in each 
group using Metamorph image analysis software, and data were analyzed with Prism 
software. Experiments were repeated three times, and representative images are presented.  
Asterisks (**p < 0.01) indicate significant differences between rottlerin treated and control 
cells. 
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FIGURE 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  PKCδ inhibition regulates TH activity and DA synthesis in N27 
dopaminergic neuronal cells.  A, In situ co-localization of TH and PKCδ.  
Differentiated N27 cells were grown on poly-L-lysine coated cover slips and processed for 
double immunostaining with anti-PKCδ monoclonal and anti-TH polyclonal antibodies or 
anti-PKCδ monoclonal and anti-P-TH-ser40 polyclonal antibodies, as described in the 
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methods section.  B, TH activity in PKCδ inhibitor rottlerin-treated cells and 
PKCδ-dominant negative mutant (PKCδ-DN) cells.  Differentiated N27 cells stably 
expressing LacZ or PKCδ-DN were pretreated with 2 mM NSD-1015 for 1 hr and lysed, and 
extracts were used for determining L-DOPA levels by HPLC.  Also, cell extracts from N27 
cells incubated with 2 mM NSD-1015 for 1 hr prior to treatment with 0.01% DMSO (vehicle 
control) or rottlerin (5 μM for 3 hr) were also used for measuring DOPA levels.  C and D, 
DA synthesis: cell extracts from N27 cells stably expressing LacZ and PKCδ-DN, or treated 
with rottlerin (5 μM for 3 hr) were used for determining DA and DOPAC levels by HPLC.  
The data represent a mean + SEM of six to eight individual measurements.  Asterisks 
(**p<0.01 and ***p<0.001) indicate significant differences between rottlerin-treated cells 
and vehicle control cells, or between LacZ- and PKCδ-DN-expressing cells. 
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FIGURE 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Effect of PKCδ-DN and rottlerin on TH-ser40 phosphorylation. A, Western 
blot: Cell extracts from rottlerin treated, PKCδ-DN and LacZ expressing N27 cells were 
subjected to Western blot, as described in the methods section. P-TH-ser40, P-TH-ser31 and 
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TH levels were detected using appropriate phospho-specific and TH antibodies.  
Densitometric analysis of 60 kDa P-TH-ser40, P-TH-ser31 and TH bands are shown next to 
the Western blot image. The data represent the mean ± SEM from three separate experiments 
(**p<0.01). B, TH-ser40 phosphorylation in stably expressing PKCδ-DN and LacZ N27 cells 
and C, primary mesencephalic cultures transiently expressing PKCδ-DN and LacZ constructs.  
Briefly, N27 cells and primary mesencephalic neurons expressing PKCδ-DN and LacZ (these 
constructs express V5 fusion protein) were cultured and processed for double immunostaining 
of P-TH-ser40 and V5 using specific antibodies.  Stained cells were mounted on slides and 
viewed under a Nikon TE2000 fluorescence microscope, and images were captured with a 
SPOT digital camera, as described in the methods section.  P-TH-ser40 levels were 
quantitatively analyzed from six different areas in each group using Metamorph image 
analysis.  Experiments were repeated three times and representative images are shown.  
Asterisks (**p<0.01) indicate significant differences between LacZ and PKCδ-DN 
expressing cells. 
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FIGURE 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  Effect of RNAi-mediated knockdown of PKCδ on P-TH-ser40 levels and DA 
synthesis.  A, Western blot of TH-ser40 phosphorylation.  Briefly, N27 cells were 
transfected with PKCδ-siRNA and non-specific siRNA (NS-siRNA) and then extracts from 
siRNA transfected N27 cells were subjected to Western blot analyses of PKCδ, P-TH-ser40 
and total TH.  Densitometric analysis of the 74 kDa native PKCδ band and 60 kDa 
P-TH-ser40 and TH bands were normalized to β-actin levels, and are plotted below their 
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respective Western blots.  B, DA synthesis.  Cell extracts from PKCδ-siRNA and 
NS-siRNA transfected N27 cells were used for determining DA and DOPAC levels by HPLC.  
The data represent a mean + SEM of six to eight individual measurements.  Asterisks 
(*p<0.05 and **p<0.01) indicate significant differences between PKCδ-siRNA and 
NS-siRNA transfected N27 cells. 
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FIGURE 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  P-TH-ser40 levels in primary mesencephalic cultures from PKCδ knockout 
(-/-) animals.  Primary mesencephalic neurons were cultured on laminin coated cover slips 
from PKCδ (-/-) and PKCδ (+/+) E16-18 pups.  Primary cultures from PKCδ (+/+) animals 
were also incubated with 5 μM rottlerin for 3 hr.  Cells were fixed and processed for 
P-TH-ser40 immunocytochemistry.  Cy3-conjugated secondary antibody was used for 
visualization of P-TH-ser40 and viewed under a Nikon TE2000 fluorescence microscope.  
P-TH-ser40 levels were quantitatively analyzed from six different areas in each group using 
Metamorph image analysis. Asterisks (***p<0.001) indicate significant differences from 
controls.  Experiments were repeated three times and representative images are shown.   
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FIGURE 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Effect of PP2A inhibition on TH-ser40 phosphorylation, TH activity and 
dopamine levels.  A, Western blot analysis of P-TH-ser40.  N27 cells were treated with 
0.01% DMSO (vehicle control) or 2 μM okadaic acid for 2 hr and then cell lysates were 
subjected to immunoblot for total TH, P-TH-ser40 and β-actin.  B, Effect of okadaic acid on 
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TH activity and C, dopamine content.  N27 cells were treated with 2 μM okadaic acid for 2 
hr. To determine TH activity, N27 cells were incubated with a DOPA decarboxylase inhibitor 
(2 mM NSD-1015 for 1 hr) prior to okadaic acid treatment.  After treatment, cells were lysed 
and neurochemicals were extracted for determining L-DOPA and dopamine levels by HPLC.  
The data represent the mean ± SEM from three separate experiments.  Asterisks (*p<0.05 
and **p<0.01) indicate significant differences between untreated and okadaic acid-treated 
N27 cells. 
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FIGURE 9. 
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Figure 9.  PKCδ associates with PP2Ac and modulates PP2A activity. 
Immunoprecipitation assays:  A, PKCδ (+/+) mouse subtantia nigra; B, PKCδ (-/-) mouse 
substantia nigra and C, N27 cells.  Anti-PKCδ polyclonal antibody was used for 
immunoprecipitation and immunoblotted with mouse monoclonal PP2Ac antibody. In reverse 
immunoprecipitation studies, anti-PP2Ac mouse monoclonal antibody was used for 
immunoprecipitation followed by immunoblotting with rabbit polyclonal PKCδ antibody.  
Anti-PKCδ polyclonal antibody was co-incubated with antigenic blocking peptide in the 
immunoprecipitation studies as a negative control.  Rabbit IgG and mouse IgG were also 
used as negative controls.  D, In vitro kinase assay, PKCδ phosphorylates PP2Ac. The top 
panel is a representative autoradiography showing [32P] phosphorylation of the 
immunoprecipitated PP2Ac (IP-PP2Ac) and recombinant PP2Ac (R-PP2Ac) by recombinant 
PKCδ (R-PKCδ).  PP2Ac immunoprecipitates from N27 cell homogenates represent 
endogenous PP2Ac.  Recombinant PKCδ protein was purchased from Sigma. 
Immunoprecipitation and phosphorylation assays were performed as described in the 
methods section. The quantitative data in the bottom panel represent the mean ± SEM from 
three assays.  Histone H1 was used as positive control substrate, and for negative controls, 
no substrate was added.  
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FIGURE 10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Effect of PKCδ inhibition on PP2A activity.  A, Cell free system, 
Recombinant PP2A enzyme (R-PP2A) was incubated with recombinant PKCδ (R- PKCδ) in 
the presence or absence of 5 μM rottlerin for 1 hr.  PP2A enzyme activity was measured by 
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using a serine/threonine phosphatase assay kit from Promega.  2 μM okadaic acid was used 
as a positive control to inhibit PP2A activity.  B, N27 cells:  N27 cells were treated with 
0.01% DMSO (vehicle control) or 3 μM rottlerin for 3 hr, or expressed LacZ or PKCδ-DN.  
The data represent a mean + SEM of four to six individual measurements.  Asterisks 
(**p<0.01 and ***p<0.001) indicate significant differences between either rottlerin treated 
and vehicle control cells or LacZ and PKCδ-DN-expressing N27 cells. C, Effect of PKCδ 
inhibition on PP2A protein level. Cell lysates from control, rottlerin treated N27 cells, or 
LacZ and PKCδ-DN expressing N27 cells were used for determination of PP2A protein level 
by Western blot.   
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FIGURE 11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.  Increased TH-ser40 phosphorylation, dopamine levels and PP2A activity in 
PKCδ (-/-) knockout animals.  A, Western blot analysis of P-TH-ser40.  Substantia nigral 
lysates from PKCδ (-/-) knockout and PKCδ (+/+) naïve animals were subjected to 
immunoblotting of PKCδ, P-TH-ser40, and total TH.  B, PP2A activity: PP2A activity was 
measured in substantia nigra homogenates obtained from PKCδ (+/+) and PKCδ (-/-) animals. 
The data represent a mean + SEM from four to six animals. Asterisks (**p<0.01) indicate 
 104
significant differences between PKCδ (+/+) and PKCδ (-/-) animals. C, Neurotransmitter 
levels:  DA and DOPAC levels were determined in the striatal extracts of PKCδ (-/-) and 
PKCδ (+/+) animals by HPLC.  The data represent a mean + SEM from six to ten animals.  
Asterisks (*p<0.05) indicate significant differences between PKCδ (-/-) and PKCδ (+/+) 
animals.  
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SUPPLEMENTAL FIGURE 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 1. A schematic depiction of TH regulation by PKCδ in 
dopaminergic cells.  PKCδ enhances phosphatase 2A (PP2A) activity by phosphorylation 
of PP2Ac.  Increased PP2A activity decreases TH phosphorylation at site ser40, which leads 
to inactivation of TH and reduction of its activity and an ultimate decrease in dopamine 
synthesis.  Inhibition of PKCδ by rottlerin, PKCδ-DN mutant, PKCδ KO or PKCδ siRNA 
suppresses PP2A activity due to a decreased phosphorylation of PP2A.  The okadaic acid 
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inhibits the PP2A phosphatase activity, thereby preventing the dephosphorylation of 
P-TH-ser40 and enhancing the TH enzymatic activity.  In conclusion, our data suggest that 
PKCδ negatively regulates TH via PP2A.   
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CHAPTER III: NEUROPROTECTIVE EFFECT OF PKCδ INHIBITOR 
ROTTLERIN IN CELL CULTURE AND ANIMAL MODELS OF PARKINSON’S 
DISEASE 
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Abstract 
Recent studies from our laboratory demonstrated that the protein kinase C delta 
(PKCδ) isoform is an oxidative stress-sensitive kinase and a key mediator of apoptotic cell 
death in PD models (Kaul et al., 2003; Yang et al., 2004). We showed that native PKCδ is 
proteolytically activated by caspase-3 and that suppression of PKCδ by dominant negative 
mutant or siRNA against the kinase can effectively block apoptotic cell death in cellular 
models of PD.  In an attempt to translate the mechanistic studies to a neuroprotective 
strategy targeting PKCδ, we systematically characterized the neuroprotective effect of a 
PKCδ inhibitor, rottlerin, in MPP+-treated primary mesencephalic neuronal cultures, as well 
as in an MPTP animal model of PD.  Rottlerin treatment in primary mesencephalic cultures 
significantly attenuated MPP+-induced TH-positive neuronal cell and neurite loss.  
Administration of rottlerin, either intraperitoneally or orally, to C57 black mice showed 
significant protection against MPTP-induced locomotor deficits and striatal depletion of 
dopamine and its metabolite DOPAC.  Notably, rottlerin post-treatment was effective, even 
when dopamine/metabolite depletion by MPTP was greater than 60%, demonstrating its 
neurorescue potential.  Additionally, the dose of rottlerin used in neuroprotective studies 
effectively attenuated the MPTP-induced PKCδ kinase activity.  Importantly, stereological 
analysis of nigral neurons revealed rottlerin treatment significantly protected against 
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MPTP-induced TH-positive neuronal loss in the substantia nigra compacta.  Collectively, 
our findings demonstrate the neuroprotective effect of rottlerin in both cell culture and 
preclinical animal models of PD, and suggest that pharmacological modulation of PKCδ may 
offer a novel therapeutic strategy for treatment of PD. 
 
Introduction 
Parkinson’s disease (PD) is a major neurodegenerative disorder characterized by 
progressive and substantial loss of dopaminergic neurons in the substantia nigra compacta 
(SNc), resulting in debilitating motor signs including tremors, bradykinesia, and rigidity.  
PD affects more than 1% of the population over the age of 60 in the US (Allam et al., 2005; 
West et al., 2005), ranking it as the second most common neurodegenerative disorder.  
Although the existing approaches to PD treatment alleviate the signs, they fail to prevent the 
progression of the neurodegenerative process.  Currently, no available drugs prevent the 
progressive loss of nigral dopaminergic neurons.  The mechanisms underlying the 
dopaminergic degenerative process observed in PD are not well understood, which has 
hampered development of successful neuroprotective drugs.  Several clinical studies in 
post-mortem PD human brain tissues and experimental studies in animal PD models indicate 
that oxidative stress, mitochondrial and ubiquitin proteasomal dysfunction, and apoptosis all 
contribute to the dopaminergic degenerative process, primarily due to the higher vulnerability 
of nigral neurons to oxidative damage, compared to other brain regions (Zigmond et al., 2002; 
Dawson and Dawson, 2003; Greenamyre and Hastings, 2004; Maguire-Zeiss et al., 2005).  
However, identification of the key cellular target responsible for mediating the degenerative 
process following oxidative insult is being actively pursued by examining various apoptotic 
cell death signaling pathways (Santiago et al., 1997; Saporito et al., 1999; Du et al., 2001; 
Duan et al., 2002; Obata, 2006). 
Recently, we discovered that the caspase-3 mediated proteolytic activation of PKCδ, a 
member of the novel PKC isoform family, plays a critical role in oxidative stress-induced 
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dopaminergic cell death in cell culture models of PD (Anantharam et al., 2002; Kaul et al., 
2003; Yang et al., 2004).  Proteolytic cleavage of PKCδ (74 kDa) by caspase-3 results in a 
41-kDa catalytic subunit and a 38-kDa regulatory subunit, leading to a persistent activation 
of the kinase (Kaul et al., 2003; Yang et al., 2004).  Blockage of proteolytic activation of 
PKCδ by overexpression of the kinase-dominant negative PKCδ mutant, cleavage-resistant 
PKCδ mutant, or siRNA directed against PKCδ almost completely prevented the 
dopaminergic cell death (Kaul et al., 2003; Yang et al., 2004).  Therefore, in the present 
study, we examined the neuroprotective efficacy of the PKCδ inhibitor rottlerin in both 
primary cell culture and animal models.  Herein, we report that rottlerin not only protects 
against MPP+-induced degeneration of TH-positive neurons in primary mesencephalic 
culture models but, most importantly, is clearly neuroprotective in an MPTP animal model of 
Parkinson’s disease.    
 
Materials and Methods 
Chemicals and Biological Reagents. Rottlerin, 1-methyl-4-phenylpyridinium, 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, protease cocktail, ATP, Protein A-Sepharose®, 
protein-G-sepharose and anti-β-actin antibody were obtained from Sigma-Aldrich (St. Louis, 
MO); mouse tyrosine hydroxylase (TH) antibody was purchased from Chemicon (Temecula, 
CA); rabbit PKCδ antibody was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, 
CA); anti-rabbit and anti-mouse secondary antibodies and the ECL chemiluminescence kit 
were purchased from Amersham Biosciences (Piscataway, NJ). [γ-32P]ATP was purchased 
from Perkin Elmer Life Science (Boston, MA). The Bradford protein assay kit was purchased 
from Bio-Rad Laboratories (Hercules, CA). Neurobasal medium, B27 supplement, 
L-glutamine, penicillin, and streptomycin were purchased from Invitrogen (Gaithersburg, 
MD). 
 
Mesencephalic primary neuron cultures and treatment. Primary mesencephalic neuronal 
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cultures were prepared from the ventral mesencephalon of gestational 16-18-day-old mice 
embryos as described in our previous publication (Yang et al., 2004).  Mesencephalic tissues 
were dissected and maintained in ice-cold Ca2+-free HBSS and then dissociated in HBSS 
solution containing trypsin-EDTA (0.25%) for 20 min at 37°C.  The dissociated cells were 
then plated at equal density (0.5 × 106 cells) on 12 mm coverslips precoated with 
poly-D-lysine (1 mg/ml).  Cultures were maintained in a chemically defined medium 
consisting of neurobasal medium fortified with B-27 supplements, L-glutamine (500 μM), 
penicillin (100 IU/ml), and streptomycin (100 μg/ml) (Life Technologies). The cells were 
maintained in a humidified CO2 incubator (5% CO2, 37°C) for 24 hr and then treated with 
cytosine arabinoside (10 μM) for 24 hr to inhibit glial cell proliferation.  Half of the culture 
medium was replaced every 2 days. Approximately 6–7-day-old cultures were used for 
experiments. Primary mesencephalic dopaminergic neuronal cells were exposed to 10 μM 
MPP+ in the presence or absence of rottlerin (0.3 and 1 μM) for 48 hrs. Then cells were fixed 
and stained for TH.  
 
Immunocytochemistry. After treatment, the primary mesencephalic neurons were fixed with 
4% paraformaldehyde and processed for immunocytochemical staining. First, non-specific 
sites were blocked with 5% normal goat serum containing 0.4% BSA and 0.2% Triton-X 100 
in PBS for 20 min.  Cells were then incubated with antibody directed against TH (1:500 
dilution) at 4°C overnight, followed by incubation with Cy3-conjugated (red, 1:1000) 
secondary antibody for 1 hr at room temperature.  Secondary antibody treatments were 
followed by incubation with Hoechst 33342 (10 μg/ml) for 3 min at room temperature to 
stain the nucleus. Then the coverslips containing stained cells were washed with PBS, 
mounted on a slide, and viewed under a Nikon inverted fluorescence microscope (Model 
TE-2000U); images were captured with a SPOT digital camera (Diagnostic Instruments, 
Sterling Heights, MI). 
 
 111
Quantification of TH+ cell count and neuronal processes. Metamorph software (Version 
5.0, Molecular Devices Corp., Sunnyvale, CA) was used for measurement of TH+ cells and 
neuronal processes in primary neurons from each coverslip. For measurement of TH cell 
count, the images were first thresholded, and then neuronal count and volume were measured 
using the Integrated Morphometry Analysis (IMA) function. The data were logged to an 
Excel spreadsheet and analyzed. For measurement of neuronal processes, the lengths of the 
processes were marked by applying the region and length measurement function in the IMA. 
The data were exported to an Excel spreadsheet and analyzed. TH+ neurons and their 
processes were counted in at least six individual cultures for each treatment. This is a 
modified version of a method recently used for quantification of neuronal processes (Yang et 
al., 2004). 
 
Animal studies and rottlerin treatment. Six- to 8-week-old 26/C57/bL mice weighing 
25-30 g were housed in standard conditions: constant temperature (22 ± 1°C), humidity 
(relative, 30%), and a 12-h light/dark cycle. Mice were allowed free access to food and water. 
Use of the animals and protocol procedures were approved and supervised by the Committee 
on Animal Care (COAC) at Iowa State University. Rottlerin was dissolved in 1% dimethyl 
sulfoxide (DMSO) and administered either intraperitoneally or orally at various doses 
ranging from 3 mg/kg to 20 mg/kg. An equal volume of DMSO was given to controls. For 
rottlerin pre-treatment study, rottlerin and DMSO administrations were started 24 hr before 
the injections of MPTP, and continued for 5 days. In the subchronic regimens of MPTP 
administration, MPTP in phosphate-buffered saline (PBS) was injected intraperitoneally at 
doses of 30 mg/kg, once per day. For rottlerin post-treatement study, mice were treated with 
MPTP (20 mg/kg, i.p.) once a day for 3 days and then rottlerin was administered (20 mg/kg, 
p.o.) once a day for an additional 7 days. Mice were sacrificed 7 days after the MPTP 
injections, and the striata were dissected for catecholamine analysis. The mesencephalons 
were fixed in 4% paraformaldehyde for TH immunostaining.  
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Immunohistological and stereological analysis of nigral sections. Briefly, brains were 
harvested following cervical dislocation, post-fixed in paraformaldehyde, and used for TH 
immunolabelling and stereological analysis as described previously (Thiruchelvam et al., 
2003; Thiruchelvam et al., 2004) . Fixed brains were cut into 30-µm sections and collected in 
cryoprotectant. Sections were rinsed in PBS at room temperature before immunostaining, and 
then incubated with anti-TH antibody.  The total number of TH+ and Nissl-stained neurons 
in the SNpc were counted using an optical fractionator with the criteria previously described 
by others (Thiruchelvam et al., 2003; Thiruchelvam et al., 2004). After delineation of the 
region at low magnification (4× objective), every fourth section from the entire substantia 
nigra was sampled at higher magnification (100× objective) using a StereoImager 
(Microbrightfield, VT). 
 
PKCδ kinase assay. PKCδ enzymatic activity was assayed using an immunoprecipitation 
kinase assay as described by Reyland et al. (Reyland et al., 1999). Briefly, substantia nigra 
brain tissue from rottlerin, MPTP, MPTP+rottlerin treated mice, and control mice was 
washed once with PBS and resuspended in 1 ml of PKC lysis buffer (25 mM HEPES, pH 
7.5, 20 mM -glycerophosphate, 0.1 mM sodium orthovanadate, 0.1% Triton X-100, 0.3 M 
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 10 mM NaF, and 4 µg/ml each 
aprotonin and leupeptin). The lysates were cooled on ice for 30 min, and then centrifuged at 
13,000 × g for 5 min, and the supernatants were collected as cytosolic fraction. Protein 
concentration was determined using a Bradford assay. Cytosolic protein (0.25-0.5 mg) was 
immunoprecipitated overnight at 4°C using 2 µg of anti-PKCδ antibody. The 
immunoprecipitates were then incubated with Protein A-Sepharose® (Sigma) for 1 hr at 4°C. 
The protein A-bound antigen-antibody complexes were then washed three times with 2× 
kinase buffer (40 mM Tris, pH 7.4, 20 mM MgCl2, 20 µM ATP, and 2.5 mM CaCl2), and 
resuspended in 20 µl of 2× kinase buffer. The reaction was started by adding 20 µl of reaction 
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buffer containing 0.4 mg histone H1, 50µg/ml phosphatidylserine, 4.1 µM dioleoylglycerol, 
and 5 µCi of [γ-32P] ATP (3000 Ci/mM) to the immunoprecipitated samples and incubated for 
10 min at 30°C. SDS gel-loading buffer (2×) was added to terminate the reaction, the samples 
were boiled for 5 min, and the products were separated on a 12.5% SDS-PAGE gel. The H1 
phosphorylated bands were detected using a Personal Molecular Imager (FX model; 
Bio-Rad), and quantified using Quantity One 4.2.0 software. 
 
HPLC analysis of neurotransmitters. DA and DOPAC levels in brain striatal tissues were 
determined by high-performance liquid chromatography with electrochemical detection 
(HPLC-EC); samples were prepared as described previously (Kitazawa et al., 2001).  
Briefly, neurotransmitters were extracted from samples using 0.1 M perchloric acid 
containing 0.05% Na2EDTA and 0.1% Na2S2O5.  The extracts were filtered in 0.22 µm spin 
tubes, and 20 μl of the samples was loaded for analysis.  DA and DOPAC were separated 
isocratically by a reversed-phase column with a flow rate of 0.7 ml/min.  An HPLC system 
(ESA Inc., Bedford, MA) with an automatic sampler (ESA model 542) was used for these 
experiments.  The electrochemical detection (EC) system consisted of an ESA Coulochem 
model 5100A with a microanalysis cell (model 5014A) and a guard cell (model 5020) (ESA 
Inc., Bedford, MA).  One mg DA and DOPAC standards were dissolved in 1 ml antioxidant 
solution separately to prepare standards for HPLC.  Peaks representing DA and DOPAC in 
the samples were identified on the basis of their retention times and co-chromatography of 
the respective authentic standards in several different chromatographic conditions. The DA 
and DOPAC levels were measured as ng /mg protein. 
 
Western blot. Brain lysates containing equal amounts of protein were loaded in each lane 
and separated on a 10-12% SDS-PAGE gel as described previously (Kaul et al., 2003).  
After the separation, proteins were transferred to a nitrocellulose membrane, and nonspecific 
binding sites were blocked by treating with 5% nonfat dry milk powder.  The membranes 
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were then treated with primary antibodies directed against TH (mouse monoclonal, 1:1000). 
The primary antibody treatments were followed by treatment with secondary 
HRP-conjugated anti-mouse IgG (1:2000) for 1 hr at room temperature.  Secondary 
antibody-bound proteins were detected using an ECL chemiluminescence kit (Amersham 
Biosciences).  To confirm equal protein loading, blots were reprobed with a ß-actin antibody 
(1:5000 dilution).  Western blot images were captured with a Kodak 2000 MM imaging 
system and data were analyzed using 1D Kodak Imaging Analysis software.  
 
Locomotor activity. Behavioral data were collected using VersaMax Animal Activity 
Monitors (AccuScan Model RXYZCM-16, Columbus, OH). Each chamber was 
40×40×30.5 cm, made of clear Plexiglas and covered with a Plexiglas lid with holes for 
ventilation. Infrared monitoring sensors were located every 2.54 cm along the perimeter (16 
infrared beams along each side) and 2.5 cm above the floor. Two additional sets of 16 sensors 
were located 8.0 cm above the floor on opposite sides. Data were collected and analyzed by a 
VersaMax Analyzer (AccuScan Model CDA-8, Columbus, OH) which in turn sent 
information to a computer where it was stored for future analyses. Locomotor activity was 
presented as horizontal movement and vertical movement. All data are expressed as percent 
of the vehicle-treated control group (mean ± SEM, n=6) and were obtained 1 day after MPTP 
or vehicle treatment in a 20-min test session. 
 
Data analysis. Data analysis was performed using Prism 4.0 software (GraphPad Software, 
San Diego, CA). Data were first analyzed as raw by using one-way ANOVA and then 
Bonferroni's post-test was performed to compare all treatment groups, and differences with p < 
0.05 were considered significant. 
 
Results 
Rottlerin rescues TH+ neuronal loss from MPP+ in primary mesencephalic 
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cultures. First, we examined whether the PKCδ inhibitor rottlerin (Figure 1) can rescue TH+ 
neurons from MPP+ toxicity in primary mesencephalic cultures. Primary mesencephalic 
cultures were isolated from E16-18 C57 black mice embryos and exposed to 10 μM MPP+ in 
the presence or absence of rottlerin (0.3 and 1 μM) for 48 hr. After treatment, primary 
neurons were processed for TH immunochemistry.  As shown in Fig. 2A, MPP+ treatment 
induced about 90% loss of both TH cell count and neurite processes.  Quantitative analysis 
of TH+ cell counts showed 0.3 μM and 1 μM rottlerin treatment significantly protected 
against MPP+ neurotoxicity.  Similarly, average lengths of TH+ neuronal processes in MPP+ 
plus rottlerin-treated primary neurons were significantly longer than the processes of neurons 
treated only with MPP+ (Fig. 2B). These data suggest that the PKCδ inhibitor rottlerin 
possesses neuroprotective properties in the MPP+-induced dopaminergic degenerative model.   
 
PKCδ kinase activity is significantly suppressed in rottlerin-treated animals.  
We previously showed that pretreatment with rottlerin significantly attenuated oxidative 
stress-induced increases in PKCδ kinase activity in an immortalized mesencephalic 
dopaminergic neuronal cell line (Kaul et al., 2003). We also observed a high expression of 
PKCδ in TH positive nigral neurons (unpublished observation). In this experiment, we 
examined whether rottlerin effectively inhibits PKCδ kinase activity in mouse substantia 
nigra.  Rottlerin was administered at doses of 3-20 mg/kg.  As shown in Fig. 3, PKCδ 
kinase activity was significantly suppressed in the substantia nigra of rottlerin-treated animals 
in a dose-dependent manner compared to vehicle-treated control animals.  Densitometric 
analysis of phosphorylated histone H1 bands revealed 48%, 37%, and 29% decreases in 
protein kinase activity in SN of mice treated with 20, 10, and 7 mg rottlerin, respectively. 
These results indicate that rottlerin significantly inhibits PKCδ activity, as observed in our 
previous cell culture experiments (Kaul et al., 2003).   
 
Rottlerin attenuates striatal dopamine depletion induced by MPTP-treatment.  
 116
After characterizing the neuroprotective effect of rottlerin in cell culture models of PD, as 
well as verifying rottlerin’s ability to suppress PKCδ activity in the brain, we examined the 
neuroprotective efficacy of rottlerin in an MPTP-induced mouse model of PD.  In order to 
determine the optimal route of rottlerin treatment, we chose the intraperitoneal route for low 
doses of rottlerin (3 and 7 mg/kg) and the oral route for high doses (10 and 20 mg/kg).  
Animals were administered rottlerin (3-20 mg/kg body weight) 24 hr prior to MPTP 
administration. Animals were then co-treated with rottlerin and MPTP (30 mg/kg, i.p.) daily 
for 5 days.  Saline- and vehicle-injected animals were used as controls. To assess the 
protective effect of rottlerin, we first examined whether rottlerin could block MPTP-induced 
loss of striatal dopamine and its metabolites.  As shown in Fig. 4, MPTP treatment induced 
loss of (A) dopamine (>94%), (B) DOPAC (>95%), and (C) HVA (>95%) in mouse striatum.   
The dopamine levels were determined to be 187.5 ± 7.4, 14.5 ± 3.8, and 112.8 ± 25.3 ng/mg 
protein in control-, MPTP-, and MPTP + rottlerin (20 mg/kg)-treated animals, respectively.   
Pretreatment with rottlerin (20 mg/kg) afforded nearly a 50% protection against 
MPTP-induced striatal dopamine loss. Similar results were found for DOPAC and HVA (Fig. 
4).  These data suggest that rottlerin treatment could afford protection against 
MPTP-induced striatal dopamine and dopamine metabolite loss in animal PD models.  
Rottlerin inhibits PKCδ kinase activity in MPTP-treated animals. In a previous 
study, we showed that PKCδ activity was increased in MPP+-treated N27 dopaminergic cells 
as a result of proteolytic kinase activation (Kaul et al., 2003).  Therefore, we examined 
whether 20 mg/kg rottlerin, the most effective dose against MPTP-induced dopamine 
depletion, suppressed MPTP-induced increases in PKCδ kinase activity in nigral tissue.  In 
Fig. 5, MPTP-treated mice showed nearly a 2-fold increase in PKCδ activity compared with 
control mice, and rottlerin treatment almost completely suppressed PKCδ kinase activity 
induced by MPTP treatment.  These results suggest rottlerin protects against PKCδ 
activation. 
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Rottlerin prevents TH cell loss induced by MPTP toxicity in SNc. Since rottlerin 
effectively attenuated MPTP-induced loss of dopamine and its metabolites in the striatum, we 
next examined whether rottlerin could protect the TH+ neurons from MPTP-induced toxicity 
in the SNc.  MPTP treatment caused a 40% loss of TH+ neurons in the SNpc as compared to 
saline-treated animals. However, MPTP induced only a 13% loss of TH+ neurons in animals 
treated with 20 mg/kg (p.o) rottlerin (Fig. 6).  Data analysis revealed that rottlerin treatment 
afforded a 37% protection against MPTP.  In addition, there was a noticeable loss of TH+ 
fiber density in MPTP-treated animals, while fiber density in the rottlerin-treated animals was 
close to that of the vehicle-treated group (Fig. 6A). 
 
Rottlerin prevents MPTP-induced reduction of TH protein in SNc. Based on our 
finding that rottlerin counteracted the MPTP-induced dopamine and TH+ neuronal loss, we 
further confirmed nigral TH protein levels by Western blot. MPTP treatment greatly reduced 
TH protein levels in mouse SN (Fig. 7), which may have resulted from the loss of TH+ 
neurons in this region.  Treatment with rottlerin (3-20 mg/kg) restored the TH levels in 
MPTP-treated animals to those of control animals, further confirming the protective effect of 
rottlerin against TH-positive neuronal loss.  
 
Rottlerin attenuates MPTP-induced motor deficits. With evidence suggesting that 
rottlerin protects against MPTP-induced dopamine and TH neuronal loss, we next determined 
if rottlerin treatment could also afford protection against MPTP-induced motor deficits.  We 
compared the motor activity of vehicle, MPTP, and MPTP plus rottlerin-treated animals, 
using a Versamax computerized activity monitoring system (Accuscan, Columbus, OH).  
This system uses infrared sensors to measure repetitive movements both in the horizontal and 
vertical planes in real time, and provides color-coded output.  Representative activity maps 
of the animals are presented in Fig. 8A.  The cumulative horizontal and vertical activities 
are shown in Fig. 8B.  All data are expressed as percent of the vehicle-treated group and 
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were obtained 1-2 hr before sacrificing the animals for neurochemical and histological 
studies.  The data indicate that both the vertical and horizontal motor activity were 
significantly reduced (>45%) in MPTP-treated animals compared to the vehicle-treated group.  
However, administration of rottlerin partially restored both vertical and horizontal motor 
activity of MPTP-treated animals to the levels observed in control animals.  These results 
demonstrate rottlerin treatment attenuates MPTP-induced locomotor deficits in mice.  
 
Rottlerin post-treatment rescues striatal dopamine depletion induced by MPTP 
treatment. To determine whether rottlerin post-treatment can protect against MPTP-induced 
dopaminergic toxicity, we created a PD model that shows over 60% of striatal dopamine 
depletion by pretreating the mice with 20 mg/kg MPTP (i.p.) for 3 days.  Following the 
MPTP treatment, animals were given 20 mg/kg rottlerin for 3 days.  As shown in Fig. 9, 
post-treatment with rottlerin significantly attenuated the loss of dopamine induced by MPTP 
pretreatment.  Post-treatment with rottlerin (20 mg/kg) afforded nearly a 33% protection 
against MPTP pretreatment-induced striatal dopamine loss. Similar results were found for 
DOPAC and HVA (Fig. 9).  These data demonstrate that rottlerin has the potential to rescue 
MPTP-induced dopaminergic neurotoxicity in animal PD models.  
 
Discussion 
The present study demonstrates that the PKCδ inhibitor rottlerin protects against 
MPTP-induced motor deficits, striatal dopamine depletion, and nigral dopaminergic neuronal 
loss.  The neuroprotective effect of rottlerin was also evident against dopaminergic 
neurodegeneration, as the inhibitor rescued TH+ neurons from MPP+-induced neurotoxicity 
in primary mesencephalic cultures.  To our knowledge, this is the first demonstration of a 
neuroprotective strategy using a pharmacological inhibitor of PKCδ in an animal model of 
Parkinson’s disease.   
The PKC family of kinases consists of 13 isoforms classified into three distinct 
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sub-families based on their activation profiles.  Conventional isoforms of PKCs (cPKCs), 
PKCα, βΙ, βΙΙ, and γ, require both intracellular calcium and diacylglycerol (DAG) for their 
activation, whereas the novel PKC (nPKC) isoforms, PKCδ, ε, η, θ, and μ require only DAG.  
The atypical PKCs (aPKCs), PKCζ and λ(ι), require neither calcium nor phospholipids for 
activation.  The expression patterns and biological functions of these isoforms in CNS are 
only beginning to be recognized.  For example, PKCγ is expressed predominantly in the 
brain, and has been implicated in neural plasticity, including long term potentiation (Saito 
and Shirai, 2002) and ischemic injury (Aronowski and Labiche, 2003).  The levels of 
another novel PKC isoform, PKCε, are greatly reduced in Alzheimer’s brains, and are linked 
to increased production of amyloid β protein (Matsushima et al., 1996).  In the CNS, PKCε 
is localized mainly in the presynaptic region and induces neurite outgrowth during 
differentiation and mediates apoptosis during embryonic development, among other 
functions (Matsushima et al., 1996).   
Recent studies from our laboratory and others have demonstrated that PKCδ, a key 
member of nPKCs, plays a proapoptotic role in various cell types (Anantharam et al., 2002; 
Kanthasamy et al., 2003).  We also showed that PKCδ is an oxidative stress kinase in CNS 
(Kanthasamy et al., 2003; Kaul et al., 2005).  Oxidative stress and apoptotic cell death have 
been implicated in several neurodegenerative disorders including Parkinson’s disease (Allam 
et al., 2005; Maguire-Zeiss et al., 2005; West et al., 2005; Smith et al., 2006).  We showed 
that oxidative stress, in dopaminergic neuronal models, persistently activates PKCδ by 
proteolysis via caspase-3 cleavage of the native kinase (72-74-kDa), which yields a 41-kDa 
catalytically active fragment and a 38-kDa regulatory fragment (Anantharam et al., 2002).  
We also demonstrated that the proteolytic activation of PKCδ contributes to apoptotic cell 
death in cell culture models of PD (Kaul et al., 2003; Yang et al., 2004).  In addition to the 
proapoptotic role, PKCδ amplifies apoptotic signaling via positive feedback activation of the 
caspase cascade (Anantharam et al., 2002; Kaul et al., 2003), demonstrating the dual role of 
PKCδ as a mediator and amplifier of apoptosis.  Overexpression of the dominant negative 
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mutants, PKCδD327A (caspase-cleavage resistant), PKCδK376R (kinase inactive), and 
PKCδY311F (phosphorylation defective) loss-of-function mutants, as well as suppression of 
PKCδ by siRNA provided protection against apoptotic cell death induced by various 
dopaminergic toxins, including MPP+, in dopaminergic neuronal cells (Kaul et al., 2003; 
2005; Yang et al., 2004).   Recently, another study showed that glutamate-induced cell 
death was significantly attenuated in cells transfected with PKCδ siRNA, suggesting that 
PKCδ may play an important role in excitotoxicity (Choi et al., 2006).  A common 
mechanism has been proposed in degenerative processes of PD (Dawson and Dawson, 2003; 
Greenamyre and Hastings, 2004).  Together, these studies indicate that PKCδ plays an 
important role as downstream effector of apoptotic cell death in PD models, and that the 
kinase is a valid pharmacological target for development of novel inhibitors against oxidative 
stress-induced dopaminergic degenerative processes in PD. 
Small molecule inhibitors of protein kinases are being increasingly evaluated for 
therapeutic use for various human diseases.  In this study, we show that the pharmacological 
inhibitor of PKCδ, rottlerin, is neuroprotective in an MPTP model of PD.  Rottlerin is 
isolated from the seeds of Mallotus phillippinensis and has been shown to be a potent 
inhibitor of PKCδ, with an IC50 of 3-6 µM, whereas the Kis for other PKC isoforms (α, β, γ, 
ε and λ) are at least 5-10 times higher (Gschwendt et al., 1994; Davies et al., 2000; Soltoff, 
2001).  Toxicity data for rottlerin indicate that the compound has a low toxicity profile 
(LDLo 750 mg/kg, rat oral); 120 mg/kg (oral 6-day rat study) is the lowest toxic dose (Varma 
et al., 1959).  The relative safety, combined with its efficacy, make rottlerin quite attractive 
as a potential therapeutic agent.   
Previous studies have shown rottlerin treatment rescues non-neuronal cells from 
apoptotic death induced by various stimuli (Reyland et al., 1999); in addition, rottlerin 
inhibits PKCδ enzyme activity in vitro (Anantharam et al., 2002).  Recently, we showed 
MPP+-induced increases in PKCδ kinase activity were effectively blocked by rottlerin 
treatment in an immortalized dopaminergic mesencephalic neuronal cell line (Kaul et al., 
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2003).  In the present study, we provide evidence that rottlerin treatment can also rescue 
TH+ neurons from MPP+-induced neurotoxicity in primary mesencephalic cultures.  
Extension of these studies in animal models revealed rottlerin can effectively attenuate the 
MPTP-induced increase in PKCδ kinase activity in mouse SNc.  Further, rottlerin 
administration attenuated neurochemical depletion and locomotor activity of MPTP-treated 
animals, demonstrating protection against both behavioral and neurochemical deficits.  
Rottlerin treatment also protected against MPTP-induced loss of TH neurons in the SNc, 
revealing the neuroprotective effect in a well-characterized preclinical model of PD.  Taken 
together, the observed protective effect of the PKCδ inhibitor rottlerin in an MPTP model of 
PD strongly supports our previous mechanistic studies demonstrating proapoptotic function 
of PKCδ in dopaminergic neuronal cell death (Kaul et al. 2003; 2005; Yang et al., 2005).  
Rottlerin is also shown to be able to inhibit CaM kinase III and MAPKAP kinase 2. 
MAPKAP kinase 2 is an essential component in the inflammatory response which regulates 
biosynthesis of TNF-alpha at a post-transcriptional level. Inhibition of MAPKAP kinase 2 
might help to against MPTP toxicity (Kotlyarov et al., 1999).  
A number of researchers have attempted to develop neuroprotective agents targeting 
cell death signaling molecules.  Inhibitors targeted against mixed lineage kinase (MLK) and 
poly-ADP-ribose polymerase (PARP) have been shown to protect nigral dopaminergic 
neurons in animal models (Cosi et al., 1996), and some of these agents are currently being 
evaluated in human clinical trials (Parashar et al., 2005).  Previous studies have shown 
PKCδ can indirectly regulate PARP and MLK (Merritt et al., 1999; Yoshida et al., 2002; 
Kitazawa et al., 2004), suggesting that PKCδ may be an attractive upstream neuroprotective 
therapeutic target.  Saporito et al. showed systemic injection of the c-Jun N-terminal kinase 
(JNK) inhibitor CEP-1347/KT-7515 protected against MPTP toxicity in the C57 black mouse 
model (Saporito et al., 1999).  However, CEP-1347 was effective only in the pretreatment 
regimen, and not in the post-exposure period to MPTP. The outcome of recent clinical trials 
with the CEP-1347 compound was not encouraging due to the lack of clinical improvement 
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in PD patients, which may be related to the failure of the compound in the preclinical model 
during post-treatment to prevent the progression of the disease (Burke, 2007).  In the 
present study, rottlerin post-treatment protects against degenerative processes even 3 days 
after MPTP exposure, demonstrating its neurorescue properties.  Normally, PD patients lose 
around 70% of dopaminergic innervation before they develop signs of PD and therefore, the 
effective rottlerin post-treatment regimen shows real promise for therapeutic development. 
Advantageously, rottlerin is orally active. 
Maruyama et al. developed a class of compounds with multiple putative properties, 
including iron chelation, MAO inhibition, and antioxidant effects (Maruyama et al., 2002), 
but the preclinical and clinical evaluations of these compounds have not yet been evaluated.  
Recent Phase II clinical trials with 12 compounds have demonstrated creatine and 
minocycline as effective; these compounds have been recommended to proceed to Phase III 
trials to determine if they alter the long term progression of PD (NINDS, 2006).  
Minocycline, a tetracycline derivative with anti-inflammatory properties, prevented 
dopaminergic neurodegeneration in MPTP models of PD (Du et al., 2001).  Minocycline 
also inhibits microglial-associated inflammation and apoptosis (Ravina et al., 2003; Kelly et 
al., 2004).  Oral administration of the nutritional supplement creatine attenuated MPTP 
toxicity, which is similar to our findings with rottlerin (Matthews et al., 1999). Creatine 
exhibits neuroprotective properties by inhibiting mitochondrial permeability, as well as 
indirectly acting as an antioxidant (Tarnopolsky and Beal, 2001). Very recently, the National 
Institute of Neurological Disorders and Stroke (NINDS) launched a multicenter large scale 7 
year phase III clinical trial, at the cost of about 60 million dollars, to evaluate the 
neuroprotective effect of a purified form of creatine (Couzin, 2007).  In addition to creatine, 
the antioxidant Coenzyme-Q is being evaluated in PD clinical trials (Shults and Haas, 2005).  
Release of cytochrome C resulting from increased mitochondrial permeability during 
oxidative stress has been shown to initiate PKCδ activation (Anantharam et al., 2002), and 
antioxidant treatment attenuates proapoptotic action of the kinase (Kaul et al., 2003), 
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indicating that PKCδ is closely associated with two leading PD pathological mechanisms, i.e., 
oxidative insult and mitochondrial dysfunction.   
In conclusion, we demonstrate that inhibition of a PKCδ isoform with rottlerin can 
offer protection against behavioral deficits, neurochemical depletion, and nigral 
dopaminergic neuronal damage in animal models of PD.  Our results provide evidence that 
PKCδ may serve as a novel therapeutic target for development of neuroprotective agents and 
suggest that development of selective and systemically-active small molecule PKCδ isoform 
inhibitors may translate to an effective neuroprotective agent for treatment of PD.   
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FIGURE 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Chemical structure of rottlerin. 
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FIGURE 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Effect of rottlerin on the number of TH-positive cells and their neurite 
length in MPP+-treated mesencephalic primary culture. Primary neurons were cultured 
and grown on laminin-coated cover slips. The cultures were then exposed to 10 µM MPP+ for 
48 hr in the presence or absence of 0.3 μM or 1 μM rottlerin. After treatment, primary 
neurons were fixed and immunostained for TH and viewed under a Nikon TE2000 
fluorescence microscope, as described in the methods section. TH cell count and neuronal 
process length were quantified using Metamorph image analysis software, as described in the 
methods section. Asterisks (*p<0.05 and ***p<0.001; N=4) indicate significant difference 
compared with MPP+-treated neurons. 
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FIGURE 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Effect of rottlerin on PKCδ kinase activity in mouse substantia nigra. C57 
black mice were treated with rottlerin (3-20 mg/kg) for 5 days. Substantia nigra tissue was 
homogenized and used in the immunoprecipitation kinase assay as described in the methods. 
The bands were quantified by a PhosphoImager after scanning the dried gel, and are 
expressed as a percentage of vehicle-treated bands. The data represent mean ± SEM from 4-6 
animals per group. Asterisks (**p<0.01) indicate significant differences compared with 
control. 
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FIGURE 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Effects of rottlerin on MPTP-induced depletions of dopamine, DOPAC, 
and HVA.  C57 black mice were pretreated with different doses of rottlerin (3-20 mg/kg, i.p. 
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or p.o.) 24 hr before MPTP treatment and then co-treated with MPTP (30 mg/kg, i.p.) once a 
day for 5 days. 1% DMSO served as vehicle control. Animals were sacrificed 7 days 
following the treatment, and neurochemical analysis was performed by HPLC in striatal 
tissues.  The data represent mean ± SEM from 6-8 animals per group. Asterisks (**p<0.01 
and ***p<0.001) indicate significant difference compared with the MPTP group. 
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FIGURE 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Effect of rottlerin on MPTP-induced PKCδ kinase activity. C57 black 
mice were pretreated with different doses of rottlerin (20 mg/kg, p.o.) 24 hr before MPTP 
treatment and then co-treated with MPTP (30 mg/kg, i.p.) once a day for 5 days. 1% DMSO 
served as vehicle control.  Substantia nigra tissue was homogenized and used in the 
immunoprecipitation kinase assay.  Recombinant PKCδ protein was used as a positive 
control.  PKCδ kinase activity was measured in the absence of lipid activators. The bands 
were quantified by a PhosphoImager after scanning the dried gel, and are expressed as a 
percentage of control. The data represent mean ± SEM from 4-6 animals per group.  
Asterisks (**p<0.01; N=4) indicate significant differences compared with control. 
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FIGURE 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Stereological evaluation of neuroprotective effect of rottlerin on number 
and morphology of SNpc neurons in brains of MPTP-treated mice. C57 black mice were 
pretreated with different doses of rottlerin (20 mg/kg, p.o.) 24 hr before MPTP treatment and 
then co-treated with MPTP (30 mg/kg, i.p.) once a day for 5 days. 1% DMSO served as 
vehicle control. Total numbers of TH+ neurons in the substantia nigra pars compacta in 
groups exposed to vehicle (1% DMSO), 30 mg/kg MPTP, or the combination with rottlerin 
(20 mg/kg) were counted and are shown in the figure. TH+ neurons were measured using 
unbiased stereology two days after the last treatment. The data represent mean ± SEM from 3 
animals per group. Asterisks (**p<0.01) indicate significant difference compared with MPTP 
group, n=3 per group.  
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FIGURE 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Effect of different doses of rottlerin on TH expression level in SN of 
MPTP-treated mice. C57 black mice were pretreated with different doses of rottlerin (3-20 
mg/kg, i.p. or p.o.) 24 hr before MPTP treatment and then co-treated with MPTP (30 mg/kg, 
i.p.) once a day for 5 days. 1% DMSO served as vehicle control. Substantia nigra tissue was 
homogenized and used for Western blotting, as described. Tyrosine hydroxylase expression 
was detected using monoclonal antibody raised against TH. The membrane was reprobed 
with β-actin antibody to confirm equal protein loading in each lane. The data represent mean 
± SEM from 3 animals per group. Asterisks (**p<0.01) indicate significant difference 
compared with MPTP group, n=3 per group.  
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FIGURE 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8. Effects of rottlerin on MPTP-induced locomotor deficits. C57 black mice 
were pretreated with different doses of rottlerin (20 mg/kg, p.o.) 24 hr before MPTP 
treatment and then co-treated with MPTP (30 mg/kg, i.p.) once a day for 5 days. 1% DMSO 
served as vehicle control. Locomotor activity was measured using VersaMax Analyzer 1-2 
days before sacrificing the animals. A, Moving track of mice. B, Total horizontal and vertical 
movement. The vehicle-treated group served as control and was set at 100%.  The data 
represent mean ± SEM from 6 animals per group.  Asterisks (*p<0.05) indicate significant 
difference compared with MPTP group. 
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FIGURE 9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. Effects of rottlerin post-treatment on MPTP-induced depletions of 
dopamine, DOPAC, and HVA.  C57 black mice were treated with MPTP (20 mg/kg, i.p.) 
once a day for 3 days and then rottlerin was administered (20 mg/kg, p.o.) once a day for an 
additional 10 days. 1% DMSO served as vehicle control. Animals were sacrificed following 
the treatment and neurochemical analysis was performed by HPLC in striatal tissues.  The 
data represent mean ± SEM from 6 animals per group. Asterisks (*p<0.05) indicate 
significant difference compared with MPTP group. 
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CHAPTER IV: INHIBITION OF PKC-DELTA ISOFORM IN NIGROSTRIATAL 
DOPAMINERGIC SYSTEM ENHANCES DOPAMINE SYNTHESIS AND 
NEUROBEHAVIORAL ALTERATIONS IN MICE: DUAL NEUROPROTECTIVE 
STRATEGIES IN PARKINSON’S DISEASE 
Danhui Zhang, Arthi Kanthasamy, Vellareddy Anantharam and Anumantha Kanthasamy 
 
Abstract 
Recently, we reported a novel finding that PKCδ, a novel PKC isoform, negatively 
regulates tyrosine hydroxylase (TH) and curtails dopamine synthesis through activation of 
protein phosphatase PP2A.  In the present study, we examined whether inhibition of PKCδ 
by the kinase inhibitor rottlerin enhances dopaminergic neurotransmission and 
neurobehavioral characteristics in animal models.  Treatment with the PKCδ inhibitor 
rottlerin in C57 black mice effectively increased a number of key neurochemical events in 
the dopamine pathway, including TH phosphorylation, TH enzymatic activity, and striatal 
dopamine and DOPAC levels.  Time course studies revealed that TH-ser31 and -ser40 
phosphorylation and dopamine synthesis were increased within 1hr of rottlerin treatment.  
Increased dopamine synthesis was accompanied by stimulation of locomotor activity and 
stereotypic behavior.  To further explore the neurochemical mechanisms responsible for the 
behavioral super-sensitivity observed during rottlerin treatment, neuropharmacological 
approaches were used.  Administration of a nonselective DA receptor agonist, apomorphine 
(10 mg/kg), significantly augmented locomotor activity in rottlerin-treated mice, suggesting 
that postsynaptic dopaminergic function is altered during rottlerin treatment.  Additionally, 
pretreatment with the D1-like antagonist SCH 23390 or D2-like antagonist spiperone 
effectively suppressed rottlerin-induced hyperlocomotion and stereotypy, indicating the 
possible involvement of both D1 and D2 receptors in the behavioral changes.  Consistent 
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with the pharmacological effects of rottlerin, naïve PKCδ-knockout mice showed enhanced 
striatal dopamine levels and behavioral function as compared to wild-type mice.  Taken 
together with our recent studies showing the neuroprotective effect of rottlerin in MPTP 
models of PD, these results suggest that inhibition of PKCδ in the nigrostriatal dopaminergic 
system can offer dual benefits of neuroprotection and enhanced dopaminergic function in the 
development of therapeutic agents for treatment of Parkinson’s disease. 
 
Introduction 
Parkinson’s disease (PD) is a major neurodegenerative disorder characterized by 
progressive and substantial loss of dopaminergic neurons in the substantia nigra compacta 
(SNc), resulting in debilitating motor signs including tremors, bradykinesia, and rigidity. The 
PKC family consists of more than 12 isoforms and is subdivided into three major subfamilies, 
which include conventional PKC (α, βI, βII, γ), novel PKC (δ, ε, µ, η, θ), and atypical PKC 
(τ, λ, ζ) (Gschwendt 1999; Dempsey, Newton et al. 2000; Maher 2001; Kanthasamy, 
Kitazawa et al. 2003).  PKCδ, a key member of the novel PKC family, plays a role in a 
variety of cell functions including cell differentiation, proliferation and secretion.  Our 
recent studies demonstrate that PKCδ is an oxidative stress-sensitive kinase, and activation of 
this kinase via caspase-3 dependent proteolysis induces apoptotic cell death in cell culture 
models of Parkinson’s disease (Kanthasamy, Kitazawa et al. 2003; Kaul, Kanthasamy et al. 
2003; Yang, Kaul et al. 2004; Latchoumycandane, Anantharam et al. 2005). Blockage of 
proteolytic activation of PKCδ by overexpression of the kinase-dominant negative PKCδ 
mutant, cleavage-resistant PKCδ mutant, or siRNA directed against PKCδ almost completely 
prevented the dopaminergic cell death (Kaul, Kanthasamy et al. 2003; Kitazawa, Anantharam 
et al. 2003; Anantharam, Kitazawa et al. 2004; Yang, Kaul et al. 2004; Latchoumycandane, 
Anantharam et al. 2005). Furthermore, we demonstrated that inhibition of PKCδ activation 
by the pharmacological inhibitor rottlerin offers neuroprotection in the MPTP-induced 
animal model of PD (Zhang, Kanthasamy et al. 2007). We also observed a high level of 
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PKCδ expression in the nigral dopaminergic neurons and a physical association of PKCδ 
with tyrosine hydroxylase (TH). TH is a rate-limiting enzyme in the biosynthesis of 
catecholamines and catalyzes the first step of a biochemical synthetic pathway in which 
L-tyrosine is converted to L-3,4-dihydroxyphenylalanine (L-dopa).  Phosphorylation and 
dephosphorylation of TH represent important post-translational regulatory mechanisms of the 
enzymatic activity that mainly determine the amount of catecholamine synthesis.  A number 
of phosphorylation sites have been identified in TH, and phosphorylation of TH greatly 
influences the enzyme activity (Lee, Lew et al. 1989).     
General PKCs can phosphorylate TH-ser40 and TH-ser31 (Albert, Wu et al. 1984; 
McTigue, Cremins et al. 1985; Tachikawa, Tank et al. 1987; Cahill, Horwitz et al. 1989; 
Haycock, Ahn et al. 1992; Bunn and Saunders 1995; Bobrovskaya, Cheah et al. 1998), 
however, direct phosphorylation of TH by PKA and not by PKC results in activation of the 
enzymatic activity (Funakoshi, Okuno et al. 1991).  The role of PKC isoforms in the 
regulation of TH activity is not well studied.  Recently, we showed that PKCδ can 
negatively regulate TH activity and dopamine synthesis by enhancing protein 
phosphatase-2A activity in dopaminergic neurons (Zhang, Anantharam et al. 2007). In the 
present study, we characterized the dopamine synthesis and neurobehavioral alterations in 
PKCδ-knockout mice, as well as PKCδ inhibition in treated mice.  
 
Materials and Methods 
Chemicals and Biological Reagents. Rottlerin, Apomorphine, SCH 23390, spiperone, 
protease cocktail, 3-hydroxylbenzylhydrazine (NSD-1015), ATP, Protein A-Sepharose®, and 
anti-β-actin antibody were obtained from Sigma-Aldrich (St. Louis, MO); mouse tyrosine 
hydroxylase (TH) antibody, PhosphoTH-ser40 and ser31 antibodies were purchased from 
Chemicon (Temecula, CA); rabbit PKCδ antibody was purchased from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA); anti-rabbit and anti-mouse secondary antibodies and 
the ECL chemiluminescence kit were purchased from Amersham Biosciences (Piscataway, 
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NJ). [γ-32P]ATP was purchased from Perkin Elmer Life Science (Boston, MA). The Bradford 
protein assay kit was purchased from Bio-Rad Laboratories (Hercules, CA).  
 
Animal studies. Six to 8-week-old C57/bL mice weighing approximately 30g were housed 
in standard conditions. Rottlerin was dissolved in 1% DMSO and administered 
intraperitoneally or orally at various doses (3-20 mg/kg). An equal volume of 1% DMSO was 
given to the vehicle control group. Mice were sacrificed after the last dose of rottlerin, and 
the striata were dissected for catecholamine analysis. To characterize dopaminergic 
behavioral changes, mice were given 10mg/kg apomorphine or 0.1mg/kg D1 receptor 
antagonist SCH-23390 (s.c.) or 0.1mg/kg D2 receptor antagonist spiperone (s.c.) 30min 
before rottlerin treatment.  
 
PKCδ kinase assay. PKCδ enzymatic activity was assayed using an immunoprecipitation 
kinase assay as described in our previous publications (Kaul, Kanthasamy et al. 2003; Zhang, 
Kanthasamy et al. 2007). Briefly, substantia nigra brain tissue from rottlerin treated mice and 
control mice was washed once with PBS and resuspended in 1 ml of PKCδ lysis buffer 
(25 mM HEPES, pH 7.5, 20 mM -glycerophosphate, 0.1 mM sodium orthovanadate, 0.1% 
Triton X-100, 0.3 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 10 mM NaF, and 
4 µg/ml each aprotonin and leupeptin). The lysates were cooled on ice for 30 min, and then 
centrifuged at 13,000 × g for 5 min, and the supernatants were collected as cytosolic fraction. 
Protein concentration was determined using a Bradford assay. Cytosolic protein (0.25-0.5 mg) 
was immunoprecipitated overnight at 4°C using 2 µg of anti-PKCδ antibody. The 
immunoprecipitates were then incubated with Protein A-Sepharose® (Sigma) for 1 hr at 4°C. 
The protein A-bound antigen-antibody complexes were then washed three times with 2× 
kinase buffer (40 mM Tris, pH 7.4, 20 mM MgCl2, 20 µM ATP, and 2.5 mM CaCl2), and 
resuspended in 20 µl of 2× kinase buffer. The reaction was started by adding 20 µl of reaction 
buffer containing 0.4 mg histone H1, 50µg/ml phosphatidylserine, 4.1 µM dioleoylglycerol, 
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and 5 µCi of [γ-32P] ATP (3000 Ci/mM) to the immunoprecipitated samples and incubated for 
10 min at 30°C. SDS gel-loading buffer (2×) was added to terminate the reaction, the samples 
were boiled for 5 min, and the products were separated on a 12.5% SDS-PAGE gel. The H1 
phosphorylated bands were detected using a Personal Molecular Imager (FX model; 
Bio-Rad), and quantified using Quantity One 4.2.0 software. 
 
Tyrosine hydroxylase activity.  Tyrosine hydroxylase activity was measured via L-DOPA 
levels in striatum after blocking DOPA decarboxylase activity using NSD-1015 (Nir, Haque 
et al. 2000).  The drug was dissolved in phosphate-buffered saline (pH 7.0) and injected 
intraperitoneally (150 mg/kg body weight) 30min before the mice were sacrificed. 
 
HPLC assay for catecholamines. DA, DOPAC, HVA and L-DOPA levels in brain striatal 
tissues were determined by high-performance liquid chromatography with electrochemical 
detection (HPLC-EC); samples were prepared as described previously (Zhang, Anantharam 
et al. 2007; Zhang, Kanthasamy et al. 2007). Briefly, neurotransmitters were extracted from 
samples using 0.1 M perchloric acid containing 0.05% Na2EDTA and 0.1% Na2S2O5.  The 
extracts were filtered in 0.22 µm spin tubes, and 20 μl of the samples was loaded for analysis.  
DA, DOPAC and HVA were separated isocratically by a reversed-phase column with a flow 
rate of 0.7 ml/min.  An HPLC system (ESA Inc., Bedford, MA) with an automatic sampler 
(ESA model 542) was used for these experiments.  The electrochemical detection (EC) 
system consisted of an ESA Coulochem model 5100A with a microanalysis cell (model 
5014A) and a guard cell (model 5020) (ESA Inc., Bedford, MA).  Peaks representing DA, 
DOPAC and HVA in the samples were identified on the basis of their retention times and 
co-chromatography of the respective authentic standards in several different chromatographic 
conditions. The DA, DOPAC and HVA levels were measured as ng /mg protein. 
 
Locomotor and stereotypy activity. Behavioral data were collected using VersaMax Animal 
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Activity Monitors (AccuScan Model RXYZCM-16, Columbus, OH). Each chamber was 
40×40×30.5 cm, made of clear Plexiglas and covered with a Plexiglas lid with holes for 
ventilation. Infrared monitoring sensors were located every 2.54 cm along the perimeter (16 
infrared beams along each side) and 2.5 cm above the floor. Two additional sets of 16 sensors 
were located 8.0 cm above the floor on opposite sides. Data were collected and analyzed by a 
VersaMax Analyzer (AccuScan Model CDA-8, Columbus, OH) which in turn sent 
information to a computer where it was stored for future analyses. All data are expressed as 
percent of the vehicle-treated control group (mean ± SEM, n=6) and were obtained in a 2hr 
test session. 
 
Western blot. Brain lysates containing equal amounts of protein were loaded in each lane 
and separated on a 10-12% SDS-PAGE gel as described previously (Kaul, Kanthasamy et al. 
2003).  After the separation, proteins were transferred to a nitrocellulose membrane, and 
nonspecific binding sites were blocked by treating with 5% nonfat dry milk powder.  The 
membranes were then treated with primary antibodies directed against TH (mouse 
monoclonal, 1:1000) or PhosphoTH-ser40 (rabbit, 1:1000) or phosphoTH-ser31 (rabbit, 
1:1000). The primary antibody treatments were followed by treatment with secondary 
HRP-conjugated anti-mouse IgG (1:2000) or anti-rabbit IgG (1:1000) for 1 hr at room 
temperature.  Secondary antibody-bound proteins were detected using an ECL 
chemiluminescence kit (Amersham Biosciences).  To confirm equal protein loading, blots 
were reprobed with a ß-actin antibody (1:5000 dilution).  Western blot images were captured 
with a Kodak 2000 MM imaging system and data were analyzed using 1D Kodak Imaging 
Analysis software (Zhang, Anantharam et al. 2007). 
 
Data analysis. Data analysis was performed using Prism 4.0 software (GraphPad Software, 
San Diego, CA). Data were first analyzed as raw by using one-way ANOVA and then 
Bonferroni's post-test was performed to compare all treatment groups, and differences with p 
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< 0.05 were considered significant. 
 
Results 
Rottlerin inhibits PKCδ activity in the mouse substantia nigra. In this experiment, 
we examined whether rottlerin effectively inhibits PKCδ kinase activity in mouse substantia 
nigra.  In order to determine the optimal route of rottlerin treatment, we chose the 
intraperitoneal route for low doses of rottlerin (3 and 7 mg/kg) and the oral route for high 
doses (10 and 20 mg/kg). Vehicle-injected animals were used as controls. As shown in Fig. 1, 
PKCδ kinase activity was significantly suppressed in the substantia nigra of rottlerin-treated 
animals in a dose-dependent manner compared to vehicle-treated control animals.  
Densitometric analysis of phosphorylated histone H1 bands revealed 48%, 37%, and 29% 
decreases in protein kinase activity in SN of mice treated with 20, 10, and 7 mg rottlerin, 
respectively. These results indicate that rottlerin significantly inhibits PKCδ activity, as 
observed in our previous cell culture experiments (Kaul, Kanthasamy et al. 2003).   
 
Rottlerin increases dopamine and its metabolites in the striatum in mice. We 
previously showed that rottlerin significantly enhanced dopamine synthesis in dopaminergic 
cells (Zhang, Kanthasamy et al. 2007). So after verifying rottlerin’s ability to suppress PKCδ 
activity in the brain, we examined the effect of rottlerin on the dopamine synthesis level in 
the mouse brain.  Mice were treated with 20mg/kg rottlerin for 5 days, and DA, DOPAC 
and HVA levels between rottlerin-treated animals and vehicle-treated animals were 
compared.  HPLC analysis revealed that striatal DA and DOPAC levels were significantly 
higher in the striatum of rottlerin-treated animals compared to vehicle-treated animals (Fig. 
2).  DA levels were determined to be 235.7±41.03 ng/mg protein in rottlerin-treated mice 
compared to 190.6±19.25 ng/mg protein in vehicle-treated animals, an increase of 20%.  
Similarly, striatal DOPAC levels were estimated to be 47.29±5.99 ng/mg protein in 
rottlerin-treated mice compared to 31.77±3.21 ng/mg protein in PKC vehicle-treated animals, 
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an increase of 40%.  Together, these in vivo data further demonstrate that rottlerin enhances 
dopamine synthesis in the mouse brain. 
 
Rottlerin increases TH activity and TH phosphorylation level in the substantia 
nigra. Tyrosine hydroxylase (TH) is a rate-limiting enzyme in the biosynthesis of 
catecholamines and catalyzes the first step of a biochemical synthetic pathway in which 
L-tyrosine is converted to L-3,4-dihydroxyphenylalanine (L-dopa).  Since rottlerin can 
increase dopamine synthesis, we next determined whether the effect of rottlerin occurs by 
altering TH activity in dopaminergic neurons in the mouse brain. To check TH activity, mice 
were injected intraperitoneally with AAAD inhibitor NSD-1015 (150mg/kg) 30 min before 
sacrifice (Nir, Haque et al. 2000). Inhibition of AAAD results in accumulation of DOPA, 
which is used as an estimation of TH activity and DA synthesis. The level of DOPA in 
rottlerin-treated (20mg/kg, 5 days) mice was 149.8±11.41 ng/mg protein, while DOPA levels 
in vehicle-treated animals was 110.2±10.04 ng/mg protein (Fig. 3A), indicating increased TH 
activity in mouse brain induced by rottlerin treatment. 
Since rottlerin treatment resulted in enhanced TH activity, we examined whether 
rottlerin has any effect on the phosphorylation status of TH.  It is well established that TH 
activity can be regulated by phosphorylation of multiple serine residues (Campbell, Hardie et 
al. 1986; Mitchell, Hardie et al. 1990), and serine phosphorylation at positions 31 and 40 has 
been suggested to play a key role in TH activation and increased dopamine biosynthesis 
(Haycock 1990).  We measured the extent of TH-ser40 phosphorylation in immunoblots 
using phosphospecific antibodies directed against TH-ser40.  As shown in Fig. 3B, the level 
of TH-ser40 phosphorylation was significantly enhanced in substantia nigra of 
rottlerin-treated animals.  But the level of total TH was unaltered in rottlerin-treated animals 
as compared to vehicle-treated animals, indicating that rottlerin treatment does not alter the 
expression of TH in mouse brain.  Nitrocellulose membranes were reprobed with β-actin 
antibody and the density of the 43 kDa β-actin band was identical in all lanes, confirming 
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equal protein loading (Fig. 3B).   
 
Rottlerin increases striatal dopamine and its metabolites in a time dependent 
manner. Continuous treatment with rottlerin for 5 days increased dopamine synthesis in 
mouse brain (Fig. 2). To further determine whether acute treatment with rottlerin also 
promotes dopamine synthesis in mouse brain, we treated mice with 20mg/kg rottlerin for 
different time points, from 1-7 hr. Dopamine levels in striatum were determined by similar 
methods previously shown. Interestingly, dopamine levels significantly increased first at 1hr 
of rottlerin treatment and continued increasing to the 7hr time point. However, the trend of 
increase is not time dependent. Dopamine metabolites DOPAC and HVA increased in the 
same pattern as dopamine (Fig. 4). 
 
Rottlerin treatment promotes TH activity and phosphorylation in mice. Since 
dopamine synthesis was enhanced in acute rottlerin treated mice, we further examined 
whether rottlerin increases the activity and phosphorylation status of TH in acute rottlerin 
treated mouse brain. Tyrosine hydroxylase activity was measured via L-DOPA levels in 
striatum after blocking DOPA decarboxylase activity using NSD-1015 (Nir, Haque et al. 
2000).  The drug was injected intraperitoneally (150 mg/kg body weight) 30min before the 
mice were sacrificed. As shown in Fig. 5A, L-DOPA levels significantly increased at 1hr, 3hr, 
5hr and 7hr rottlerin treatment. Increase in TH activity should result in increase in dopamine 
synthesis, which is consistent with the increased dopamine level shown in Fig 4. Substantia 
nigra tissue was used to check TH phosphorylation level after different time points of 
rottlerin treatment. We measured the extent of TH-ser31 and TH-ser40 phosphorylation in 
immunoblots using phosphospecific antibodies directed against TH-ser31 and TH-ser40.  
As shown in Fig. 5B, the level of TH-ser40 and TH ser31 phosphorylation was significantly 
enhanced in substantia nigra of rottlerin-treated animals.  But the level of total TH was 
unaltered in rottlerin-treated animals as compared to vehicle-treated animals, indicating that 
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rottlerin treatment does not alter the expression of TH in mouse brain.  Nitrocellulose 
membranes were reprobed with β-actin antibody and the density of the 43 kDa β-actin band 
was identical in all lanes, confirming equal protein loading (Fig. 5B).   
 
Rottlerin stimulates locomotor activity and stereotypy in mice. Increased brain 
dopamine content should be accompanied by behavior changes in animals; after 20mg/kg 
rottlerin treatment, the spontaneous locomotor activity was measured during the dark phase 
of the cycle for 2hr (Figure 6). Rottlerin treated mice exhibited increased locomotion as 
expected: 40% increased locomotor activity compared to vehicle treated mice. Stereotypic 
movement was also examined at the same time and was increased: 37% increased movement 
in rottlerin treated mice compared with vehicle treated mice. These results indicate that the 
rottlerin-treated mice were hyperlocomotive 
 
Apomorphine enhances hyperlocomotor activity and stereotypy induced by 
rottlerin. To further explore the mechanism responsible for the behavioral supersensitivity to 
rottlerin observed in the mice, we tested the locomotor response to the nonselective DA 
receptor agonist apomorphine. A high dose (10 mg/kg) was used in order to probe 
postsynaptic DA receptor function. Data shown in Figure 7 revealed that the rottlerin treated 
mice exhibited significantly higher (two-fold) locomotor activity as compared to vehicle 
treated mice in both locomotor activity and stereotypy behavior. This result indicates that 
PKCδ inhibition by acute rottlerin treatment is associated with postsynaptic DA receptor 
supersensitivity. 
 
D1and D2-like antagonist SCH 23390 and spiperone alter rottlerin-induced 
locomotor and stereotypy stimulation. Since rottlerin induces locomotor stimulation in 
mice, we next investigated the role of dopamine receptors and presynaptic dopamine neurons 
in the locomotor effects of rottlerin. The selective D2 antagonist spiperone (0.1 mg/kg, s.c.) 
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significantly diminished the stimulant actions of rottlerin (Fig. 8), whereas D1 antagonist 
R(±)-SCH 23390 (0.1 mg/kg, s.c.) did not, although both antagonists reduced the locomotor 
and stereotypy activity of mice when administered alone (Fig. 8). However, the locomotor 
stimulant effect of rottlerin can be expressed in the presence of D1 dopamine receptor 
blockade. These results support a role for dopamine receptor in the stimulation of normally 
coordinated locomotion by rottlerin.  
 
Enhanced striatal dopamine levels and behavioral function in PKCδ knockout 
mice. Further validation of the role of PKCδ in the regulation of DA synthesis was sought by 
extending these studies to PKCδ (-/-) knockout animals. We compared DA and DOPAC 
levels between PKCδ (-/-) animals and PKCδ (+/+) animals.  HPLC analysis revealed that 
striatal DA and DOPAC levels were significantly higher in the striatum of PKCδ (-/-) 
animals compared to PKCδ (+/+) animals (Fig. 9A).  DA levels were determined to be 
311.7±24.88 ng/mg protein in PKCδ (-/-) compared to 190±14.24 ng/mg protein in PKCδ 
(+/+) animals, an increase of 60%.  Similarly, striatal DOPAC levels were estimated to be 
83.64±12.02 ng/mg protein in PKCδ (-/-) compared to 59.41±8.697 ng/mg protein in PKCδ 
(+/+) animals, an increase of 40%.   
Spontaneous locomotor activity measured during the dark phase of PKCδ (+/+) and 
PKCδ (-/-) mice is shown in Fig. 9B. PKCδ (-/-) mice displayed increased locomotion in 
comparison with PKCδ (+/+) mice.  Stereotypy activity of PKCδ (-/-) mice was slightly 
higher than PKCδ (+/+) mice, but not significantly. These results indicate that the KO mice 
were hypolocomotive. 
 
Discussion 
In the present study, we characterized the in vivo regulation of TH and dopamine 
synthesis by a member of the novel class of the protein kinase C family, PKCδ, and 
demonstrated that (i) inhibition of PKCδ enhances TH activity and TH phosphorylation in an 
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animal model, (ii) inhibition of PKCδ increases striatal DA levels, (iii) locomotor activity and 
stereotypy are significantly elevated during rottlerin treatment or in PKCδ knockout in mice, 
and (iv) PKCδ inhibition-induced hyperlocomotor and stereotypy activity are significantly 
enhanced by DA receptor agonists and inhibited by DA receptor antagonists.  
The PKC family of kinases consists of 13 isoforms classified into three distinct 
sub-families based on their activation profiles.  Conventional isoforms of PKCs (cPKCs), 
PKC α, βΙ, βΙΙ, and γ, require both intracellular calcium and diacylglycerol (DAG) for their 
activation, while PKCδ, ε, η, θ, and μ require only DAG.. The atypical PKCs (aPKCs), PKCζ 
and λ(ι), require neither calcium nor phospholipids for activation.  The expression patterns 
and biological functions of these isoforms in CNS are only beginning to be recognized.  For 
example, PKCγ is expressed predominantly in the brain, and has been implicated in neural 
plasticity, including long term potentiation (Saito and Shirai 2002) and ischemic injury 
(Aronowski and Labiche 2003).  The levels of another novel PKC isoform, PKCε, are 
greatly reduced in Alzheimer’s brains, and are linked to increased production of amyloid β 
protein (Kinouchi, Sorimachi et al. 1995; Matsushima, Shimohama et al. 1996).  In the CNS, 
PKCε is localized mainly in the presynaptic region and induces neurite outgrowth during 
differentiation and mediates apoptosis during embryonic development, among other 
functions (Matsushima, Shimohama et al. 1996; Akita 2002).   
Recent studies from our laboratory have demonstrated PKCδ is highly expressed in 
nigral dopaminergic neurons, and that suppression of PKCδ activity by kinase inhibitors, 
dominant negative mutants or RNAi-mediated knockdown increases TH-ser40 
phosphorylation, TH activity, and dopamine levels. PKCδ phosphorylates PP2A to promote 
dephosphorylation of TH-ser40, and inhibition of PKCδ attenuates PP2A activity, resulting in 
elevated TH-ser40 phosphorylation, TH activity, and dopamine levels in a cell culture model 
(Zhang, Kanthasamy et al. 2007). In this study, we showed that PKCδ inhibition by its 
pharmacological inhibitor of PKCδ, rottlerin, and PKCδ knockout enhances TH activity and 
dopamine synthesis in mouse brain. Excessive DA production may not only alter 
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neurotransmission, but may also contribute to neuronal cell death through increased oxidative 
stress (Hoyt, Reynolds et al. 1997; Luo, Umegaki et al. 1998). In this regard, we wish to 
point out that PKCδ can be activated by at least two independent mechanisms in neuronal 
cells: membrane translocation and caspase-3-dependent proteolytic cleavage (Kikkawa, 
Matsuzaki et al. 2002; Brodie and Blumberg 2003; Kanthasamy, Kitazawa et al. 2003).  Of 
the two activation mechanisms, PKCδ activated by membrane translocation following tonic 
stimulation by lipid activators contributes to cell survival and proliferation (Kanthasamy, 
Kitazawa et al. 2003; Jackson and Foster 2004).  As demonstrated in our recent studies, 
another form of activation is caspase-3-dependent proteolytic cleavage of native PKCδ into 
regulatory and catalytic fragments resulting in persistent activation during exposure to 
neurotoxic agents such as MPP+, MMT, manganese or dieldrin (Anantharam, Kitazawa et al. 
2002; Kaul, Kanthasamy et al. 2003; Latchoumycandane, Anantharam et al. 2005).  This 
form of proteolytic activation contributes to apoptotic cell death of dopaminergic neurons 
(Kanthasamy, Kitazawa et al. 2003).  In the case of a lipid activator, TPA induced 
membrane translocation of native PKCδ, but did not induce apoptotic cell death in 
dopaminergic cell lines (Anantharam, Kitazawa et al. 2002).  Furthermore, recent studies 
from our lab and others have shown that unlike the native 74 kDa PKCδ, the 41 kDa 
catalytically active PKCδ fragment, upon proteolytic cleavage, is targeted to various 
sub-cellular organelles including the mitochondria (Majumder, Pandey et al. 2000) and 
nucleus (DeVries, Neville et al. 2002) to activate apoptotic cell death signaling molecules.  
These results suggest that native and cleaved PKCδ have different substrate profiles. Small 
molecule inhibitors of protein kinases are being increasingly evaluated for therapeutic use for 
various human diseases. Rottlerin is isolated from the seeds of Mallotus phillippinensis and 
has been shown to be a potent inhibitor of PKCδ, with an IC50 of 3-6 µM, whereas the Kis 
for other PKC isoforms (α, β, γ, ε and λ) are at least 5-10 times higher (Gschwendt, Muller et 
al. 1994; Samokhin, Jirousek et al. 1999; Davies, Reddy et al. 2000; Soltoff 2001).  Toxicity 
data for rottlerin indicate that the compound has a low toxicity profile (LDLo 750 mg/kg, rat 
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oral); 120 mg/kg (oral 6-day rat study) is the lowest toxic dose (Varma, Sareen et al. 1959).  
Previous studies have shown that the PKCδ inhibitor rottlerin protects against MPTP-induced 
motor deficits, striatal dopamine depletion, and nigral dopaminergic neuronal loss (Zhang, 
Anantharam et al. 2007); in addition, rottlerin inhibits PKCδ enzyme activity in vitro 
(Anantharam, Kitazawa et al. 2002).  In the present study, we provide evidence that rottlerin 
treatment can increase brain dopamine synthesis by enhancing TH activity and 
phosphorylation in an animal model. PKCδ knockout mice also have higher brain dopamine 
levels than wild-type mice. This negative regulation may be important for maintaining 
optimal dopamine levels. In addition to the function of regulating dopamine synthesis, under 
the condition of enhanced oxidative stress induced by neurotoxic insults, PKCδ serves as a 
key downstream proapoptotic effector of caspase-3, resulting in proteolytic activation of the 
kinase which contributes to cell death (Anantharam, Kitazawa et al. 2002; Kaul, Kanthasamy 
et al. 2003; Kitazawa, Anantharam et al. 2003; Yang, Kaul et al. 2004). Rottlerin is also 
shown to inhibit CaM kinase III and MAPKAP kinase 2 (Kotlyarov, Neininger et al. 1999), 
but these kinases are not related to dopamine synthesis in animal studies. 
Regulation of TH activity and DA levels is critical for normal dopaminergic 
neurotransmission in the CNS. Excessive DA production may alter neurotransmission (Hoyt, 
Reynolds et al. 1997; Luo, Umegaki et al. 1998). In the present study, PKCδ knockout 
induced mouse hyperlocomotor activity and stereotypy activity following acute rottlerin 
administration demonstrate an important role of PKCδ in modulating basal locomotor activity. 
A relatively high dose of apomorphine (10 mg/kg) resulted in enhanced locomotion in the 
rottlerin-treated animals. Selective activation of D1- or D2-like receptors produces different 
locomotor activity in mice. As a nonselective DA receptor agonist, apomorphine induced a 
modest increase in locomotor activity in the rottlerin  treated mice but did not change 
control animals. This may well reflect a combined effect of apomorphine on both D1- and 
D2-like receptors. Only the D2 receptor antagonist spiperone attenuated rottlerin-induced 
locomotor stimulation, while the D1 receptor antagonist SCH did not, indicating that these 
 152
hyperlocomotor responses caused by PKCδ inhibition might be mediated via D2-like 
receptors. Previous studies suggested that PKC-mediated phosphorylations of D1 and D2 
receptors were involved in receptor internalization (Namkung and Sibley 2004), and this 
rapid receptor sequestration is involved in agonist induced receptor desensitization. Thus, 
PKCδ inhibition may affect the postsynaptic sensitivity by altering the receptor 
phosphorylation state and/or interfering with receptor desensitization. Mice treated acutely 
with rottlerin showed good response to dopamine receptor agonist and antagonist but PKCδ 
knockout mice did not (data not shown here). Permanent knockout of PKCδ protein might 
change the dopamine receptor sensitivity or cause desensitization, but this possibility needs 
to be further tested. 
Taken together with our recent studies, these results demonstrate that PKCδ 
negatively regulates TH activity and that inhibition of the kinase enhances dopaminergic 
function. 
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FIGURE 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Effect of rottlerin on PKCδ activity in mouse substantia nigra. C57 black 
mice were treated with rottlerin (3-20 mg/kg) for 5 days. Substantia nigra tissue was 
homogenized and used in the immunoprecipitation kinase assay as described in the methods. 
The bands were quantified by a PhosphoImager after scanning the dried gel, and are 
expressed as a percentage of vehicle-treated bands. The data represent mean ± SEM from 4-6 
animals per group. Asterisks (**p<0.01) indicate significant differences compared with 
control. 
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FIGURE 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Effect of rottlerin on dopamine content in mouse striatum. C57 black mice 
were treated with rottlerin (20 mg/kg, p.o.) once a day for 5 days. 1% DMSO served as 
vehicle control. Animals were sacrificed 1 day after the last dose of rottlerin, and 
neurochemical analysis was performed by HPLC in striatal tissues.  The data represent 
mean ± SEM from 6-8 animals per group. Asterisks (*p<0.05) indicate significant difference 
compared with the vehicle treated group.  
 159
FIGURE 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Effects of rottlerin on TH activity and TH phosphorylation level in the 
substantia nigra. A, TH activity: Tyrosine hydroxylase activity was measured via L-DOPA 
levels in striatum after blocking DOPA decarboxylase activity using NSD-1015.  The drug 
was dissolved in phosphate-buffered saline (pH 7.0) and injected intraperitoneally (150 
mg/kg body weight) 30min before the mice were sacrificed. L-DOPA level was determined 
by HPLC. Inhibition of AAAD results in accumulation of DOPA, which is used as an 
estimation of TH activity. The data represent a mean + SEM from 6-10 animals.  Asterisks 
(*p<0.05) indicate significant difference compared with vehicle-treated animals. B, Western 
blot analysis of P-TH-ser40.  Substantia nigral lysates from vehicle treated mice and 
rottlerin treated mice were subjected to immunoblotting of P-TH-ser40, and total TH. To 
confirm equal protein loading in each lane, the membranes were reprobed with β-actin 
antibody. The immunoblots were visualized using the Amersham’s ECL detection agents. 
FIGURE 4. 
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Fig. 4. Effects of rottlerin on striatal dopamine and its metabolites levels at 
different treatment time points. Mice were treated with 20mg/kg rottlerin (p.o) for different 
time points from 0-7 hr. Striatum tissue was collected at 0hr, 1hr, 3hr, 5hr and 7hr time points. 
Striatal dopamine, DOPAC and HVA levels were determined by HPLC. The data represent 
mean ± SEM from 6-8 animals per group. Asterisks (*p<0.05 and **p<0.01) indicate 
significant differences compared with the 0hr time point group. 
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FIGURE 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Effects of acute rottlerin treatment on TH activity and phosphorylation in 
mice. A, TH activity: Mice were treated with 20mg/kg rottlerin (p.o) for different time 
points ranging from 0-7 hr. 150 mg/kg NSD-1015 was injected intraperitoneally 30min 
before the mice were sacrificed. Striatum tissue was collected at 0hr, 1hr, 3hr, 5hr and 7hr 
time points. Striatal L-DOPA level was determined by HPLC. The data represent a mean + 
SEM from 6-10 animals.  Asterisks (*p<0.05) indicate significant difference compared with 
the 0hr time point rottlerin-treated animals. B, Western blot analysis of P-TH-ser40.  
Substantia nigral tissue was collected at 0hr, 1hr, 3hr, 5hr and 7hr time points from 20mg/kg 
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rottlerin-treated mice. SN lysates from all these groups were subjected to immunoblotting of 
P-TH-ser40, and total TH. To confirm equal protein loading in each lane, the membranes 
were reprobed with β-actin antibody. The immunoblots were visualized using Amersham’s 
ECL detection agents 
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FIGURE 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Effects of rottlerin on mouse locomotor activity and stereotypy. C57 black 
mice were treated with a single dose of rottlerin (20 mg/kg, p.o.), and locomotor and 
stereotypy activity of mice was measured using a VersaMax Analyzer right after rottlerin 
treatment. Control mice were treated with 1% DMSO. The vehicle-treated group served as 
control and was set at 100%.  The data represent mean ± SEM from 6 animals per group.  
Asterisks (*p<0.05) indicate significant difference compared with vehicle-treated group.  
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FIGURE 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Effects of apomorphine on mouse hyperlocomotor activity and stereotypy 
induced by rottlerin. Mice were treated with 10mg/kg apomorphine (i.p.) 10min before a 
single dose of rottlerin (20 mg/kg, p.o.). Immediately after rottlerin treatment, mouse 
locomotor and stereotypy activity was measured using a VersaMax Analyzer. The 
apomorphine alone group was treated with 10mg/kg apomorphine (i.p.), and the rottlerin 
alone group was treated with a single dose of 20mg/kg rottlerin (p.o.). Control mice were 
treated with 1% DMSO. The vehicle-treated group served as control, set at 100%.  The data 
represent mean ± SEM from 6 animals per group.  Asterisks (*p<0.05, **P<0.01) indicate 
significant difference compared with vehicle-treated group. 
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FIGURE 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8. Effects of SCH 23390 and spiperone on rottlerin-induced locomotor and 
stereotypy stimulation. Mice were treated with selective D1 antagonist R(±)-SCH 23390 
(0.1 mg/kg, s.c.) or selective D2 antagonist spiperone (0.1 mg/kg, s.c.) 10min before a single 
dose of rottlerin (20 mg/kg, p.o.). Immediately after rottlerin treatment, mice A, locomotor 
activity and B, stereotypy activity were measured using a VersaMax Analyzer. The SCH 
alone group was treated with 0.1mg/kg R(±)-SCH 23390 ( s.c.), and the spiperone alone 
group was treated with 0.1mg/kg spiperone ( s.c.). Control mice were treated with 1% DMSO. 
The vehicle-treated group served as control, set at 100%.  The data represent mean ± SEM 
from 6 animals per group.  Asterisks (**p<0.01, ***P<0.001) indicate significant difference 
compared with vehicle-treated group.  
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FIGURE 9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. Striatal dopamine levels and behavioral changes of PKCδ knockout mice. 
A, Neurotransmitter levels:  DA and DOPAC levels were determined in the striatal 
extracts of PKCδ (-/-) and PKCδ (+/+) animals by HPLC.  The data represent a mean + 
SEM from 6-10 animals.  Asterisks (*p<0.05) indicate significant differences between 
PKCδ (-/-) and PKCδ (+/+) animals. B, Locomotor and stereotypy activity.  Locomotor 
and stereotypy activity of PKCδ (+/+) and PKCδ (-/-) mice was measured using a VersaMax 
Analyzer. The PKCδ (+/+) group served as control, set at 100%.  The data represent mean ± 
SEM from 6 animals per group. 
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CHAPTER V: EFFECTS OF MANGANESE ON TYROSINE HYDROXYLASE 
ACTIVITY AND PHOSPHORYLATION IN DOPAMINERGIC NEURONAL CELLS  
 
Abstract 
Manganese (Mn) exposure causes manganism, a neurological disorder similar to 
Parkinson's disease. However, the cellular mechanism by which Mn induces dopaminergic 
neuronal cell death remains unclear. We found that caspase-3-dependent proteolytic 
activation of protein kinase Cδ (PKCδ) plays a key role in Mn-induced apoptotic cell death. 
Tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis, can be regulated 
by phosphorylation at multiple serine residues, including serine-31 and serine-40.  In the 
present study, we report that acute Mn treatment promotes TH activity by increasing TH 
phosphorylation, which can’t be reduced by PKCδ inhibition; chronic Mn treatment 
suppresses TH activity, which is accompanied by increased PKCδ cleavage in the 
dopaminergic cells. The reduced TH activity induced by chronic Mn treatment can be 
attenuated by the PKCδ inhibitor rottlerin. Both the acute and chronic Mn treatment 
concentrations were not cytotoxic to dopaminergic cells, so the effects of Mn on TH activity 
and phosphorylation in this study occurred under physiological conditions. Previously, we 
reported an interaction between PKCδ and TH, in which the kinase modulates dopamine 
synthesis by negatively regulating TH activity via protein phosphatase 2A (PP2A). Here we 
also showed that Mn treatment can increase PP2A activity, which may contribute to the 
decreased TH activity induced by MnCl2. The increased PP2A activity induced by chronic 
MnCl2 treatment is suppressed by PKCδ inhibitor rottlerin, which may suggest that the 
activation of PKCδ induced by Mn increased PP2A activity, which might decrease the TH 
activity induced by chronic Mn treatment.  
 
Introduction 
Exposure to high levels of manganese (Mn) has been shown to cause a 
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Parkinson's-like syndrome known as manganism. Increased incidences of manganism have 
been observed among miners and industrial welders as well as farmers exposed to Mn-based 
pesticides such as fungicides Maneb (Mn ethylene-bis-dithiocarbamate) and Mancozeb (Mn 
Cu Zn ethylene-bis-dithiocarbamate) (Roth and Garrick, 2003; Dobson et al., 2004; Olanow, 
2004). Adverse neurological effects of Mn also occurred in people who drank water 
containing high levels of Mn in Japan, Greece, and Australia and in abusers who used the 
Mn-containing compound Bazooka, a cocaine-based drug (Ensing, 1985). Several lines of 
evidence suggest that exposure to Mn or Mn-containing compounds induces a variety of 
cellular changes, including glutathione and dopamine depletion, increased oxidative stress, 
and impairment of energy metabolism and antioxidant systems (Hirata, 2002; Kitazawa et al., 
2002; Roth and Garrick, 2003; Dobson et al., 2004; Olanow, 2004). Recently, several studies 
have demonstrated effects of Mn on neuronal cells, but the mechanism of Mn-induced 
dopaminergic neurodegeneration remains unclear. Recently, we developed an in vitro model 
of dopaminergic neurotoxicity, namely, N27 cells derived from the mesencephalon, a brain 
region directly affected by PD. N27 cells also represent a homogenous population of 
dopaminergic tyrosine hydroxylase-positive cells with functional characteristics, including 
cellular signaling, similar to dopaminergic neurons (Anantharam et al., 2002; Kaul et al., 
2003).  
The PKC family consists of more than 12 isoforms and is subdivided into three major 
subfamilies, which include conventional PKC (α, βI, βII, γ), novel PKC (δ, ε, µ, η, θ), and 
atypical PKC (τ, λ, ζ) (Gschwendt, 1999; Dempsey et al., 2000; Maher, 2001; Kanthasamy et 
al., 2003).  PKCδ, a key member of the novel PKC family, plays a role in a variety of cell 
functions including cell differentiation, proliferation, and secretion.  Our recent studies 
demonstrate that PKCδ is an oxidative stress-sensitive kinase, and activation of this kinase 
via caspase-3 dependent proteolysis induces apoptotic cell death in cell culture models of 
Parkinson’s disease (Kanthasamy et al., 2003; Kaul et al., 2003; Yang et al., 2004; 
Latchoumycandane et al., 2005). Tyrosine hydroxylase (TH), a rate-limiting enzyme in the 
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biosynthesis of catecholamines, catalyzes the first step of a biochemical synthetic pathway in 
which L-tyrosine is converted to L-3,4-dihydroxyphenylalanine (L-dopa).  Phosphorylation 
and dephosphorylation of TH represent important post-translational regulatory mechanisms 
of the enzymatic activity that mainly determines the amount of catecholamine synthesis.  A 
number of phosphorylation sites have been identified in TH, and phosphorylation of TH 
greatly influences the enzyme activity (Lee et al., 1989).  Phosphorylation of TH at 
amino-terminal serine (Ser) amino sites at Ser8, Ser19, Ser31, and Ser40 leads to activation 
of TH.  A number of protein kinases have been shown to phosphorylate these serine 
residues to varying degrees.  For example, THser19 is phosphorylated by CaMKII, 
TH-ser40 by Protein kinase A (PKA), Protein kinase G by MSK, and Protein kinase C (PKC) 
and TH-ser31 by ERK1/ERK2 kinases and indirectly by PKC (Haycock, 1990).  Among 
these serine phosphorylation sites, TH-ser40 is a major residue that positively regulates the 
TH activity in vivo (Campbell et al., 1986; Wu et al., 1992).  The phosphorylation state of 
TH can also be regulated by dephosphorylation reactions mediated by phosphatases.  
Haavik et al. demonstrated that phosphatase 2A (PP2A) is the major serine/threonine 
phosphatase that dephosphorylates TH, resulting in reduced TH activity (Haavik et al., 1989).  
General PKCs can phosphorylate TH-ser40 and TH-ser31 (Albert et al., 1984; McTigue et al., 
1985; Tachikawa et al., 1987; Cahill et al., 1989; Haycock et al., 1992; Bunn and Saunders, 
1995; Bobrovskaya et al., 1998); however, direct phosphorylation of TH by PKA and not by 
PKC results in activation of the enzymatic activity (Funakoshi et al., 1991). We reported a 
novel functional interaction between PKCδ and TH in which PKCδ negatively regulates TH 
activity and dopamine synthesis by enhancing PP2A activity in dopaminergic neurons (Zhang 
et al., 2007). We demonstrated that caspase-3-mediated proteolytic activation of PKCδ plays 
a pivotal role in Mn-induced apoptosis in N27 mesencephalic dopaminergic cells 
(Latchoumycandane C et al., 2005). We further examined in the present study whether Mn 
has any physiological role in regulating TH activity or phosphorylation, and if PKCδ has a 
functional role during this process.  Herein, we report that activation of PKCδ induced by 
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chronic Mn treatment can increase PP2A activity and lead to a suppression of TH activity in 
dopaminergic cells. 
 
Materials and Methods 
Chemicals. Rottlerin, manganese chloride (MnCl2, 99%), NSD-1015, dibutyryl cAMP, 
protease cocktail, and anti-β-actin antibody were obtained from Sigma-Aldrich (St. Louis, 
MO); Z-Asp-Glu-Val-Asp-fluoromethyl ketone (Z-DEVD) was obtained from Alexis 
Biochemicals (San Diego, CA); phosphoTH-ser40 antibody was purchased from Chemicon 
(Temecula, CA); rabbit PKCδ antibody was purchased from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA); and the Bradford protein assay kit was purchased from Bio-Rad 
Laboratories (Hercules, CA).  Anti-rabbit and anti-mouse secondary antibodies and the ECL 
chemiluminescence kit were purchased from Amersham Pharmacia Biotech (Piscataway, NJ).  
RPMI, fetal bovine serum, L-glutamine, penicillin, and streptomycin were purchased from 
Invitrogen (Gaithersburg, MD).  
 
Cell culture models.  Differentiated N27 cells were cultured as described earlier (Adams et 
al., 1996; Anantharam et al., 2002; Kaul et al., 2003).  Briefly, cells were grown in RPMI 
1640 medium containing 10% fetal bovine serum, 2 mM L-glutamine, 50 units of penicillin, 
and 50 µg/ml streptomycin.  Cells were maintained in a humidified atmosphere of 5% CO2 
at 37°C.  N27 cells were differentiated with 2 mM dibutyryl cAMP for 3-5 days and then 
used for experiments described below. 
 
Treatment paradigm.  Differentiated N27 dopaminergic cells were exposed to 0.1-10 μM 
MnCl2 for the duration of the experiment. 3μM Rottlerin and 30μM Z-DEVD were used for 
PKCδ inhibition during chronic MnCl2 treatment. For measurement of TH activity, cells were 
exposed to 2 mM NSD-1015 for 1 hr prior to MnCl2 treatment.  Untreated cells were used 
as control samples.  We derived the concentrations of rottlerin used in this study based on 
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previously published literature.  Rottlerin inhibits PKCδ kinase activity with a Ki of 3-6 μM, 
while PKCα, β, γ, ε and λ Ki values are at least 5-10 times higher (Gschwendt, 1999; Davies 
et al., 2000; Way et al., 2000; Soltoff, 2001).  In our previous study, we showed 3-10 μM 
rottlerin dose-dependently attenuated kinase activity to a greater extent (Anantharam et al., 
2002).  We used 3 μM rottlerin in the study, which was lower than Ki values of other PKC 
isoforms. 
 
Tyrosine hydroxylase activity.  TH enzyme activity was measured by the modified method 
of Hayashi et al. (Hayashi et al., 1988) in which DOPA levels are quantified as an index of 
TH activity after inhibition of DOPA decarboxylase with the decarboxylase inhibitor 
NSD-1015 (Hayashi et al., 1988).  Briefly, cells were incubated with Krebs-HEPES buffer 
(pH 7.4) containing 2 mM NSD-1015 at 37°C for 1 hr prior to subjection  to the treatment 
paradigm as described earlier.  After treatment, cells were collected and resuspended in 
antioxidant solution, sonicated, centrifuged, and DOPA levels in the supernatants were 
measured by high-performance liquid chromatography with electrochemical detection 
(HPLC-EC); samples were prepared as described previously (Kitazawa et al., 2001; Sun et al., 
2006).  Briefly, neurotransmitters were extracted from samples using 0.1 M perchloric acid 
containing 0.05% Na2EDTA and 0.1% Na2S2O5.  The extracts were filtered in 0.22 micron 
spin tubes and 20 μl of the samples was loaded for analysis.  DOPA was separated 
isocratically by a reversed-phase column with a flow rate of 0.7 ml/min.  An HPLC system 
(ESA Inc., Bedford, MA) with an ESA automatic sampler (model 542) was used for these 
experiments.  The electrochemical detection (EC) system consisted of an ESA coulochem 
model 5100A with a microanalysis cell model 5014A and a guard cell model 5020 (ESA Inc., 
Bedford, MA).  The peak areas of standard DOPA were compared with peak areas of 
samples.  The DOPA level in the samples was measured and expressed as pg/μg protein, 
with a retention time for DOPA of 2.5-4 min.  
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PP2A assay.  To determine PP2A phosphatase activity, we used the Serine/Threonine 
phosphatase assay kit from Promega.  For in vivo PP2A activity measurement, N27 cells 
were homogenized in lysis buffer (25 mM Tris-HCl, 10 mM β-mercaptoethanol, 2 mM 
EDTA, protease inhibitor) supplied with the kit.  After centrifugation, the supernatants were 
used for the assay.  PP2A activity was determined by measuring the amount of free 
phosphate generated in a reaction by measuring the absorbance of a molybdate: malachite 
green: phosphate complex at 600 nm using a Spectramax plate reader (Molecular Devices).  
The effective range for the detection of phosphate released in this assay is 100–4,000 pmol of 
phosphate. 
 
Western blotting.  Cell lysates containing equal amounts of protein were loaded in each 
lane and separated on a 10-12% SDS-PAGE gel as described previously (Kaul et al., 2003).  
After the separation, proteins were transferred to nitrocellulose membrane, and nonspecific 
binding sites were blocked by treating with 5% nonfat dry milk powder.  The membranes 
were then treated with primary antibodies directed against PKCδ (rabbit polyclonal or mouse 
monoclonal, 1:2000 dilution) and phospho TH-ser40 (rabbit polyclonal, 1:1000).  The 
primary antibody treatments were followed by treatment with secondary HRP-conjugated 
anti-rabbit IgG (1:2000) for 1 hr at RT.  Secondary antibody-bound proteins were detected 
using Amersham's ECL chemiluminescence kit.  To confirm equal protein loading, blots 
were reprobed with a β-actin antibody (1:5000 dilution).  Western blot images were 
captured with a Kodak 2000 MM imaging system and data were analyzed using 1D Kodak 
imaging analysis software.  
 
Data analysis.  Data analysis was performed using Prism 4.0 software (GraphPad Software, 
San Diego, CA).  Data were first analyzed using one-way ANOVA and then Bonferroni's 
post-test was performed to compare all treatment groups, and differences with p<0.05 were 
considered significant. 
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Results 
 
Acute Mn exposure induces increases in TH activity in differentiated 
dopaminergic cells. We recently demonstrated that protein kinase C delta negatively 
regulates tyrosine hydroxylase activity and dopamine synthesis by enhancing protein 
phosphatase-2A activity in dopaminergic neurons both in cell culture and in animal brain 
(Zhang et al., 2007).  We have also shown that PKCδ mediates Mn-induced cytotoxic and 
apoptotic cell death in undifferentiated N27 dopaminergic neuronal cells (Latchoumycandane 
et al., 2005).  In this study we examined whether Mn at non-toxic doses has any effect on 
TH activity. Differentiated N27 cells were exposed to 3 µM and 10 µM Mn; after 3 hr, cells 
were harvested, lysed, and TH activity was measured.   As shown in Fig. 1A, the both 3 
µM and 10 µM Mn increased TH activity by 77% compared to untreated control cells.  To 
determine if PKCδ mediates Mn-induced increases in TH activity, N27 cells were pretreated 
with 3 µM rottlerin for 30 min prior to Mn treatment.  The results show that Mn-induced 
increases in TH-activity were unaffected by rottlerin treatment (Fig. 1B). 
 
Acute Mn exposure increases TH phosphorylation in dopaminergic cells. We 
previously demonstrated that PKCδ colocalizes with TH and also negatively regulates 
TH-ser40 phosphorylation (Zhang et al., 2007).  Since acute Mn exposure resulted in 
enhanced TH activity, we examined whether acute Mn treatment has any effect on the 
TH-ser40 phosphorylation status.  Differentiated N27 cells were exposed to 3 µM and 10 
µM Mn for 3 hr; the cell lysates were subjected to Western blot analysis and the membranes 
were probed with phospho-specific-antibody directed against P-TH-ser40.  As shown in Fig. 
2, Mn treatment dose-dependently increased the levels of P-TH-ser40. Densitometry analysis 
of the 60 kDa P-TH-ser40 band in Fig. 2 revealed a 2-fold increase in phosphorylation in 10 
µM Mn treated cells compared to untreated control cells. Nitrocellulose membranes were 
reprobed with β-actin antibody and the density of the 43 kDa β-actin band was identical in all 
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lanes, confirming equal protein loading.  Densitometric analysis of the 60 kDa P-TH-ser40 
band in Fig. 2 revealed a 2-fold increase in phosphorylation as compared to control cells.  
These results demonstrate that acute MnCl2 exposure results in enhanced TH 
phosphorylation. 
 
Acute Mn exposure is not toxic to differentiated N27 cells. In this experiment we 
determined if 3 hr exposure to 3-10 µM Mn induces cytotoxicity in different N27 cells.  
Cytotoxicity was measured using the Sytox Green assay. An increase in the number of 
Sytox-positive green cells indicates an increase in cell death, because the Sytox green dye 
permeates compromised cell membranes to stain nuclear chromatin.  Fig. 3 shows the 
phase-contrast and fluorescent images of Sytox Green treated cells. No Sytox positive cells 
were observed in N27 cells exposed to either 3 or 10 µM Mn for 3 hr (Fig. 3). Quantitative 
analysis of Sytox fluorescence using a fluorescence plate reader also revealed that different 
N27 cells were unaffected by acute Mn treatment (Fig. 3). These results suggest that the Mn 
concentration used in acute experiments is not toxic to the cells. 
 
PKCδ regulates TH activity in N27 cells chronically exposed to Mn. In this 
experiment we examined whether chronic Mn treatment also increases TH activity.  N27 
cells were exposed to 0.1-1 µM Mn, and after 24 hr TH activity was measured in the cell 
lysates. As shown in Fig. 4A, Mn dose-dependently decreased TH activity.  Densitometric 
analysis revealed that TH activity was decreased to 70%, 61%, and 59% in 0.1, 0.3, and 1 
µM Mn-treated cells, respectively, compared to untreated control cells (Fig. 4B). Therefore, 
unlike acute exposure, chronic Mn treatment decreases TH activity in differentiated N27 cells. 
To determine whether PKCδ mediates Mn-induced decreases in TH activity, differentiated 
N27 cells were cotreated with 3 µM rottlerin.  As shown in Fig. 4C, TH activity levels in 
Mn and rottlerin-treated cells were restored to levels comparable to untreated control cells.  
These data strongly suggest that PKCδ mediates Mn-induced decreases in TH activity levels.  
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Chronic Mn exposure is not toxic to differentiated N27 cells. In this experiment 
we determined if 24 hr exposure to 0.1-1µM Mn induces cytotoxicity in different N27 cells.  
Cytotoxicity was measured using the Sytox Green assay. Fig. 5A shows the phase-contrast 
and fluorescent images of Sytox Green treated cells. No Sytox positive cells were observed in 
N27 cells exposed to 0.1, 0.3, and 1µM Mn for 24 hr (Fig. 5). Quantitative analysis of Sytox 
fluorescence using a fluorescence plate reader also revealed that different N27 cells were 
unaffected by chronic Mn treatment (Fig. 5). These results suggest that the Mn concentration 
used in chronic experiments is not toxic to the cells. 
 
Chronic Mn exposure induces increased PKCδ kinase activity. Since rottlerin 
treatment prevented Mn-induced decreases in TH activity, we examined if chronic Mn 
treatment increased PKCδ kinase activity. Immunoprecipitation kinase assays were 
performed by measuring PKCδ phosphorylation of histone H1 using [32P]-ATP, as described 
previously (Kaul et al., 2005).  Differentiated N27 cells were exposed to 1 µM Mn in the 
presence or absence of 3 µM rottlerin, and the cell lysates were subjected to kinase assay.  
As shown in Fig. 6, 24 hr exposure to 1µm Mn resulted in a 48% increase in histone 
phosphorylation compared to untreated control cells.  Rottlerin cotreatment completely 
suppressed the 1 µM Mn-induced increase in kinase activity.  Together, these data imply 
that chronic Mn exposure induces increases in PKCδ kinase activity, which can be prevented 
by cotreatment with 3 µM rottlerin. Previously, we determined that caspase-mediated PKCδ 
cleavage and activation occur with 300 µM Mn treatment for 24 hr. We believe that increased 
PKCδ kinase activity induced by 0.1-1µM Mn may be due to activation of native PKCδ. 
 
PKCδ mediates Mn-induced increases in PP2A activity in dopaminergic cells. We 
previously demonstrated that PKCδ negatively regulates TH activity by enhancing protein 
phosphatase-2A activity in dopaminergic neurons (Zhang et al., 2007). In that study we 
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showed that PKCδ can directly phosphorylate PP2A and increase its phosphatase activity.  
Activated PP2A would then dephosphorylate P-Ser40 and inactivate TH.  Since chronic Mn 
treatment induced increases in PKCδ kinase activity and decreased TH activity, we examined 
whether PP2A activity is increased in Mn-treated cells.  As shown in Fig. 7, PP2A enzyme 
activity was increased by almost 50% in differentiated N27 cells exposed to 1 µM Mn for 24 
hr. Further, 3 µM rottlerin significantly blocked Mn-induced increases in PP2A activity, 
suggesting that PKCδ may be activating PP2A by direct phosphorylation, consistent with our 
previous study findings (Zhang et al., 2007).   
 
 
Discussion 
In the present study, we demonstrate that an inorganic form of Mn changes tyrosine 
hydroxylase activity following different treatment methods in mesencephalic 
dopamine-producing N27 cells. We demonstrated that (i) acute manganese exposure activates 
tyrosine hydroxylase; (ii) chronic manganese exposure suppresses tyrosine hydroxylase 
activity; (iii) chronic manganese exposure causes PKCδ activation and increases PP2A 
activity; and (iv) the reduced TH activity induced by chronic Mn exposure might occur 
through the PKCδ-induced activation of PP2A. Importantly, to our knowledge, this is the first 
report showing that manganese modifies tyrosine hydroxylase in dopaminergic neuronal cells 
and that PKCδ is a key biochemical target in this process. 
Mn has been shown to primarily target the nigrostriatal system, including the globus 
pallidus and substantia nigra (Baek et al., 2003). Mn exposure varies from moderate, as 
occurs via drinking water and food sources, to high, occurring via occupational and industrial 
exposure through mining, welding, and steel manufacturing (Woolf et al., 2002; Roth and 
Garrick, 2003; Dobson et al., 2004; Olanow, 2004). Mn can cross the blood-brain barrier via 
specific carriers such as transferrin and divalent metal transporter 1 and also by diffusion 
(Yokel and Crossgrove, 2004). The normal concentration of manganese in human adult 
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tissues ranges from 3 to 20 µM (Roth and Garrick, 2003), with an average human blood 
manganese level of 7.2 µg/l (Hauser et al., 1996). Markesbery et al. (1984) reported that the 
mean brain manganese level is 0.261 µg/g, and Zecca et al. (1994) reported Mn levels in 
putamen, substantia nigra, and neuromelanin of 6.31, 0.34, and 58.5 ng/mg wet weight, 
respectively. Depending on the level of exposure, blood manganese concentrations can 
increase from 10- to 200-fold (Hauser et al., 1996; Lucchini et al., 1999; Mergler et al., 1999; 
Woolf et al., 2002; McKinney et al., 2004).  
Tyrosine hydroxylase is the enzyme responsible for catalyzing the conversion of the 
amino acid L-tyrosine to dihydroxyphenylalanine (DOPA). DOPA is a precursor for 
dopamine, which in turn is a precursor for norepinephrine (noradrenaline) and epinephrine 
(adrenaline). The enzyme, an oxygenase, is found in the cytosol of all cells containing 
catecholamines. This initial reaction is the rate limiting step in the production of 
catecholamines. Tyrosine hydroxylase is regularly used as a marker for dopaminergic 
neurons, which is particularly relevant for Parkinson's disease reseach. Since Mn primarily 
targets the nigrostriatal system, we sought to evaluate the effect of Mn on the activity of 
tyrosine hydroxylase, an enzyme with a key role in the physiology of adrenergic neurons, in 
dopaminergic neurons. We chose lower, nontoxic concentrations of MnCl2 for our studies. 
We also found that acute Mn exposure leads to increased TH activity and phosphorylation, 
while chronic Mn exposure causes decreased TH activity. Neither kinds of exposure are 
lethal to dopaminergic neuronal cells.  
Phosphorylation is a key post-translational mechanism to regulate TH activity. 
Phosphorylation of serine residues at 8, 19, 31 and 40 can activate TH, resulting in enhanced 
dopamine synthesis (Campbell et al., 1986; Haycock, 1990; Mitchell et al., 1990; Lindgren et 
al., 2001; McCulloch et al., 2001; Dunkley et al., 2004).  A number of kinases, including 
PKC, PKA, CaMPK-II, and MAPkinase, have been shown to phosphorylate one or more of 
these sites to increase TH activity, depending on the cell type.  General PKC increases ser40 
phosphorylation and TH activity (Cahill et al., 1989; Haycock, 1990; Haycock and Haycock, 
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1991; Waymire et al., 1991; Haycock, 1993; Bobrovskaya et al., 1998); however, the effect of 
PKC subtypes has never been explored.  At the present time, 12 different isoforms of PKC 
have been identified and grouped into three major classes (Gschwendt, 1999; Dempsey et al., 
2000; Maher, 2001; Kanthasamy et al., 2003).  The conventional class of PKC isoforms, 
PKC α, βI, βII, and γ, require DAG and Ca2+ for activation, the novel PKC isoforms, PKCδ, ε, 
µ, η, and θ, require only DAG but not Ca2+ for activation, and the atypical PKCs, PKC τ, λ, 
and ζ, require neither Ca2+ nor DAG for activation.  The isoform-specific physiological 
functions of each subtype of PKCs are yet to be characterized in CNS.  The recently 
available, more specific pharmacological inhibitors, genetic mutants, and siRNAs specific for 
subtypes of isoforms are extremely useful in characterizing the functional significance of 
PKC isoforms. The enhanced TH activity we observed induced by pharmacological inhibitors 
and siRNA in three different cell culture models clearly demonstrated that PKCδ can 
negatively regulate TH activity (Zhang et al., 2007). In Fig. 6 we showed that chronic Mn 
exposure increased cleavage of PKCδ, which was attenuated by the PKCδ cleavage inhibitor 
Z-DEVD. PKCδ can be proteolytically cleaved by caspase-3 at the 324DIPD327 residue, 
resulting in 41-kDa catalytic and 38-kDa regulatory subunits, leading to a persistent 
activation of the kinase (Kaul et al., 2003; Yang et al., 2004; Anantharam et al., 2004). While 
TH was inactivated by chronic Mn exposure, PKCδ was activated in dopaminergic cells. To 
determine if TH inactivation by Mn treatment is PKCδ dependent, we cotreated Mn with the 
PKCδ inhibitor rottlerin. We found that the PKCδ inhibitor can successfully recover from the 
suppressed TH activity induced by Mn.  
An active PP2A enzyme consists of a heterotrimer of the structural A subunit, a 
catalytic C subunit, and a regulatory B subunit (Dobrowsky and Hannun, 1993; Sontag et al., 
1995; McCright et al., 1996; Ruvolo et al., 2002). The exact nature of the physical 
association and dynamic regulation of TH, PKCδ, and PP2A are yet to be characterized; 
however, recent literature provides some information regarding this interaction. PKCδ, TH, 
or PP2A have recently been shown to physically associate with each other, as well as other 
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putative chaperone proteins such as α-synuclein and 14-3-3 (Ostrerova et al., 1999; Kleppe et 
al., 2001; Srivastava et al., 2002; Kjarland et al., 2006).  Recently, Peng et al. (Peng et al., 
2005) demonstrated that a functional interaction between α-synuclein and PP2A can regulate 
TH phosphorylation and TH activity.  Srivastava et al. reported a physical interaction 
between PKCδ and PP2A in NIH3T3 cells, and that dephosphorylation of PKCδ by PP2A 
results in its inactivation (Srivastava et al., 2002). In our recent study, we showed that 
α-synuclein interacts with PKCδ and regulates its activity following neurotoxic insults (Kaul 
et al., 2005). Therefore, in the dopaminergic system, the physical and functional association 
between PKCδ, TH, and PP2A could be facilitated and/or regulated by chaperone proteins 
such as α-synuclein (Kaul et al., 2005; Peng et al., 2005) and 14-3-3 (Ostrerova et al., 1999; 
Kleppe et al., 2001; Kjarland et al., 2006). We previously provided novel evidence that PKCδ 
negatively regulates TH activity and DA synthesis via activation of PP2A (Zhang et al., 
2007). According to our hypothesis, after activation of PKCδ by chronic Mn treatment, the 
PP2A phosphorylation level will increase and activated PP2A will cause more 
dephosphorylation of TH, which will lead to the inactivation of TH enzyme. To check our 
hypothesis, we measured PP2A activity after chronic Mn treatment with or without rottlerin, 
and the results showed that chronic Mn treatment significantly promotes PP2A activity, 
which is attenuated by the PKCδ inhibitor rottlerin. Collectively, our data on Mn, TH, PKCδ, 
and PP2A suggest that chronic Mn induces activation of PP2A through activation of PKCδ, 
which leads to the decreased TH activity in the dopaminergic neuronal cells. Following acute 
Mn exposure, the PKCδ inhibitor does not attenuate the increased TH activity induced by Mn 
exposure, suggesting that PKCδ might not be involved in this process. 
Regulation of TH activity and DA levels is critical for normal dopaminergic 
neurotransmission in the CNS.  Excessive DA production may not only alter 
neurotransmission, but may also contribute to neuronal cell death through increased oxidative 
stress (Hoyt et al., 1997; Luo et al., 1998). In this regard, we wish to point out that PKCδ can 
be activated by at least two independent mechanisms in neuronal cells.  These include 
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membrane translocation and caspase-3-dependent proteolytic cleavage (Kikkawa et al., 2002; 
Brodie and Blumberg, 2003; Kanthasamy et al., 2003).  Of the two activation mechanisms, 
PKCδ activated by membrane translocation following tonic stimulation by lipid activators 
contributes to cell survival and proliferation (Kanthasamy et al., 2003; Jackson and Foster, 
2004).  As demonstrated in our recent studies, another form of activation is 
caspase-3-dependent proteolytic cleavage of native PKCδ into regulatory and catalytic 
fragments resulting in persistent activation during exposure to neurotoxic agents such as 
MPP+, MMT, manganese, or dieldrin (Anantharam et al., 2002; Kaul et al., 2003; 
Latchoumycandane et al., 2005).  This form of proteolytic activation contributes to 
apoptotic cell death of dopaminergic neurons (Kanthasamy et al., 2003).  In the case of lipid 
activator, TPA induced membrane translocation of native PKCδ, but did not induce apoptotic 
cell death (Anantharam et al., 2002).  Furthermore, recent studies from our lab and others 
have shown that unlike the native 74 kDa PKCδ, the 41 kDa catalytically active PKCδ 
fragment, upon proteolytic cleavage, is targeted to various sub-cellular organelles including 
the mitochondria (Majumder et al., 2000) and nucleus (DeVries et al., 2002) to activate 
apoptotic cell death signaling molecules.  These results suggest that native and cleaved 
PKCδ have different substrate profiles.   
In conclusion, we provide novel evidence that Mn exposure leads to changes in TH 
enzyme activity, while chronic Mn exposure induces activation of PP2A through activation of 
PKCδ, which leads to the decreased TH activity in the dopaminergic neuronal cells. We 
suggest that Mn-mediated regulation of TH through PKCδ may have important implications 
in neurological dopaminergic system disorders, such as Parkinson’s disease.   
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FIGURE 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Effect of acute Mn treatment on TH activity in differentiated N27 cells. N27 
cells were differentiated by using 2 mM dbcAMP for 3 days; differentiated N27 cells were 
incubated with 3 or 10 μM MnCl2 for 3 hr with or without 3 μM rottlerin. For measurement 
of TH activity, cells were exposed to 2 mM NSD-1015 for 1 hr prior to MnCl2 treatment. 
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Cells were lysed after treatment, and extracts were used for determining L-DOPA levels by 
HPLC. A, Data were presented as pg DOPA/μg protein; B, data were presented as percentage 
of control. The data represent a mean + SEM of six to eight individual measurements.  
Asterisks (*p<0.05) indicate significant differences between MnCl2-treated cells and control 
cells. 
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FIGURE 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Effect of acute Mn treatment on TH phosphorylation level in differentiated 
N27 cells. Differentiated N27 cells were exposed to 3 or 10 μM MnCl2 for 3 hr. Cell extracts 
were prepared and separated by SDS-polyacrylamide gel electrophoresis and transferred to 
nitrocellulose membrane. TH antibody (mouse, 1:1000) and phospho-specific antibodies 
directed against P-TH-ser40 (rabbit, 1:1000) were used for immunoblotting. To confirm 
equal protein loading in each lane, the membranes were reprobed with β-actin antibody. The 
immunoblots were visualized using the Amersham’s ECL detection agents. Densitometric 
analysis of 60 kDa P-TH-ser40 bands represents the mean ± SEM from three separate 
experiments (*p < 0.05, **p < 0.01). 
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FIGURE 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Cytotoxicity of acute MnCl2 treatment in differentiated N27 cells. 
Differentiated N27 cells were treated with 3 μM or 10 μM MnCl2 for 3 hr. The effect of acute 
manganese treatment on cell death was quantified by Sytox Green fluorescence assay (green 
dots represent the dead cells). Then the density of fluorescence was measured using a 
fluorescence plate reader and was presented as % of control. 100 μM H2O2 treated cells were 
used as positive control. The data represent a mean + SEM of four individual measurements. 
Asterisks (***p<0.001) indicate significant differences between H2O2-treated cells and 
control cells. 
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FIGURE 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Effect of chronic MnCl2 on TH activity and phosphorylation level in 
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differentiated N27 cells. Differentiated N27 cells were incubated with 0.1 μM, 0.3 μM, or 1 
μM MnCl2 for 24 hr. For measurement of TH activity, cells were exposed to 2 mM 
NSD-1015 for 1 hr prior to MnCl2 treatment. Cells were lysed after treatment, and extracts 
were used for determining L-DOPA levels by HPLC. A, Data were presented as pg DOPA/μg 
protein; B, data were presented as percentage of control. The data represent a mean + SEM of 
six to eight individual measurements.  Asterisks (*p<0.05) indicate significant differences 
between MnCl2-treated cells and control cells. C, Differentiated N27 cells were treated with 1 
μM MnCl2 or cotreated with 3 μM rottlerin for 24 hr. Cells were pretreated with 2 mM 
NSD-1015 for 1 hr before MnCl2 treatment, were lysed and extracts were used for determining 
L-DOPA levels by HPLC. The data represent a mean + SEM of six to eight individual 
measurements.  Asterisks (**p<0.01) indicate significant differences between 
MnCl2-treated cells and control cells. 
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FIGURE 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Cytotoxicity of chronic MnCl2 treatment in differentiated N27 cells. 
Differentiated N27 cells were treated with 0.1 μM, 0.3 μM, or 1 μM MnCl2 for 24 hr. The 
effect of chronic manganese treatment on cell death was quantified by Sytox Green 
fluorescence assay (green dots represent the dead cells). Then the density of fluorescence was 
measured using a fluorescence plate reader and was presented as % of control. 100 μM H2O2 
treated cells were used as positive control. The data represent a mean + SEM of four 
individual measurements.  Asterisks (***p<0.001) indicate significant differences between 
H2O2-treated cells and control cells. 
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FIGURE 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Effect of MnCl2 on PKCδ activity in differentiated N27 cells. Differentiated 
N27 cells were treated with 1 μM MnCl2 or cotreated with 3 μM rottlerin for 24 hr. Cell 
extracts from the above treatment were used in the immunoprecipitation kinase assay.  
Recombinant PKCδ protein was used as a positive control.  The bands were quantified by a 
PhosphoImager after scanning the dried gel, and are expressed as a percentage of control. 
The data represent a mean + SEM of three individual measurements.  Asterisks (**p<0.01) 
indicate significant differences between MnCl2 treated and control cells. 
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FIGURE 7. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  Effect of Mn on PP2A activity in dopaminergic cells. Differentiated N27 cells 
were treated with 1 μM MnCl2 or cotreated with 3 μM rottlerin for 24 hr, then cells were 
lysed and PP2A enzyme activity was measured using a serine/threonine phosphatase assay kit 
from Promega. The data represent a mean + SEM of four to six individual measurements.  
Asterisks (*p<0.05) indicate significant differences between MnCl2 treated and control cells.   
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Chapter VI: GENERAL CONCLUSION 
 
The major findings of each research chapter included in this thesis have been 
described, and the implications for dopaminergic function have been interpreted in the 
discussion section of each individual chapter. This section presents an overview of the results 
and findings of the thesis, with special emphasis on the contributory role of PKCδ protein in 
the dopaminergic system, and its relevance to the pathogenesis of Parkinson’s disease.  
 
Interaction of PKCδ-PP2A-TH regulates dopamine synthesis in both 
dopaminergic cells and animal brain. Tyrosine hydroxylase (TH) is a rate-limiting enzyme 
in the biosynthesis of dopamine and catalyzes the first step of a biochemical synthetic 
pathway in which L-tyrosine is converted to L-3,4-dihydroxyphenylalanine (L-dopa).  
Phosphorylation and dephosphorylation of TH represent important post-translational 
regulatory mechanisms of the enzymatic activity that largely determine the amount of 
dopamine synthesis (Lee et al., 1989). Regulation of TH activity and DA levels is critical for 
normal dopaminergic neurotransmission in the CNS. The results from our studies show that 
PKCδ phosphorylates PP2Ac to enhance its activity and thereby reduces TH-ser40 
phosphorylation and TH activity and ultimately dopamine synthesis in dopaminergic neurons. 
PKCδ, TH, or PP2A sometimes physically associate together, or with other putative 
chaperone proteins such as α-synuclein and 14-3-3 (Ostrerova et al., 1999; Kleppe et al., 
2001; Srivastava et al., 2002; Kjarland et al., 2006).  Recently, Peng et al. (Peng et al., 2005) 
demonstrated that a functional interaction between α-synuclein and PP2A can regulate TH 
phosphorylation and TH activity.  Srivastava et al. reported a physical interaction between 
PKCδ and PP2A in NIH3T3 cells, and that dephosphorylation of PKCδ by PP2A results in 
its inactivation (Srivastava et al., 2002). The novel finding of our study demonstrates that 
physical association of PKCδ and PP2A was accompanied by PP2Ac phosphorylation by 
PKCδ, resulting in PP2A activation. We found that PP2A activity was significantly 
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decreased, without altering the PP2A protein levels, by the PKCδ inhibitor rottlerin.  Basal 
PP2A enzymatic activity was also significantly reduced in dopaminergic cells stably 
expressing loss of function kinase inactive PKCδ-DN mutant compared to LacZ cells.  
Furthermore, substantia nigra of PKCδ (-/-) mice showed significantly lower basal PP2A 
activity compared to naïve animals, indicating that PKCδ can augment PP2A activity.  
Additionally, in vitro kinase assays also revealed that PKCδ can phosphorylate PP2Ac. 
Treatment with the PP2A inhibitor okadaic acid increased the TH-ser40 level and enhanced 
TH activity, suggesting that PP2A effectively regulates TH activity and ser40 
phosphorylation. Our results agree with a recent study showing attenuation of TH activity 
and TH-ser40 phosphorylation by PP2A (Peng et al., 2005).  Collectively, our data on 
PKCδ and PP2A suggest that PKCδ negatively regulates TH-ser40 phosphorylation and 
activity and dopamine synthesis via increased PP2A activity by direct phosphorylation of 
PP2A. Future studies may need to focus on finding the phosphorylation sites of PP2A by 
PKCδ in dopaminergic neurons.   
PKCδ inhibitor rottlerin rescued MPTP-induced dopaminergic cell death and 
dopamine loss in mice. Although the existing approaches to PD treatment alleviate the 
symptoms, they fail to prevent the progression of the neurodegenerative process.  
Therapeutics that prevent the progressive loss of nigral dopaminergic neurons are not 
currently available.  The mechanisms underlying the dopaminergic degenerative process 
observed in PD are not well understood, which has hampered development of successful 
neuroprotective drugs. Recent studies from our laboratory demonstrated that the PKCδ 
isoform is an oxidative stress-sensitive kinase and a key mediator of apoptotic cell death in 
PD models (Kaul et al., 2003; Yang et al., 2004). We showed that native PKCδ is 
proteolytically activated by caspase-3 and that suppression of PKCδ by dominant negative 
mutant or siRNA against the kinase can effectively block apoptotic cell death in cellular 
models of PD. In an attempt to translate the mechanistic studies to a neuroprotective strategy 
targeting PKCδ, we systematically characterized the neuroprotective effect of a PKCδ 
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inhibitor, rottlerin, in MPP+-treated primary mesencephalic neuronal cultures, as well as in an 
MPTP animal model of PD. Administration of rottlerin, either intraperitoneally or orally, to 
C57 black mice significantly protected against MPTP-induced locomotor deficits and striatal 
depletion of dopamine and its metabolite DOPAC. Importantly, stereological analysis of 
nigral neurons revealed rottlerin treatment significantly protected against MPTP-induced 
TH-positive neuronal loss in the substantia nigra compacta.  Collectively, our findings 
demonstrate the neuroprotective effect of rottlerin in both cell culture and preclinical animal 
models of PD, and suggest that pharmacological modulation of PKCδ may offer a novel 
therapeutic strategy for treatment of PD. Small molecule inhibitors of protein kinases are 
being increasingly evaluated for therapeutic use for various human diseases. A number of 
researchers have attempted to develop neuroprotective agents targeting cell death signaling 
molecules.  Inhibitors targeted against mixed lineage kinase (MLK) and poly-ADP-ribose 
polymerase (PARP) have been shown to protect nigral dopaminergic neurons in animal 
models (Cosi et al., 1996), and some of these agents are currently being evaluated in human 
clinical trials (Parashar et al., 2005).  Previous studies have shown PKCδ can indirectly 
regulate PARP and MLK (Merritt et al., 1999; Yoshida et al., 2002; Kitazawa et al., 2004), 
suggesting that PKCδ may be an attractive upstream neuroprotective therapeutic target.  
Saporito et al. showed systemic injection of the c-Jun N-terminal kinase (JNK) inhibitor 
CEP-1347/KT-7515 protected against MPTP toxicity in the C57 black mouse model 
(Saporito et al., 1999). Maruyama et al. developed a class of compounds with multiple 
putative properties, including iron chelation, MAO inhibition, and antioxidant effects 
(Maruyama et al., 2002). Minocycline, a tetracycline derivative with anti-inflammatory 
properties, prevented dopaminergic neurodegeneration in MPTP models of PD (Du et al., 
2001).  Minocycline also inhibits microglia-associated inflammation and apoptosis (Ravina 
et al., 2003; Kelly et al., 2004).  Oral administration of the nutritional supplement creatine 
attenuated MPTP toxicity, which is similar to our findings with rottlerin (Matthews et al., 
1999). Creatine exhibits neuroprotective properties by inhibiting mitochondrial permeability, 
 200
as well as indirectly acting as an antioxidant (Tarnopolsky and Beal, 2001). In addition to 
creatine, the antioxidant Coenzyme-Q is being evaluated in PD clinical trials (Shults and 
Haas, 2005).  Release of cytochrome C resulting from increased mitochondrial permeability 
during oxidative stress has been shown to initiate PKCδ activation (Anantharam et al., 2002), 
and antioxidant treatment attenuates proapoptotic action of the kinase (Kaul et al., 2003), 
indicating that PKCδ is closely associated with two leading PD pathological mechanisms, i.e., 
oxidative insult and mitochondrial dysfunction. Our results provide evidence that PKCδ may 
serve as a novel therapeutic target for development of neuroprotective agents and suggest that 
development of selective and systemically-active small molecule PKCδ isoform inhibitors 
may translate to an effective neuroprotective agent for treatment of PD.    
PKCδ inhibition causes hyperactivity in mice. Regulation of TH activity and DA 
levels is critical for normal dopaminergic neurotransmission in the CNS. Excessive DA 
production may alter neurotransmission (Hoyt, Reynolds et al. 1997; Luo, Umegaki et al. 
1998). In the present study, acute rottlerin administration and PKCδ knockout induced 
hyperlocomotor activity as well as stereotypy in mice, demonstrating an important role of 
PKCδ in modulating basal locomotor activity. A relatively high dose of apomorphine (10 
mg/kg) resulted in enhanced locomotion in the rottlerin-treated animals. Selective activation 
of D1- or D2-like receptors produces different locomotor activity in mice. The nonselective 
DA receptor agonist apomorphine induced a modest increase in locomotor activity in the 
rottlerin-treated mice, but did not change activity in control animals. This may well reflect a 
combined effect of apomorphine on both D1- and D2-like receptors. Previous studies 
suggested that PKC-mediated phosphorylations of D1 and D2 receptors were involved in 
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receptor internalization (Namkung and Sibley 2004), and this rapid receptor sequestration is 
involved in agonist-induced receptor desensitization. Thus, PKCδ inhibition may affect the 
postsynaptic sensitivity by altering the receptor phosphorylation state and/or interfering with 
receptor desensitization. Mice administered an acute rottlerin treatment responded well to the 
dopamine receptor agonist and antagonist, while the PKCδ knockout mice did not (data not 
shown here). Permanent knockout of the PKCδ protein might change the dopamine receptor 
sensitivity or desensitization, but this possibility needs to be further tested. 
Manganese exposure changes tyrosine hydroxylase activity, which might be 
PKCδ involved. Exposure to high levels of manganese (Mn) causes a Parkinson's-like 
syndrome known as manganism. Increased incidences of manganism have been observed 
among miners and industrial welders as well as farmers exposed to Mn-based pesticides such 
as fungicides Maneb (Mn ethylene-bis-dithiocarbamate) and Mancozeb (Mn Cu Zn 
ethylene-bis-dithiocarbamate) (Roth and Garrick, 2003; Dobson et al., 2004; Olanow, 2004). 
Several studies have recently demonstrated effects of Mn on neuronal cells, but the 
mechanism of Mn-induced dopaminergic neurodegeneration remains unclear. In the present 
study, we report that chronic Mn treatment suppresses TH activity, which is accompanied by 
increased PKCδ cleavage in the dopaminergic cells. The reduced TH activity induced by 
chronic Mn treatment can be attenuated by the PKCδ inhibitor rottlerin. And such levels of 
chronic Mn treatment are not cytotoxic to dopaminergic cells, indicating physiological 
concentrations of Mn influenced TH activity and phosphorylation in this study. Previously, 
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we reported an interaction between PKCδ and TH, in which the kinase modulates dopamine 
synthesis by negatively regulating TH activity via protein phosphatase 2A (PP2A). Here we 
also showed that Mn treatment can increase PP2A activity, possibly due to decreased TH 
activity induced by MnCl2. The increased PP2A activity induced by chronic MnCl2 treatment 
is suppressed by the PKCδ inhibitor rottlerin, which may suggest that the activation of PKCδ 
induced by Mn caused increased PP2A activity, which may decrease TH activity induced by 
Mn treatment. Mn primarily targets the nigrostriatal system, including the globus pallidus 
and substantia nigra (Baek et al., 2003). Our novel finding is that Mn exposure leads to 
changes in TH enzyme activity. Specifically, chronic Mn induces activation of PP2A through 
activation of PKCδ, which leads to decreased TH activity in dopaminergic neuronal cells. We 
suggest that Mn-mediated regulation of TH through PKCδ may have important implications 
in neurological dopaminergic system disorders, such as Parkinson’s disease. Identifying 
pharmaceutical or genetic methods which inhibit PKCδ to prevent Mn-induced 
Parkinson's-like syndrome will be a promising future research endeavor.  
In summary, PKCδ enhances phosphatase 2A (PP2A) activity by phosphorylation of 
PP2Ac.  Increased PP2A activity decreases TH phosphorylation at site ser40, which leads to 
inactivation of TH and reduction of its activity and an ultimate decrease in dopamine 
synthesis.  Inhibition of PKCδ by its inhibitor rottlerin, PKCδ-DN mutant, PKCδ KO, or 
PKCδ siRNA, suppresses PP2A activity due to a decreased phosphorylation of PP2A. Our 
data suggest that PKCδ negatively regulates TH and dopamine synthesis via PP2A 
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(Scheme-1). Inhibition of PKCδ by the kinase inhibitor rottlerin enhances dopaminergic 
neurotransmission and neurobehavioral characteristics in animal models. The neuroprotective 
effect of rottlerin in both cell culture and preclinical animal models of PD suggests that 
pharmacological modulation of PKCδ may offer a novel therapeutic strategy for treatment of 
PD. PKCδ inhibition can also attenuate reduction of TH activity induced by manganese 
exposure in dopaminergic cells. These findings suggest that inhibition of PKCδ in the 
nigrostriatal dopaminergic system can offer dual benefits of neuroprotection and enhanced 
dopaminergic function in the development of therapeutic agents for treatment of Parkinson’s 
disease. 
Scheme-1 
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